Methods for the identification, assessment, and treatment of patients with cancer therapy

ABSTRACT

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. patent application Ser. No. 13/600,260, filed Aug. 31, 2012, now U.S. Pat. No. 8,889,354, which is a Continuation of U.S. patent application Ser. No. 11/449,195, filed Jun. 8, 2006, now U.S. Pat. No. 8,278,038, which claims the benefit of U.S. Provisional Application No. 60/688,634, filed Jun. 8, 2005. The entire contents of each of these applications are incorporated herein by reference.

The contents of the Sequence Listing were submitted on compact disc in the parent U.S. patent application Ser. No. 11/449,195 and are being transferred to this application. The compact disc has a copy of the Sequence Listing file, created on Sep. 26, 2008 and named “sequence listing.txt,” the contents of which are incorporated herein by this reference. This file is 5.91 MB (6,203,392 bytes) and was copied onto compact disc on Sep. 30, 2008.

BACKGROUND OF THE INVENTION

One of the continued problems with therapy in cancer patients is individual differences in response to therapies. With the narrow therapeutic index and the toxic potential of many available cancer therapies, such differential responses potentially contribute to patients undergoing unnecessary ineffective and even potentially harmful therapy regimens. If a designed therapy could be optimized to treat individual patients, such situations could be reduced or even eliminated. Furthermore, targeted designed therapy may provide more focused, successful patient therapy overall. Accordingly, there is a need to identify particular cancer patients which are particularly responsive to particular cancer therapies, either alone or in combination with other chemotherapies. It would therefore be beneficial to provide for the diagnosis, staging, prognosis, and monitoring of cancer patients, including, e.g., hematological cancer patients (e.g., multiple myeloma, leukemias, lymphoma, etc) as well as solid tumor cancer patients (e.g., lung, breast, prostate, ovary, colon, kidney, liver), who would benefit from particular cancer inhibition therapies; or to indicate a predisposition of such patients to non-responsiveness to therapy, thus resulting in appropriate preventative measures.

Proteasome inhibition represents an important strategy in cancer treatment. The proteasome is a multi-enzyme complex present in all cells which play a role in degradation of proteins involved in regulation of the cell cycle. For example, King et al., demonstrated that the ubiquitin-proteasome pathway plays an essential role in regulating cell cycle, neoplastic growth and metastasis. A number of key regulatory proteins, including p53, cyclins, and the cyclin-dependent kinases p21 and p27^(KIP1), are temporally degraded during the cell cycle by the ubiquitin-proteasome pathway. The ordered degradation of these proteins is required for the cell to progress through the cell cycle and to undergo mitosis. See, e.g., Science 274:1652-1659 (1996). Furthermore, the ubiquitin-proteasome pathway is required for transcriptional regulation. Palombella et al., teach that the activation of the transcription factor NF-kB is regulated by proteasome-mediated degradation of the inhibitor protein IkB. See International Patent Application Publication No. WO 95/25533. In turn, NF-kB plays a central role in the regulation of genes involved in the immune and inflammatory responses. For example, Read et al. demonstrated that the ubiquitin-proteasome pathway is required for expression of cell adhesion molecules, such as E-selectin, ICAM-1, and VCAM-1. See Immunity 2:493-506 (1995). Additional findings further support the role for proteasome inhibition in cancer therapy, as Zetter found that cell adhesion molecules are involved in tumor metastasis and angiogenesis in vivo, by directing the adhesion and extravastation of tumor cells to and from the vasculature to distant tissue sites within the body. See, e.g., Seminars in Cancer Biology 4:219-229 (1993). Moreover, Beg and Baltimore, found that NF-kB is an anti-apoptotic factor, and inhibition of NF-kB activation makes cells more sensitive to environmental stress and cytotoxic agents. See Science 274:782 (1996).

The first proteasome inhibitor described as having antitumor activity, bortezomib (N-pyrazinecarbonyl-L-phenylalanine-L-leucineboronic acid, PS-341) (VELCADE® for injection, Millennium Pharmaceuticals, Inc., Cambridge, Mass.; Johnson & Johnson Pharmaceutical Research and Development L.L.C.) has been approved for treatment of relapsed multiple myeloma. Presently clinical trials are underway in additional indications, including additional hematological cancers as well as solid tumors. This and other peptide boronic ester and acid proteasome inhibitors have been described by Adams et al. See, e.g., U.S. Pat. No. 5,780,454 (1998), U.S. Pat. No. 6,066,730 (2000), and U.S. Pat. No. 6,083,903 (2000). They describe the use of the disclosed boronic ester and boronic acid compounds to reduce the rate of muscle protein degradation, to reduce the activity of NF-kB in a cell, to reduce the rate of degradation of p53 protein in a cell, to inhibit cyclin degradation in a cell, to inhibit the growth of a cancer cell, and to inhibit NF-kB dependent cell adhesion.

Bortezomib specifically and selectively inhibits the proteasome by binding tightly (Ki=0.6 nM) to one of the enzyme's active sites. Bortezomib is selectively cytotoxic, and has a novel pattern of cytotoxicity in National Cancer Institute (NCI) in vitro and in vivo assays. Adams J, et al. Cancer Res 59:2615-22. (1999). In addition, bortezomib has cytotoxic activity in a variety of xenograft tumor models. Teicher B A, et al. Clin Cancer Res. 5:2638-45 (1999). Bortezomib inhibits nuclear factor-κB (NF-κB) activation, attenuates interleukin-6 (IL-6) mediated cell growth, and has a direct apoptotic effect, and possibly an anti-angiogenic effect. Additionally, bortezomib is directly cytotoxic to myeloma cells in culture, independent of their p53 status. See, e.g., Hideshima T, et al. Cancer Res. 61:3071-6 (2001). In addition to a direct cytotoxic effect of bortezomib on myeloma cells, bortezomib inhibits tumor necrosis factor alpha (TNFα□ stimulated intercellular adhesion molecule-1 (ICAM-1) expression by myeloma cells and ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) expression on bone marrow stromal cells (BMSCs), resulting in decreased adherence of myeloma cells and, consequently, in decreased cytokine secretion. Hideshima T, et al. Oncogene. 20:4519-27 (2001). By inhibiting interactions of myeloma cells with the surrounding bone marrow, bortezomib can inhibit tumor growth and survival, as well as angiogenesis and tumor cell migration. The antineoplastic effect of bortezomib may involve several distinct mechanisms, including inhibition of cell growth signaling pathways, dysregulation of the cell cycle, induction of apoptosis, and inhibition of cellular adhesion molecule expression. Notably, bortezomib induces apoptosis in cells that over express B-cell lymphoma 2 (Bcl-2), a genetic trait that confers unregulated growth and resistance to conventional chemotherapeutics. McConkey D J, et al. The proteasome as a new drug target in metastatic prostate cancer. 7th Annual Genitourinary Oncology Conference, Houston, Tex. Abstract (1999).

Glucocorticoidal steroids are capable of causing apoptotic death of many varieties of cells, and a selection of glucocorticoidal steroids have consequently be used in the treatment of various malignancies, including lymphoid malignancies, and combination therapies in solid tumors. For example, the optimal therapy for relapsed myeloma is not established, but high-dose dexamethasone is commonly used. See, e.g., Kumar A, et al. Lancet Oncol; 4:293-304 (2003); Alexanian R, et al. Ann Intern Med. 105:8-11(1986); Friedenberg W R, et al. Am J Hematol. 36:171-75. (1991). Response rates with this treatment are similar to those with vincristine, doxorubicin, and dexamethasone (VAD), and the dexamethasone component is estimated to account for 85 percent of the effect of VAD. See, e.g., Alexanian R, et al. Blood. 80:887-90 (1992); Sonneveld P, et al. Br J Haematol. 115:895-902. (2001). High-dose chemotherapy followed by autologous stem cell transplantation improves patient survival, but in most cases the disease relapses. Attal M et al. N Engl J Med. 335:91-97 (1996); Child J A, et al. N Engl J Med. 348:1875-83 (2003).

In addition to use of dexamethasone, additional corticosteroids have demonstrated use in cancer treatments, including hydrocortisone in combination therapy for prostate cancer, predisolone in leukemia, prednisolone in lymphoma treatment, and triamcinolone has recently demonstrated some anti-cancer activity. See, e.g., Scholz M., et al., J Urol. 173:1947-52. (2005); Sano J., et aL, Res Vet Sci. (May 10, 005); Zinzani P L. et al., Semin Oncol. 32(1 Suppl 1):S4-10. (2005); and Abrams, M T et al., J Cancer Res Clin Oncol. 131:347-54 (2005). It is believed gene transcription resulting from treatment with glucocorticoids results in apoptotic death and therapeutic effect. Analysis of sensitive and resistant cell lines have demonstrated differential gene expression patterns, suggesting expression differences account for varied response rates to glucocorticoid therapy. See, e.g., Thompson, E. B., et al., Lipids. 39:821-5(2004), and references cited therein.

While advances in development of successful cancer therapies progress, individual patient responses continue to demonstrate subsets of patient response to any particular therapy. We have conducted gene expression analysis studies to assess patient populations undergoing glucocorticoid therapy or proteasome inhibition therapy. Analyses were carried out to identify predictive markers associated with particular patients who respond well to treatment (responders) with a glucocorticoid and/or proteasome inhibitor versus those patients who do not respond to treatment (non-responders) with a glucocorticoid and/or proteasome inhibitor.

DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the identification of individual markers and marker sets that can be used to determine whether a tumor may be effectively treated by treatment with a proteasome inhibition therapy and/or a glucocorticoid therapy. For example, the compositions and methods provided herein can be used to determine whether a patient will be responsive or non-responsive to a proteasome inhibition therapeutic agent. Furthermore the compositions and methods provided herein can be used to determine whether a patient will be responsive or non-responsive to a glucocorticoid therapeutic agent. Based on these identifications, the present invention provides, without limitation: 1) methods and compositions for determining whether a proteasome inhibition therapy and/or a glucocorticoid therapy will or will not be effective in stopping or slowing tumor growth and patient treatment; 2) methods and compositions for monitoring the effectiveness of a proteasome inhibition therapy (a proteasome inhibitor agent or a combination of agents) and/or a glucocorticoid therapy used for the treatment of tumors; 3) methods and compositions for treatments of tumors comprising proteasome inhibition therapy and/or glucocorticoid therapy; and 4) methods and compositions for identifying specific therapeutic agents and combinations of therapeutic agents that are effective for the treatment of tumors in specific patients.

The markers of the present invention, whose expression correlates with the response to an agent, are identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3. By examining the expression of one or more of the identified markers or marker sets in a tumor, it is possible to determine which therapeutic agent or combination of agents will be most likely to reduce the growth rate of the cancer cells. By examining the expression of one or more of the identified markers or marker sets in a cancer, it is also possible to determine which therapeutic agent or combination of agents will be the least likely to reduce the growth rate of cancer cells. By examining the expression of one or more of the identified markers or marker sets, it is therefore possible to eliminate ineffective or inappropriate therapeutic agents Importantly, these determinations can be made on a patient by patient basis or on an agent by agent basis. Thus, one can determine whether or not a particular therapeutic regimen is likely to benefit a particular patient or type of patient, and/or whether a particular regimen should be continued.

The present invention is directed to methods of identifying and/or selecting a cancer patient who is responsive to a therapeutic regimen. In particular, the methods are directed to identifying or selecting a cancer patient who is responsive to a therapeutic regimen comprising proteasome inhibition therapy and/or glucocorticoid therapy. Additionally provided are methods of identifying a patient who is non-responsive to such a therapeutic regimen. These methods typically include the determining the level of expression of one or more predictive markers in a patient's tumor (e.g., a patient's cancer cells), comparing the level of expression to a reference expression level, and identifying whether expression in the sample includes a pattern or profile of expression of a selected predictive marker or marker set which corresponds to response or non-response to proteasome inhibition therapy and/or glucocorticoid therapy.

Additionally provided methods include therapeutic methods which further include the step of beginning, continuing, or commencing, or stopping, discontinuing or halting a therapy accordingly where a patient's predictive marker profile indicates that the patient would respond or not respond to the proteasome inhibition and/or glucocorticoid therapeutic regimen. In another aspect, methods are provided for analysis of a patient not yet being treated with a proteasome inhibition therapy or glucocorticoid therapy and identification and prediction that the patient would not be a responder to the therapeutic agent and such patient should not be treated with the proteasome inhibition therapy and/or glucocorticoid therapy when the patient's marker profile indicates that the patient is a non-responder. Thus, the provided methods of the invention can eliminate ineffective or inappropriate use of proteasome inhibition therapy and/or glucocorticoid therapy regimens.

Additionally provided are classifiers which can be used to develop a diagnostic test or a readable array useful for identifying patients who will be responsive or non-responsive to proteasome inhibition therapy and/or glucocorticoid therapy. Probes or peptides identified in a classifier of the invention can be included in a diagnostic or prognostic test to select a therapy, e.g., proteasome inhibition therapy and/or glucocorticoid therapy or a test which is used to determine continuation of therapy, e.g., proteasome inhibition therapy and/or glucocorticoid therapy.

Additional methods include methods to determine the activity of an agent, the efficacy of an agent, or identify new therapeutic agents or combinations. Such methods include methods to identify an agent useful as a proteasome inhibitor and/or a glucocorticoid inhibitor, for treating a cancer, e.g. a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or cancer from a solid tumor (e.g., in lung, breast, prostate, ovary, colon, kidney or liver), based on its ability to affect the expression of markers in a marker set of the invention. For example, an inhibitor which decreases or increases the level of expression of a marker or markers provided as upregulated or downregulated, respectively, in a set predictive for responsiveness to proteasome inhibition of the cancer would be a candidate inhibitor for the cancer. In another example, an inhibitor which decreases or increases the level of expression of a marker or markers provided as upregulated or downregulated, respectively, in a set predictive for responsiveness to glucocorticoid inhibition of the cancer would be a candidate inhibitor for the cancer.

The present invention is also directed to methods of treating a cancer patient, with a therapeutic regimen, in particular a proteasome inhibitor therapy (e.g., a proteasome inhibitor agent, alone, or in combination with an additional agent such as a chemotherapeutic agent) and/or glucocorticoid therapy regimen (a glucocorticoid agent, alone or in combination with an additional agent), which includes the step of selecting a patient whose predictive marker profile indicates that the patient will respond to the therapeutic regimen, and treating the patient with the proteasome inhibition therapy and/or glucocorticoid therapy.

Additional methods include selecting patients that are unlikely to experience response or increased time to progression upon treatment with a cancer therapy (e.g., proteasome inhibition therapy, glucocorticoid therapy). Furthermore provided are methods for selection of a patient having aggressive disease and more rapid time to progression.

Additional methods include a method to evaluate whether to treat or pay for the treatment of cancer, e.g. hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or cancer from a solid tumor (e.g., in lung, breast, prostate, ovary, colon, kidney or liver), by reviewing a patient's predictive marker profile for responsiveness or non-responsiveness to proteasome inhibition and/or glucococorticoid therapy.

Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described herein. The content of all database accession records (e.g., representative public identifier ID from Affymetrix HG133 annotation files, Entrez, GenBank, RefSeq) cited throughout this application (including the Tables) are also hereby incorporated by reference. The contents of files disclosing the Affymetrix HG-133A Probe Sequences and HG-133B Probe Sequences, both FASTA files dated Jun. 9, 2003 (Affymetrix, Inc., Santa Clara, Calif.), also hereby are incorporated by reference. In the case of conflict, the present specification, including definitions, will control.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e. at least one) of the grammatical object of the article. By way of example, “an element” means at least one element and can include more than one element.

A “marker” is a naturally-occurring polymer corresponding to at least one of the nucleic acids or proteins associated with Affymetrix probe set identifiers listed in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3. For example, markers include, without limitation, sequences recognized by the Affymetric probes and probeset identifiers, sense and anti-sense strands of genomic DNA (i.e. including any introns occurring therein), RNA generated by transcription of genomic DNA (i.e. prior to splicing), RNA generated by splicing of RNA transcribed from genomic DNA, and proteins generated by translation of spliced RNA (i.e. including proteins both before and after cleavage of normally cleaved regions such as transmembrane signal sequences). As used herein, a “marker” may also include a cDNA made by reverse transcription of an RNA generated by transcription of genomic DNA (including spliced RNA). A “marker set” is a group of markers, comprising two or more predictive markers of the invention. Markers of the present invention include the predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3; as identified by the particular probeset identifier, representative public identifier, title, gene symbol, and/or Entrez gene identifier, and include the representative nucleotide and/or protein sequence or fragment thereof which corresponds to the identifier.

A “predictive marker” as used herein, includes a marker which has been identified as having differential expression in tumor cells of a patient and furthermore that expression is characteristic of a patient who is responsive in either a positive or negative manner to treatment with a proteasome inhibitor regimen and/or glucocorticoid regimen. For example, a predictive marker includes a marker which is demonstrates higher expression in a non-responsive patient; alternatively a predictive marker includes a marker which demonstrates higher expression in a responsive patient. Similarly, a predictive marker is intended to include those markers which demonstrate lower expression in a non-responsive patient as well as those markers which demonstrate lower expression in a responsive patient. Thus, as used herein, predictive marker is intended to include each and every one of these possibilities, and further can include each single marker individually as a predictive marker; or alternatively can include one or more, or all of the characteristics collectively when reference is made to “predictive markers” or “predictive marker sets.” A predictive marker set also can be known as a “classifier.”

As used herein, a “naturally-occurring” refers to a molecule (e.g., RNA, DNA, protein, etc.) that occurs in nature (e.g. encodes a natural protein, a naturally produced protein, etc).

The term “probe” refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes may be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic monomers.

The “normal” level of expression of a marker is the level of expression of the marker in cells in a similar environment or response situation, in a patient not afflicted with cancer. A normal level of expression of a marker may also refer to the level of expression of a “reference sample”, (e.g., sample from a healthy subjects not having the marker associated disease). A reference sample expression may be comprised of an expression level of one or more markers from a reference database. Alternatively, a “normal” level of expression of a marker is the level of expression of the marker in non-tumor cells in a similar environment or response situation from the same patient that the tumor is derived from.

“Differential expression” of a marker refers to expression of a marker that varies in level across patients. Furthermore, in this invention we refer to a marker as “differentially expressed” when its expression level is correlated with, or otherwise indicative of, response or non-response to treatment.

“Complementary” refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds (“base pairing”) with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

As used herein, “informative” expression is intended to refer to the expression level of a differentially expressed predictive marker which corresponds to responsiveness or non-responsiveness. The expression level of a marker in a patient is “informative” if it is greater than a reference level by an amount greater than the standard error of the assay employed to assess expression. Alternatively, a marker that is differentially expressed will have typical ranges of expression level that are predictive of responsiveness or non-responsiveness. An informative expression level is a level that falls within the responsive or non-responsive range of expressions. Still further, a set of markers may together be “informative” if the combination of their expression levels either meets or is above or below a pre-determined score for a predictive marker set as determined by methods provided herein.

A given marker may be indicative of both responsive and non-responsive patients; for example, expression of a predictive marker provided herein above a given threshold (e.g., an informative expression level) may be indicative of a responsive patient, as described herein. Expression of that marker below a given threshold (e.g., below an informative level) may be indicative of a non-responsive patient

A cancer or tumor is treated or diagnosed according to the present methods. “Cancer” or “tumor” is intended to include any neoplastic growth in a patient, including an inititial tumor and any metastases. The cancer can be of the liquid or solid tumor type. Liquid tumors include tumors of hematological origin, including, e.g., myelomas (e.g., multiple myeloma), leukemias (e.g., Waldenstrom's syndrome, chronic lymphocytic leukemia, other leukemias), and lymphomas (e g, B-cell lymphomas, non-Hodgkins lymphoma). Solid tumors can originate in organs, and include cancers such as lung, breast, prostate, ovary, colon, kidney, and liver. As used herein, cancer cells, including tumor cells, refer to cells that divide at an abnormal (increased) rate. Cancer cells include, but are not limited to, carcinomas, such as squamous cell carcinoma, basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, adenocarcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, undifferentiated carcinoma, bronchogenic carcinoma, melanoma, renal cell carcinoma, hepatoma-liver cell carcinoma, bile duct carcinoma, cholangiocarcinoma, papillary carcinoma, transitional cell carcinoma, choriocarcinoma, semonoma, embryonal carcinoma, mammary carcinomas, gastrointestinal carcinoma, colonic carcinomas, bladder carcinoma, prostate carcinoma, and squamous cell carcinoma of the neck and head region; sarcomas, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordosarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, synoviosarcoma and mesotheliosarcoma; hematologic cancers, such as myelomas, leukemias (e.g., acute myelogenous leukemia, chronic lymphocytic leukemia, granulocytic leukemia, monocytic leukemia, lymphocytic leukemia), and lymphomas (e.g., follicular lymphoma, mantle cell lymphoma, diffuse large Bcell lymphoma, malignant lymphoma, plasmocytoma, reticulum cell sarcoma, or Hodgkins disease); and tumors of the nervous system including glioma, meningoma, medulloblastoma, schwannoma or epidymoma.

A cancer is “responsive” to a therapeutic agent if its rate of growth is inhibited as a result of contact with the therapeutic agent, compared to its growth in the absence of contact with the therapeutic agent. Growth of a cancer can be measured in a variety of ways, for instance, the size of a tumor or the expression of tumor markers appropriate for that tumor type may be measured. For example, the response definitions used to identify markers associated with myeloma and its response to proteasome inhibition therapy and/or glucocorticoid therapy, the Southwestern Oncology Group (SWOG) criteria as described in Blade et al., Br J Haematol. 1998 September; 102(5): 1115-23 were used (also see e.g., Table C). These criteria define the type of response measured in myeloma and also the characterization of time to disease progression which is another important measure of a tumor's sensitivity to a therapeutic agent. The quality of being responsive to a proteasome inhibition therapy and/or glucocorticoid therapy is a variable one, with different cancers exhibiting different levels of “responsiveness” to a given therapeutic agent, under different conditions. Still further, measures of responsiveness can be assessed using additional criteria beyond growth size of a tumor, including patient quality of life, degree of metastases, etc. In addition, clinical prognostic markers and variables can be assessed (e.g., M protein in myeloma, PSA levels in prostate cancer) in applicable situations.

A cancer is “non-responsive” to a therapeutic agent if its rate of growth is not inhibited, or inhibited to a very low degree, as a result of contact with the therapeutic agent when compared to its growth in the absence of contact with the therapeutic agent. As stated above, growth of a cancer can be measured in a variety of ways, for instance, the size of a tumor or the expression of tumor markers appropriate for that tumor type may be measured. For example, the response definitions used to identify markers associated with non-response of multiple myeloma to therapeutic agents, the Southwestern Oncology Group (SWOG) criteria as described in Blade et. al. were used in the experiments described herein. The quality of being non-responsive to a therapeutic agent is a highly variable one, with different cancers exhibiting different levels of “non-responsiveness” to a given therapeutic agent, under different conditions. Still further, measures of non-responsiveness can be assessed using additional criteria beyond growth size of a tumor, including patient quality of life, degree of metastases, etc. In addition, clinical prognostic markers and variables can be assessed (e.g., M protein in myeloma, PSA levels in prostate cancer) in applicable situations.

“Treatment” shall mean preventing or inhibiting further tumor growth, as well as causing shrinkage of a tumor. Treatment is also intended to include prevention of metastasis of tumor. A tumor is “inhibited” or “treated” if at least one symptom (as determined by responsiveness/non-responsiveness, time to progression, or indicators known in the art and described herein) of the cancer or tumor is alleviated, terminated, slowed, minimized, or prevented. Any amelioration of any symptom, physical or otherwise, of a tumor pursuant to treatment using a therapeutic regimen (e.g., proteasome inhibition regimen, glucocorticoid regimen) as further described herein, is within the scope of the invention.

As used herein, the term “agent” is defined broadly as anything that cancer cells, including tumor cells, may be exposed to in a therapeutic protocol. In the context of the present invention, such agents include, but are not limited to, proteasome inhibition agents, glucocorticoidal steroid agents, as well as chemotherapeutic agents as known in the art and described in further detail herein.

A “kit” is any article of manufacture (e.g. a package or container) comprising at least one reagent, e.g. a probe, for specifically detecting a marker or marker set of the invention. The article of manufacture may be promoted, distributed, or sold as a unit for performing the methods of the present invention. The reagents included in such a kit comprise probes/primers and/or antibodies for use in detecting responsive and non-predictive marker expression. In addition, the kits of the present invention may preferably contain instructions which describe a suitable detection assay. Such kits can be conveniently used, e.g., in clinical settings, to diagnose and evaluate patients exhibiting symptoms of cancer, in particular patients exhibiting the possible presence of an a cancer capable of treatment with proteasome inhibition therapy and/or glucocorticoid therapy, including, e.g., hematological cancers e.g., myelomas (e.g., multiple myeloma), lymphomas (e.g., non-hodgkins lymphoma), leukemias, and solid tumors (e.g., lung, breast, ovarian, etc.).

The present methods and compositions are designed for use in diagnostics and therapeutics for a patient suffering from cancer. The cancer can be of the liquid or solid tumor type. Liquid tumors include tumors of hematological origin, including, e.g., myelomas (e.g., multiple myeloma), leukemias (e.g., Waldenstrom's syndrome, chronic lymphocytic leukemia, other leukemias), and lymphomas (e.g., B-cell lymphomas, non-Hodgkins lymphoma). Solid tumors can originate in organs, and include cancers such as lung, breast, prostate, ovary, colon, kidney, and liver.

The invention provides methods for determining or assessing an appropriate cancer therapy regimen for treating a tumor in a patient. The cancer therapy regimens appropriate for use in or in conjunction with the provided methods comprise proteasome inhibition therapy and/or glucocorticoid therapy. For example, proteasome inhibitor therapy comprises treatment of a patient with a proteasome inhibitor (e.g., bortezomib, or any other proteasome inhibitor described in further detail herein), alone or in combination with one or more additional agents. In another example, glucocorticoid therapy comprises treatment of a patient with a glucocorticoid (e.g., dexamethasone, or any other glucocorticoid described in further detail herein), alone or in combination with one or more additional agents.

The provided methods comprise measuring the level of expression of at least one predictive marker in the patient's tumor and determining a cancer therapy regimen for treating the tumor based on the expression level of the predictive marker or markers, as relevant. An informative expression level of a predictive marker or markers in the patient sample is an indication that the patient is a responsive patient and would benefit from proteasome inhibition therapy and/or glucocorticoid therapy when the predictive marker or marker set provided herein indicate such responsiveness. Additionally, an informative expression level of a predictive marker or markers in a patient is an indication that the patient is a non-responsive patient and would not benefit from proteasome inhibition therapy and/or glucocorticoid therapy when the marker or markers provided herein indicate such non-responsiveness.

The invention further provides methods for determining whether a patient will be responsive to a cancer therapy regimen for treating a tumor. Such methods comprise measuring the level of expression of at least one predictive marker in the patient's tumor and determining a proteasome inhibition based regimen and/or glucocorticoid based regimen for treating the tumor based on the expression level of the predictive marker or marker set. An informative expression level of a predictive marker in the patient sample is an indication that the patient is a responsive patient and would benefit from proteasome inhibition and/or glucocorticoid therapy. An informative expression level of a predictive marker set in the patient is an indication that the patient is a responsive patient and would benefit from proteasome inhibition therapy and/or glucocorticoid therapy when the marker or markers provided herein indicate such responsiveness. Selected predictive markers for use in the methods comprise predictive markers which demonstrate increased expression in responsive patients and/or longer time to disease progression.

The invention provides methods for determining whether a patient has aggressive disease and will progress in disease faster than a patient not demonstrating aggressive disease. A patient indicative of having aggressive disease also may be non-responsive to a cancer therapy regimen for treating a tumor. Such methods comprise measuring the level of expression of at least one predictive marker in the patient's tumor and identifying the patient as having aggressive disease based on the expression level of the predictive marker or marker set. An informative expression level of a predictive marker in the patient sample is an indication that the patient has aggressive disease patient and is likely to progress and may not benefit from proteasome inhibition based regimen and/or glucocorticoid based regimen therapy. An informative expression level of a predictive marker set in the patient is an indication that the patient is a patient having aggressive disease and would not benefit from proteasome inhibition based regimen and/or glucocorticoid based regimen when the selected marker or marker set provided herein indicate such disease aggressiveness. Selected predictive markers for use in the methods comprise predictive markers which demonstrate increased expression in non-responsive patients and/or shorter time to disease progression in patients and are not specific to treatment with proteasome inhibition therapy or glucocorticoid therapy.

Still further, the invention provides methods for determining whether a patient will be non-responsive to a cancer therapy regimen for treating a tumor. Such methods comprise measuring the level of expression of at least one predictive marker in the patient's tumor and determining a proteasome inhibition based regimen and/or glucocorticoid based regimen for treating the tumor based on the expression level of the predictive marker or marker set. An informative expression level of a predictive marker in the patient sample is an indication that the patient is a non-responsive patient and would not benefit from proteasome inhibition based regimen and/or glucocorticoid based regimen therapy. An informative expression level of a predictive marker set in the patient is an indication that the patient is a non-responsive patient and would not benefit from proteasome inhibition based regimen and/or glucocorticoid based regimen when the selected marker or marker set provided herein indicate such non-responsiveness. Selected predictive markers for use in the methods comprise predictive markers which demonstrate increased expression in non-responsive patients and/or shorter time to disease progression.

The invention further provides methods for treating a tumor in a patient with a proteasome inhibition based regimen and/or glucocorticoid based regimen therapy. Such therapeutic methods comprise measuring the level of expression of at least one predictive marker in a patient's tumor; determining whether a proteasome inhibition based regimen and/or glucocorticoid based regimen for treating the tumor is appropriate based on the expression level of the predictive marker or markers, and treating a patient with a proteasome inhibition based therapy and/or glucocorticoid based therapy when the patient's expression level indicates a responsive patient. An informative expression level of predictive marker in the patient sample is an indication that the patient is a responsive patient and would benefit from proteasome inhibition based regimen and/or glucocorticoid based regimen therapy when the predictive marker or marker set provided herein indicate the patient is a responsive patient.

Methods of the invention use at least one of the predictive markers set forth in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3. Additionally, the methods provided can use two, three, four, five, six, or more markers to form a predictive marker set. For example, marker sets selected from the markers in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3 can be generated using the methods provided herein and can comprise between two, and all of the markers set forth in Table 1A, Table 1B, Table 2A, Table 2B, or Table 3 and each and every combination in between (e.g., four selected markers, 16 selected markers, 74 selected markers, etc.). In some embodiments, the predictive marker set comprises at least 5, 10, 20, 40, 60, 100, 150, 200, or 300 or more markers. In other embodiments, the predictive marker set comprises no more than 5, 10, 20, 40, 60, 100, 150, 200, 300, 400, 500, 600 or 700 markers. In some embodiments, the predictive marker set includes a plurality of genes associated with cancer, e.g. a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or cancer from a solid tumor (e.g., in lung, breast, prostate, ovary, colon, kidney or liver). In some embodiments, the predictive marker set includes a plurality of markers listed in Table 1A, Table 1B, Table 2A, Table 2B, or Table 3. In some embodiments the predictive marker set includes at least about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the markers listed in Table 1B, Table 2A, Table 2B, or Table 3. Selected predictive marker sets can be assembled from the predictive markers provided using methods provided herein and analogous methods known in the art. An exemplary predictive marker sets is provided in Table 4. In certain aspects, the markers comprise those set forth in Table 4.

Methods of the invention further provide the ability to construct marker sets from the individual predictive markers set forth in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 using the methods described in further detail herein. In a further aspect, more than one marker set can be used in combination for the diagnostic, prognostic and treatment methods provided.

The methods of the invention can be performed such that determination of the level of expression of a predictive marker is measured prior to tumor therapy in order to identify whether the patient will be responsive to a proteasome inhibition therapy and/or glucocorticoid therapy.

In addition, the methods of the invention can be performed concurrently with ongoing tumor therapy to determine if the patient is either responding to present proteasome inhibition therapy and/or glucocorticoid therapy or will respond to additional therapy comprising proteasome inhibition therapy and/or glucocorticoid therapy.

Still further, the methods of the invention can be performed after tumor therapy has been carried out in order to assess whether the patient will be responsive to future course of proteasome inhibition therapy and/or glucocorticoid therapy.

Whether the methods are performed during ongoing tumor therapy or after a course of tumor therapy, the tumor therapy can comprise proteasome inhibition therapy and/or glucocorticoid therapy, alone or alternative forms of cancer therapy. The methods provided are designed to determine if the patient will benefit from additional or future proteasome inhibition and/or glucocorticoid therapy, and can include such proteasome inhibition and/or glucocorticoid therapy alone or in combination with additional therapeutic agents.

In certain aspects, the level of expression of predictive marker in the patient's tumor is measured by isolating a sample of the tumor and performing analysis on the isolated sample, or a portion thereof. In another aspect, the level of expression of predictive marker in the patient's tumor is measured using in vivo imaging techniques.

In certain aspects, determining the level of expression of a predictive marker comprises detection of mRNA. Such detection can be carried out by any relevant method, including e.g., PCR, northern, nucleotide array detection, in vivo imaging using probes capable of detection of the appropriate nucleic acid. In other aspects, determining the level of expression of the predictive marker comprises detection of protein. Such detection can be carried out using any relevant method for protein detection, including e.g., ELISA, western blot, immunoassay, protein array detection, in vivo imaging using probes capable of detection of the appropriate peptide.

Determining the level of expression of a predictive marker is compared to a reference expression level. For example, a reference expression level can be a predetermined standard reference level of expression in order to evaluate if expression of a marker or marker set is informative and make an assessment for determining whether the patient is responsive or non-responsive. Additionally, determining the level of expression of a predictive marker can be compared to an internal reference marker level of expression which is measured at the same time as the predictive marker in order to make an assessment for determining whether the patient is responsive or non-responsive. For example, expression of a distinct marker or markers which is/are not predictive markers of the invention, but which is known to demonstrate a constant expression level can be assessed as an internal reference marker level, and the level of the predictive marker expression is determined as compared to the reference. In an alternative example, expression of the selected predictive marker or markers in a tissue sample which is a non-tumor sample can be assessed as an internal reference marker level. The level of expression of a marker or markers may be determined as having increased expression in certain aspects. The level of expression of a marker or markers may be determined as having decreased expression in other aspects. The level of expression may be determined as no informative change in expression as compared to a reference level. In still other aspects, the level of expression is determined against a pre-determined standard expression level as determined by the methods provided herein.

The invention also relates to various reagents and kits for diagnosing, staging, prognosing, monitoring and treating a cancer patient (e.g., a patient with a liquid tumor or a solid tumor), with proteasome inhibition therapy and/or glucocorticoid therapy. Provided are reagents for detection of markers and marker sets and for use in the methods of the invention comprising at least two isolated predictive markers set forth in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3. Such reagents include nucleic acid probes, primers, antibodies, antibody derivatives, antibody fragments, and peptide probes for detection of the relevant predictive markers set forth in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3.

Further provided are kits for use in the provided methods. The kits of the invention include reagents for assessing predictive markers (e.g., at least one predictive marker) and predictive marker sets (e.g., at least two, three, four or more markers selected from Table 1A, Table 1B, Table 2A, Table 2B, and Table 3), as well as instructions for use in accordance with the methods provided herein. In certain aspects, the kits provided contain nucleic acid probes for assessment of predictive markers. In still other aspects, the kits provided contain antibody, antibody derivative antibody fragment, or peptide reagents for assessment of predictive markers.

Identification of Responsive and Non-Responsive Markers

The present invention provides markers that are expressed in a tumor that is responsive to proteasome inhibition therapy and/or glucocorticoid therapy and whose expression correlates with responsiveness to that therapeutic agent. The present invention also provides markers that are expressed in a tumor that is non-responsive to proteasome inhibition therapy and/or glucocorticoid therapy and whose expression correlates with non-responsiveness to such therapy. Accordingly, one or more of the markers can be used to identify cancers that can be successfully treated by proteasome inhibition therapy and/or glucocorticoid therapy. One or more of the markers of the present invention can be used to identify patients that can be successfully treated using proteasome inhibition therapy and/or glucocorticoid therapy. In addition, the markers of the present invention can be used to identify a patient that has become or is at risk of becoming refractory to treatment with proteasome inhibition therapy and/or glucocorticoid therapy. The invention also features combinations of markers, referred to herein as “marker sets,” that can predict whether a patient is likely to respond or not to respond to a proteasome inhibition therapy and/or glucocorticoid therapy regimen.

Table 1 sets forth predictive markers identified using statistical analysis applied to samples from 224 patients, which are specific identifiers of response or non-response to proteasome inhibition therapy (e.g., bortezomib). The markers in Table 1 are differentially expressed in samples from patients that are either responsive or non-responsive to treatment with the proteasome inhibitor bortezomib. Thus, one would appreciate that the markers identified can function in a predictive model to prospectively identify patients' response to proteasome inhibition therapy, including response to bortezomib or other proteasome inhibition therapies known in the art as well as those described in further detail herein. In particular, the markers in Table 1 are correlated with a positive response to therapy (referred to herein as “responsive, (R)”); or a long time until disease progression (TTP) as determined by a Cox proportional hazard analysis, as described in further detail herein. A patient with a positive response (either complete, partial or minimal; see Table C) to therapy is hereinafter referred to as a “responder”. Predictors of long time to progression are useful as additional indicators of patients who are likely to progress in disease at a slower rate and may be more likely to be responsive to therapy than other patients. Additionally, the predictive markers in Table 1 are correlated with a negative or poor response to an agent (referred to herein as “non-responsive, (NR)”), or a short time to disease progression (TTP). A patient with a poor response (called a progressive or refractory disease; see Table C) to treatment is hereinafter referred to as a “non-responder”. These identified predictive markers are useful as additional indicators of patients who are likely to progress in disease at a faster rate, and less likely to be responsive to therapy than other patients. A patient with no response to treatment is hereinafter referred to as “stable”.

Table 1A provides predictive markers which are upregulated indicators of non-response and/or correlate with shorter time to progression. Marker nos. 1-547 in Table 1A are newly identified predictive markers, and predictive markers no. 548-657 have been previously identified as associated markers predictive of non-response and/or correlation with shorter time to progression. See, International Patent Publication No. WO04053066, published Jun. 24, 2004. Table 1B provides predictive markers which are upregulated indicators of response and/or correlate with longer time to progression. Marker nos. 658-876 in Table 1B are newly associated predictive markers, and predictive markers no. 877-911 have been previously identified as associated markers predictive of response and/or correlation with longer time to progression. See, International Patent Publication No. WO04053066, published Jun. 24, 2004.

Table 2 sets forth predictive markers identified using statistical analysis applied to samples from 224 patients, which are specific identifiers of response or non-response to glucocorticoid therapy (e.g., dexamethasone). The markers in Table 2 are differentially expressed in samples from patients that are either responsive or non-responsive to treatment with the glucocorticoidal steroid agent dexamethasone. Thus, one would appreciate that the markers identified can function in a predictive model to prospectively identify patients' response to glucocorticoid therapy, including response to dexamethasone or other glucocorticoid therapies known in the art as well as those described in further detail herein. As in Table 1, Table 2 sets forth predictive markers identified which are specific identifiers of response or long time to progression; or non-response or short time to progression upon therapy with glucocorticoid treatment (e.g., dexamethasone).

Table 2A provides predictive markers which are upregulated indicators of non-response and/or correlate with shorter time to progression. Table 2B provides predictive markers which are upregulated indicators of response and/or correlate with longer time to progression.

Table 3 sets forth predictive markers identified which do not distinguish between response to proteasome inhibition therapy and response to glucocorticoid therapy, rather are indicator predictive markers of response/longer time to progression or non-response/shorter time to progression with regard to either therapy, and are indicators of general disease aggressiveness. Marker nos. 1203-1423 in Table 3 are newly associated predictive markers, and predictive markers no. 1424-1474 have been previously identified as associated markers predictive of non-response/correlation with shorter time to progression and/or response/correlation with longer time to progression related to advanced stage patient's response to bortezomib treatment. See, International Patent Publication No. WO04053066, published Jun. 24, 2004.

In the methods of the present invention, the level of expression of one or more predictive markers selected from the group consisting of the markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3, is determined. As used herein, the level or amount of expression refers to the absolute level of expression of an mRNA encoded by the marker or the absolute level of expression of the protein encoded by the marker (i.e., whether or not expression is or is not occurring in the cancer cells).

Generally, it is preferable to determine the expression of two or more of the identified responsive or non-predictive markers, or three or more of the identified responsive or non-predictive markers, or still further a larger a set of the identified responsive and/or non-predictive markers, selected from the predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3. For example, Table 4 sets forth marker sets identified using the methods described herein and can be used in the methods of the present invention. Still further, additional and/or alternative marker sets comprising the predictive markers identified herein can be generated using the methods and predictive markers provided. Thus, it is possible to assess the expression of a panel of responsive and non-predictive markers using the methods and compositions provided herein.

As an alternative to making determinations based on the absolute expression level of selected markers, determinations may be based on normalized expression levels. Expression levels are normalized by correcting the absolute expression level of a predictive marker by comparing its expression to the expression of a reference marker that is not a predictive marker, e.g., a housekeeping gene that is constitutively expressed. Suitable markers for normalization include housekeeping genes, such as the actin gene. Constitutively expressed genes are known in the art and can be identified and selected according to the relevant tissue and/or situation of the patient and the analysis methods. Such normalization allows one to compare the expression level in one sample, e.g., a tumor sample, to another sample, e.g., a non-tumor sample, or between samples from different sources.

Further, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker or marker set, the level of expression of the predictive marker or marker set is determined for 10 or more individual samples, preferably 50 or more individual samples in order to establish a baseline, prior to the determination of the expression level for the sample in question. To establish a baseline measurement, mean expression level of each of the predictive markers or marker sets assayed in the larger number of samples is determined and this is used as a baseline expression level for the predictive markers or marker sets in question. The expression level of the marker or marker set determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker or marker set. This provides a relative expression level and aids in identifying extreme cases of responsive or non-responsive-ness.

Determining Responsiveness or Non-Responsiveness to an Agent

The expression level (including protein level) of the identified predictive markers of responsive/non-responsive patients and may be used to: 1) determine if a patient can be treated by an agent or combination of agents; 2) determine if a patient is responding to treatment with an agent or combination of agents; 3) select an appropriate agent or combination of agents for treating a patient; 4) monitor the effectiveness of an ongoing treatment; 5) identify new cancer therapy treatments (either single agent proteasome inhibitor and/or glucocorticoid agents or complementary agents which can be used alternatively or in combination with proteasome inhibition and/or glucocorticoid agents); 6) identify aggressiveness of a cancer; and 7) select an appropriate agent or combination of agents in treating early and late recurrence of a cancer. In particular, the identified predictive markers may be utilized to determine appropriate therapy, to monitor clinical therapy and human trials of a drug being tested for efficacy, and to develop new agents and therapeutic combinations.

A cancer may be predisposed to respond to an agent if one or more of the corresponding predictive markers identified in Table 1B, Table 2B, and Table 3 (as indicated by (+) in Table 3) demonstrate increased expression. In certain aspects of the invention, the predisposition of a cancer to be responsive to an agent is determined by the methods of the present invention, wherein informative expression of the individual predictive markers of the marker sets identified in Table 4 is evaluated. Likewise, the predisposition of a patient to be responsive to an agent is determined by the methods of the present invention, wherein a marker set generated using to the methods described herein wherein the markers comprising the marker set include predictive markers set forth in Table 1B, Table 2B, and Table 3, and the expression of the marker set is evaluated.

A cancer may be predisposed to non-responsiveness to an agent if one or more of the corresponding non-predictive markers demonstrates informative expression levels. A cancer may be predisposed to non-responsiveness to an agent if one or more of the corresponding predictive markers identified in Table 1A, Table 2A, and Table 3 (as indicated by (−) in Table 3) demonstrate informative increased expression. In certain aspects of the invention, the predisposition of a cancer to be non-responsive to an agent is determined by the methods of the present invention, wherein informative expression of the individual predictive markers of the marker sets identified in Table 4 is evaluated. Likewise, the predisposition of a patient to be non-responsive to an agent is determined by the methods of the present invention, wherein a marker set is generated using the methods described herein wherein the markers comprising the marker set include predictive markers set forth in Table 1A, Table 2A, and/or Table 3, and the expression of the marker set is evaluated.

In one aspect, the predictive marker set for evaluation of a cancer predisposed to respond or predisposed to not respond to a therapy comprises markers selected from those set forth in any of Table 1A Table 1B, Table 2A Table 2B and Table 3. Still a further aspect contemplates markers set forth in either Table 1A and Table 1B alone or in combination with markers set for the in Table 2A and Table 2B and/or Table 3, or alternatively, those markers set forth in Table 2A and Table 2B alone or in combination with Table 1A and Table 1B and/or Table 3. In still another aspect the predictive marker or markers evaluated are selected from those set forth in Table 3. In certain aspects, the marker set is selected from those set forth in Table 4. According to the methods, proteasome inhibition therapy and/or glucocorticoid therapy would be continued where the expression profile indicates continued responsiveness, or decreased non-responsiveness using the evaluation methods described herein.

The present invention provides methods for determining whether a cancer therapy e.g., a proteasome inhibitor and/or glucocorticoid agent, can be used to reduce the growth rate of a tumor comprising evaluating expression of at least one predictive marker or a predictive marker set in a tumor sample; and identifying that proteasome inhibition therapy and/or glucocorticoid therapy is or is not appropriate to reduce the growth rate of the tumor based on the evaluation.

The invention provides a method for determining whether a proteasome inhibition therapeutic regimen (e.g., a proteasome inhibitor agent (e.g., bortezomib) alone or in combination with another chemotherapeutic agent) can be used to reduce the growth rate of a tumor comprising determining the expression profile of a predictive marker or predictive marker set; and identifying that a proteasome inhibition therapeutic agent is or is not appropriate to reduce the growth rate of the myeloma cells based on the expression profile.

Additionally provided are methods for determining whether a proteasome inhibitor therapy can be used to reduce the growth of a tumor, comprising obtaining a sample of tumor cells, evaluating the expression of one or more individual markers or a marker set, both in tumor cells exposed to the agent and in tumor cells that have not been exposed to the proteasome inhibition therapy; and identifying that an agent is or is not appropriate to treat the tumor based on the evaluation.

The invention provides a method for determining whether a glucocorticoid regimen (e.g., glucocorticoidal steroid agent (e.g., dexamethasone) alone or in combination with another chemotherapeutic agent) can be used to reduce the growth rate of a tumor comprising determining the expression profile of a predictive marker or predictive marker set; and identifying that a glucocorticoid therapeutic agent is or is not appropriate to reduce the growth rate of the tumor based on the expression profile.

Additionally provided are methods for determining whether a glucocorticoid therapy can be used to reduce the growth of a tumor, comprising obtaining a sample of tumor cells, evaluating the expression of one or more individual markers or a marker set, both in tumor cells exposed to the agent and in tumor cells that have not been exposed to the glucocorticoid therapy; and identifying that an agent is or is not appropriate to treat the tumor based on the evaluation.

In such methods, a proteasome inhibition therapy and/or glucocorticoid therapy regimen is determined appropriate to treat the tumor when the expression profile of the predictive marker or predictive marker set demonstrates increased responsiveness or decreased non-responsiveness according to the expression profile of the predictive markers in the presence of the agent.

The invention also provides a method for determining whether treatment with an proteasome inhibitor therapy should be initiated in in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining one or more samples, followed by determining the level of expression of one or more markers which correspond to markers identified in any of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 in the sample; and initiating proteasome inhibitor therapy when the expression profile of the predictive markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a responsive patient to such treatment. Alternatively, the treatment is not initiated when the expression profile of the predictive markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a non-responsive patient to treatment.

The invention also provides a method for determining whether treatment with proteasome inhibition therapy should be initiated in in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining one or more samples of tumor cells from a patient, followed by determining the expression profile in the sample of a predictive marker set comprising markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3; and initiating the proteasome inhibitor treatment when the expression profile of the predictive markers identified in Table 1A, Table 1 B, Table 2A, Table 2B, and Table 3 is indicative of a responsive patient. Alternatively, the treatment is not initiated when the expression profile of the predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3 is indicative of a non-responsive patient.

The invention also provides a method for determining whether treatment with an glucocorticoid therapy should be initiated in in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining one or more samples, followed by determining the level of expression of one or more markers which correspond to markers identified in any of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 in the sample; and initiating glucocorticoid therapy when the expression profile of the predictive markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a responsive patient to such treatment. Alternatively, the treatment is not initiated when the expression profile of the predictive markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a non-responsive patient to treatment.

The invention also provides a method for determining whether treatment with glucocorticoid therapy should be initiated in in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining one or more samples of tumor cells from a patient, followed by determining the expression profile in the sample of a predictive marker set comprising markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3; and initiating the glucocorticoid treatment when the expression profile of the predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a responsive patient. Alternatively, the treatment is not initiated when the expression profile of the predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3 is indicative of a non-responsive patient.

Monitoring the Effectiveness of an Anti-Cancer Agent

As discussed above, the identified responsive and non-predictive markers can be used as pharmacodynamic markers to assess whether the tumor has become refractory to an ongoing treatment (e.g., a proteasome inhibition therapy and/or glucocorticoid therapy). When the cancer is not responding to a treatment the expression profile of the tumor cells will change: the level or relative expression of one or more of the predictive markers (e.g., those predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, Table 3) such that the expression profile represents a non-responsive patient.

In one such use, the invention provides methods for determining whether a cancer therapy comprising proteasome inhibition therapy and/or glucocorticoid therapy should be continued in a cancer patient, comprising determining the expression of at least one predictive marker or a marker set, wherein the markers are selected from those set forth in any of Table 1A, Table 1B, Table 2A, Table 2B, or Table 3, in a tumor sample of a patient exposed to a proteasome inhibition therapy and/or glucocorticoid therapy; and continuing treatment when the expression profile of the marker or marker set demonstrates responsiveness to the agent being used.

In another such use, the invention provides methods for determining whether a proteasome inhibition therapy and/or glucocorticoid therapy should be discontinued in a cancer patient, comprising determining the expression of at least one predictive marker or a predictive marker set, wherein the markers are selected from those set forth in any of Table 1A, Table 1B, Table 2A, Table 2B, or Table 3 in a tumor sample of a patient exposed to a proteasome inhibition therapy and/or glucocorticoid therapy; and discontinuing or altering treatment when the expression profile of the markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, or Table 3 demonstrates non-responsiveness to the agent being used.

As used herein, a patient refers to any subject undergoing proteasome inhibition therapy and/or glucocorticoid therapy for cancer treatment. The subject may be a human patient undergoing proteasome inhibition (e.g., bortezomib or other related agent) and/or glucocorticoid (e.g., dexamethasone) therapy using a sole therapeutic agent. The subject may be a human patient undergoing proteasome inhibition (e.g., bortezomib or other related agent) and/or glucocorticoid (e.g., dexamethasone) therapy using a therapeutic agent in conjunction with another agent (e.g., a chemotherapy treatment). The present invention also includes comparing two or more samples obtained from a patient undergoing anti-cancer treatment including proteasome inhibition therapy and/or glucocorticoid therapy. In general, it is conceivable to obtain a first sample from the patient prior to beginning therapy and one or more samples during treatment. In such a use, a baseline of expression prior to therapy is determined, then changes in the baseline state of expression is monitored during the course of therapy. Alternatively, two or more successive samples obtained during treatment can be used without the need of a pre-treatment baseline sample. In such a use, the first sample obtained from the subject is used as a baseline for determining whether the expression of a particular marker or marker set is increasing or decreasing.

In general, when monitoring the effectiveness of a therapeutic treatment, two or more samples from a patient are examined. In another aspect, three or more successively obtained samples are used, including at least one pretreatment sample.

The invention provides methods for determining whether treatment with a proteasome inhibitor therapy regimen should be continued in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining two or more samples of tumor cells from a patient at different times during the course of a proteasome inhibition therapy regimen, followed by evaluating the expression of one or more markers which correspond to markers identified in any of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 in the two or more samples; and continuing the treatment when the expression profile of the predictive markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a responsive patient during the course of the treatment. In such methods, a proteasome inhibition therapy and regimen is determined appropriate to treat the patient when the expression profile of the predictive marker or predictive marker set demonstrates increased responsiveness or decreased non-responsiveness according to the expression profile of the predictive markers in the presence of the agent.

Additionally provided are methods for determining whether treatment with a proteasome inhibitor therapy regimen should be continued in in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining two or more samples of tumor cells from a patient at different times during the course of anti-cancer therapy treatment, followed by evaluating the expression of of a predictive marker set comprising markers identified in any of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 in the two or more samples; and continuing the treatment when the expression profile of the predictive marker set indicates increased responsiveness or decreased non-responsiveness according to the expression during the course of treatment. Alternatively, the treatment is discontinued when the expression profile of the marker set demonstrates decreased responsiveness and/or increased non-responsiveness during the course of treatment.

The invention provides methods for determining whether treatment with a glucocorticoid therapy regimen should be continued in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining two or more samples of tumor cells from a patient at different times during the course of a glucocorticoid therapy regimen, followed by evaluating the expression of one or more markers which correspond to markers identified in any of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 in the two or more samples; and continuing the treatment when the expression profile of the predictive markers identified in any one of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is indicative of a responsive patient during the course of treatment. In such methods, a glucocorticoid therapy regimen is determined appropriate to treat the patient when the expression profile of the predictive marker or predictive marker set demonstrates increased responsiveness or decreased non-responsiveness according to the expression profile of the predictive markers in the presence of the agent.

Additionally provided are methods for determining whether treatment with a glucocorticoid therapy regimen should be continued in in a patient selected from a multiple myeloma patient, a lymphoma patient, a leukemia patient, a lung cancer patient, a breast cancer patient, and an ovarian cancer patient, a prostate cancer patient, a colon cancer patient, a kidney cancer patient, and a liver cancer patient; comprising obtaining two or more samples of tumor cells from a patient at different times during the course of a glucocorticoid therapy regimen, followed by evaluating the expression of of a predictive marker set comprising markers identified in any of Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 in the two or more samples; and continuing the treatment when the expression profile of the predictive marker set indicates increased responsiveness or decreased non-responsiveness according to the expression during the course of treatment. Alternatively, the treatment is discontinued when the expression profile of the marker set demonstrates decreased responsiveness and/or increased non-responsiveness during the course of treatment.

The invention certain aspects of the invention relate to methods of treatment and/or diagnosis of a patient with cancer utilizing samples. The source of the cancer cells used in the present methods will be based on how the method of the present invention is being used. For example, if the method is being used to determine whether a patient's cancer can be treated with an agent, or a combination of agents, then the preferred source of sample will be cancer cells obtained from a tumor from the patient, e.g., a tumor biopsy (including a solid or a liquid tumor), a blood sample, a plasma sample, a urine sample, a saliva sample, a lymph sample or other sample can be used. A sample obtained from a tumor can be enriched for tumor cells to increase the specificity of the analysis. A variety of methods known in the art can be used to enrich for tumor cells, including differential centrifugation, fluorescence cell sorting analysis (FACS), isolating cells based on growth independent of substrate attachment, binding to a selection agent, e.g. to an antibody to a tumor marker and furthermore attaching the antibody and thus the bound tumor cell to a solid support, etc. Alternatively, a cancer cell line similar to the type of cancer being treated can be assayed. For example, if multiple myeloma is being treated, then a myeloma cell line can be used. If the method is being used to predict or monitor the effectiveness of a therapeutic protocol, then a tissue or blood sample from a patient being treated is a preferred source. If the method is being used to determine the activity of an agent, the efficacy of an agent, or identify new therapeutic agents or combinations, any cancer cells, e.g., cells of a cancer cell line, cells isolated from a tumor of an animal model, can be used.

A skilled artisan can readily select and obtain the appropriate cancer cells that are used in the present method. For cancer cell lines, sources such as The National Cancer Institute, for the NCI-60 cells, are preferred. For cancer cells obtained from a patient, standard biopsy methods, such as a needle biopsy, can be employed.

Myeloma samples were used to identify the markers of the present invention. Further, the expression level of markers can be evaluated in other tissue types including disorders of related hematological cell types, including, e.g., Waldenstroms macrogobulinemia, Myelodysplastic syndrome and other hematological cancers including lymphomas, leukemias, as well as tumors of various solid tissues. It will thus be appreciated that cells from other hematologic malignancies including, e.g., B-cell Lymphomas, Non-Hodgkins Lymphoma, Waldenstrom's syndrome, or other leukemias will be useful in the methods of the present invention. Still further, the predictive markers predicting disease aggressiveness as well as responsiveness and non-responsiveness to proteasome inhibition therapeutic agents in solid tumors (e.g., lung, breast, prostate, ovary, colon, kidney, and liver), can also be useful in the methods of the present invention.

Preferably, the samples used will be from similar tumors or from non-cancerous cells of the same tissue origin as the tumor in question. The choice of the cell source is dependent on the use of the relative expression level data. For example, using tumors of similar types for obtaining a mean expression score allows for the identification of extreme cases of responsive or non-responsive-ness. Using expression found in normal tissues as a mean expression score aids in validating whether the responsive/non-predictive marker or marker set assayed is tumor specific (versus normal cells). Such a later use is particularly important in identifying whether a responsive or non-predictive marker or marker set can serve as a target marker or marker set. In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data.

Detection Assays

Various methods are available to examine the expression of the markers, including gene array/chip technology, RT-PCR, in-situ hybridization, immunohistochemistry, immunoblotting, FISH (fluorescence in-situ hybridization), FACS analyses, northern blot, southern blot or cytogenetic analyses. A skilled artisan can select from these or other appropriate and available methods based on the nature of the marker(s), tissue sample and disease in question. Different methods or combinations of methods could be appropriate in different cases or, for instance in different solid or hematological tumor types.

In certain aspects of the invention, the expression of predictive marker or markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is detected by measuring mRNA which corresponds to the predictive marker or marker set. In yet another aspects of the invention, the expression of markers which correspond to markers or marker sets identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3, is detected by measuring protein which corresponds to the marker or marker set.

An exemplary method for detecting the presence or absence of a nucleic acid or polypeptide corresponding to a marker of the invention in a biological sample involves obtaining a biological sample (e.g. a tumor sample) from a test subject and contacting the biological sample with a compound or an agent capable of detecting the polypeptide or nucleic acid (e.g., mRNA, genomic DNA, or cDNA). The detection methods of the invention can thus be used to detect mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include Northern hybridizations. in situ hybridizations, and TaqMan assays (Applied Biosystems) under GLP approved laboratory conditions. In vitro techniques for detection of a polypeptide corresponding to a marker of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of a polypeptide corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

A general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways.

For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one example of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another example, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay. One example of such an example includes use of an array or chip which contains a predictive marker or marker set anchored for expression analysis of the sample.

There are many established methods for anchoring assay components to a solid phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain aspects, the surfaces with immobilized assay components can be prepared in advance and stored. Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polyethylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein. In one example, when the probe is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.

It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz et al., U.S. Pat. No. 5,631,169; Stavrianopoulos, et al., U.S. Pat. No. 4,868,103). A fluorophore label on the first, ‘donor’ molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second ‘acceptor’ molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the ‘donor’ protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the ‘acceptor’ molecule label may be differentiated from that of the ‘donor’. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the ‘acceptor’ molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

In another example, determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C., 1991, Anal. Chem. 63:2338-2345 and Szabo et al., 1995, Curr. Opin. Struct. Biol. 5:699-705). As used herein, “BIA” or “surface plasmon resonance” is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

Alternatively, in another example, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A. P., 1993, Trends Biochem Sci. 18(8):284-7). Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, N. H., 1998, J Mol. Recognit. Winter 11(1-6):141-8; Hage, D. S., and Tweed, S. A. J Chromatogr B Biomed Sci Appl 1997 Oct. 10; 699(1-2):499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typically preferred. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.

The level of mRNA corresponding to the marker can be determined both by in situ and by in vitro formats in a biological sample using methods known in the art. The term “biological sample” is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject. Many expression detection methods use isolated RNA. For in vitro methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from tumor cells (see, e.g., Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Pat. No. 4,843,155).

One diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention. Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.

In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.

An alternative method for determining the level of mRNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by rtPCR (the experimental description set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA, 88:189-193), self sustained sequence replication (Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al., 1989, Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et aL, 1988, Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5′ or 3′ regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For in situ methods, mRNA does not need to be isolated from the cancer cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

As an alternative to making determinations based on the absolute expression level of the marker, determinations may be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a reference gene that is not a marker, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, e.g., a patient sample, to another sample, e.g., a non-cancer sample, or between samples from different sources.

Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker is determined for 10 or more samples of normal versus cancer cell isolates, preferably 50 or more samples, prior to the determination of the expression level for the sample in question. The mean expression level of each of the markers and marker sets assayed in the larger number of samples is determined and this is used as a baseline expression level for the marker. The expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.

In another aspect of the present invention, a polypeptide corresponding to a marker is detected. A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)₂) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, enzyme immunoassay (ETA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether a sample comprising cancer cells express a marker of the present invention.

In one format, antibodies, or antibody fragments, can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from tumor cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

Another method for determining the level of a polypeptide corresponding to a marker is mass spectrometry. For example, intact proteins or peptides, e.g., tryptic peptides can be analyzed from a sample, e.g., a tumor sample, blood, plasma, urine, etc, containing one or more polypeptide markers. The method can further include treating the sample to lower the amounts of abundant proteins, e.g. serum albumin, to increase the sensitivity of the method. For example, liquid chromatography can be used to fractionate the sample so portions of the sample can be analyzed separately by mass spectrometry. The steps can be performed in separate systems or in a combined liquid chromatography/mass spectrometry system (LC/MS, see for example, Liao, et al. Arthritis Rheum. 50:3792-3803 (2004)). The mass spectrometry system also can be in tandem (MS/MS) mode. The charge state distribution of the protein or peptide mixture can be acquired over one or multiple scans and analyzed by statistical methods, e.g. using the retention time and mass-to-charge ratio (m/z) in the LC/MS system, to identify proteins expressed at statistically significant levels differentially in samples from patients responsive or non-responsive to proteasome inhibition and/or glucocorticoid therapy. Examples of mass spectrometers which can be used are an ion trap system (ThermoFinnigan, San Jose, Calif.) or a quadrupole time-of-flight mass spectrometer (Applied Biosystems, Foster City, Calif.). The method can further include the step of peptide mass fingerprinting, e.g. in a matrix-assisted laser desorption ionization with time-of-flight (MALDI-TOF) mass spectrometry method. The method can further include the step of sequencing one or more of the tryptic peptides. Results of this method can be used to identify proteins from primary sequence databases, e.g. maintained by the National Center for Biotechnology Information, Bethesda, Md., or the Swiss Institute for Bioinformatics, Geneva, Switzerland, and based on mass spectrometry tryptic peptide m/z base peaks.

Electronic Apparatus Readable Arrays

Electronic apparatus, including readable arrays comprising at least one predictive marker of the present invention is also contemplated for use in conjunction with the methods of the invention. As used herein, “electronic apparatus readable media” refers to any suitable medium for storing, holding or containing data or information that can be read and accessed directly by an electronic apparatus. As used herein, the term “electronic apparatus” is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the present invention and monitoring of the recorded information include stand-alone computing apparatus; networks, including a local area network (LAN), a wide area network (WAN) Internet, Intranet, and Extranet; electronic appliances such as a personal digital assistants (PDAs), cellular phone, pager and the like; and local and distributed processing systems. As used herein, “recorded” refers to a process for storing or encoding information on the electronic apparatus readable medium. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising the markers of the present invention.

For example, microarray systems are well known and used in the art for assessment of samples, whether by assessment gene expression (e.g., RNA detection, protein detection), or metabolite production, for example. Microarrays for use according to the invention include one or more probes of predictive marker(s) of the invention characteristic of response and/or non-response to a therapeutic regimen as described herein. In one embodiment, the microarray comprises one or more probes corresponding to one or more of markers selected from the group consisting of markers which demonstrate increased expression in responsive patients, and genes which demonstrate non-response in patients. A number of different microarray configurations and methods for their production are known to those of skill in the art and are disclosed, for example, in U.S. Pat. Nos. 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,556,752; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,561,071; 5,571,639; 5,593,839; 5,624,711; 5,700,637; 5,744,305; 5,770,456; 5,770,722; 5,837,832; 5,856,101; 5,874,219; 5,885,837; 5,919,523; 5,981,185; 6,022,963; 6,077,674; 6,156,501; 6,261,776; 6,346,413; 6,440,677; 6,451,536; 6,576,424; 6,610,482; 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,848,659; and 5,874,219; Shena, et al., Tibtech 16:301, 1998; Duggan, et al., Nat. Genet. 21:10, 1999; Bowtell, et al., Nat. Genet. 21:25, 1999; Lipshutz, et al., 21 Nature Genet. 20-24, 1999; Blanchard, et al., 11 Biosensors and Bioelectronics, 687-90, 1996; Maskos, et al., 21 Nucleic Acids Res. 4663-69, 1993; Hughes, et al., Nat. Biotechol. 19:342, 2001; each of which are herein incorporated by reference. A tissue microarray can be used for protein identification (see Hans et al Blood 103:275-282 (2004)). A phage-epitope microarray can be used to identify one or more proteins in a sample based on whether the protein or proteins induce auto-antibodies in the patient (Bradford et al. Urol. Oncol. 24:237-242 (2006)).

A microarray thus comprises one or more probes corresponding to one or more predictive markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and Table 3. The microarray may comprise probes corresponding to, for example, at least 10, at least 20, at least 50, at least 100, or at least 1000 predictive markers of the invention characteristic of patient response to proteasome inhibition therapy and/or glucocorticoid therapy. The microarray may comprise probes corresponding to one or more predictive markers as set forth herein. Still further, the microarray may comprise complete marker sets as set forth herein and which may be selected and compiled according to the methods set forth herein. The microarray can be used to assay expression of one or more predictive markers or predictive marker sets in the array. In one example, the array can be used to assay more than one predictive marker or marker set expression in a sample to ascertain an expression profile of markers in the array. In this manner, up to about 44,000 markers can be simultaneously assayed for expression. This allows a profile to be developed showing a battery of markers specifically expressed in one or more samples. Still further, this allows a profile to be developed to assess responsiveness to one or more therapies (e.g., glucocorticoid therapy or proteasome inhibition therapy).

The array is also useful for ascertaining differential expression patterns of one or more markers in normal and abnormal (e.g., sample, e.g., tumor) cells. This provides a battery of predictive markers that could serve as a tool for ease of identification of responsive and non-responsive patients. Further, the array is useful for ascertaining expression of reference markers for reference expression levels. In another example, the array can be used to monitor the time course of expression of one or more predictive markers in the array.

In addition to such qualitative determination, the invention allows the quantitation of marker expression. Thus, predictive markers can be grouped on the basis of marker sets or responsive and non-responsive indications by the level of expression in the sample. This is useful, for example, in ascertaining the responsive or non-responsive indication of the sample by virtue of scoring the expression levels according to the methods provided herein.

The array is also useful for ascertaining the effect of the expression of a marker on the expression of other predictive markers in the same cell or in different cells. This provides, for example, a selection of alternate molecular targets for therapeutic intervention if the proteasome inhibition regimen and/or glucocorticoid therapy regimen is non-responsive.

Reagents and Kits

The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a sample (e.g. a tumor sample). Such kits can be used to determine if a subject is predisposed to response or non-response to an anti-cancer therapy regimen. In another aspect, the invention provides a test kit for monitoring the efficacy of a compound or therapeutic in a sample. For example, the kit may comprise a labeled probe capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker of the invention in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits may further include instructions for use of the provided kits and interpreting the results obtained using the kit; additional reagents for preparation of probes for use in the methods provided; and detectable label, alone or conjugated to the provided probe(s).

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention; (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention; or (3) a marker set comprising oligonucleotides which hybridize to at least two nucleic acid sequences encoding polypeptide predictive markers of the invention. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). For marker sets, the kit can comprise a marker set array or chip for use in detecting the predictive markers. The kit can also contain a reference sample or a series of reference samples which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

Therapeutic Agents

The markers and marker sets of the present invention are predictive of patients who are responsive or non-responsive (sensitive or resistant) proteasome inhibition therapy and/or glucocorticoid therapy regimens, generally.

Therapeutic agents for use in the methods of the invention include a class of therapeutic agents known as proteosome inhibitors. “Proteasome inhibitor” shall mean any substance which directly or indirectly inhibits the 20S or 26S proteasome or the activity thereof. Preferably, such inhibition is specific, i.e., the proteasome inhibitor inhibits proteasome activity at a concentration that is lower than the concentration of the inhibitor concentration required to produce another, unrelated biological effect. Preferably, the concentration of the proteasome inhibitor required for proteasome inhibition is at least 2-fold lower, more preferably at least 5-fold lower, even more preferably at least 10-fold lower, and most preferably at least 20-fold lower than the concentration required to produce an unrelated biological effect. Proteasome inhibitor compounds of this invention are those compounds which are useful for inhibiting tumor growth, (e.g., multiple myeloma tumor growth, other hematological or solid tumors as described in further detail herein) in patients. Proteasome inhibitor also is intended to include pharmaceutically acceptable salts of the compounds.

Proteasome inhibition therapy, generally comprises at least an agent which inhibits proteasome activity in a cell, and can comprise additional therapeutic agents. In certain applications of the invention, the agent used in methods of the invention is a proteasome inhibitor. One example of a proteosome inhibitor has been approved for treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy and is presently being tested in clinical trials for additional indications is bortezomib. Proteasome inhibition therapy regimens can also include additional therapeutic agents such as chemotherapeutic agents. Some examples of traditional chemotherapeutic agents are set forth in Table A. Alternatively or in combination with these chemotherapeutic agents, newer classes of chemotherapeutic agents can also be used in proteasome inhibition therapy.

The examples described herein entail use of the proteasome inhibitor N-pyrazinecarbonyl-L-phenylalanine-L-leucineboronic acid, bortezomib ((VELCADE™); formerly known as MLN341 or PS-341). The language “proteasome inhibitor” is intended to include bortezomib, compounds which are structurally similar to bortezomib and/or analogs of bortezomib. “Proteasome inhibitor” can also include “mimics”. “Mimics” is intended to include compounds which may not be structurally similar to bortezomib but mimic the therapeutic activity of bortezomib or structurally similar compounds in vivo.

Proteasome inhibitors for use in the practice of the invention include additional peptide boronic acids such as those disclosed in Adams et al., U.S. Pat. No. 5,780,454 (1998), U.S. Pat. No. 6,066,730 (2000), U.S. Pat. No. 6,083,903 (2000), U.S. Pat. No. 6,548,668 (2003), and Siman et al. WO 91/13904, each of which is hereby incorporated by reference in its entirety, including all compounds and formulae disclosed therein. Preferably, a boronic acid compound for use in the present invention is selected from the group consisting of: N-(4-morpholine)carbonyl.-beta.-(1-naphthyl)-L-alanine-L-leucine boronic acid; N-(8-quinoline)sulfonyl-.beta.-(1-naphthyl)-L-alanine-L-alanine-L-leucine boronic acid; N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid, and N-(4-morpholine)carbonyl-[O-(2-pyridylmethyl)]-L-tyrosine-L-leucine boronic acid.

Additionally, proteasome inhibitors include peptide aldehyde proteasome inhibitors such as those disclosed in Stein et al. U.S. Pat. No. 5,693,617 (1997), and International patent publications WO 95/24914 published Sep. 21, 1995 and Siman et al. WO 91/13904 published Sep. 19, 1991; Iqbal et al. J. Med. Chem. 38:2276-2277 (1995), as well as Bouget et al. Bioorg Med Chem 17:4881-4889 (2003) each of which is hereby incorporated by reference in its entirety, including all compounds and formulae disclosed therein.

Further, proteasome inhibitors include lactacystin and lactacycstin analogs which have been disclosed in Fentany et al, U.S. Pat. No. 5,756,764 (1998), and U.S. Pat. No. 6,147,223(2000), Schreiber et al U.S. Pat. No. 6,645,999 (2003), and Fenteany et al. Proc. Natl. Acad. Sci. USA (1994) 91:3358, each of which is hereby incorporated by reference in its entirety, including all compounds and formulae disclosed therein.

Additionally, synthetic peptide vinyl sulfone proteasome inhibitors and epoxyketone proteasome inhibitors have been disclosed and are useful in the methods of the invention. See, e.g., Bogyo et al., Proc. Natl. Acad. Sci. 94:6629 (1997); Spaltenstein et al. Tetrahedron Lett. 37:1343 (1996); Meng L, Proc. Natl. Acad Sci 96: 10403 (1999); and Meng L H, Cancer Res 59: 2798 (1999), each of which is hereby incorporated by reference in its entirety.

Still further, naturally occuring compounds have been recently shown to have proteasome inhibition activity can be used in the present methods. For example, TMC-95A, a cyclic peptide, or Gliotoxin, both fungal metabolites or polyphenols compounds found in green tea have been identified as proteasome inhibitors. See, e.g., Koguchi Y, Antibiot (Tokyo) 53:105. (2000); Kroll M, Chem Biol 6:689 (1999); and Nam S, J. Biol Chem 276: 13322(2001), each of which is hereby incorporated by reference in its entirety.

Additional therapeutic agents for use in the methods of the invention comprise a known class of therapeutic agents comprising glucocorticoid steroids. Glucocorticoid therapy, generally comprises at least one glucocorticoid agent (e.g., dexamethasone). In certain applications of the invention, the agent used in methods of the invention is a glucocorticoid agent. One example of a glucocorticoid utilized in the treatment of multiple myeloma patients as well as other cancer therapies is dexamethasone. Additional glucocorticoids utilized in treatment of hematological and combination therapy in solid tumors include hydrocortisone, predisolone, prednisone, and triamcinolone. Glucocorticoid therapy regimens can be used alone, or can be used in conjunction with additional chemotherapeutic agents. Chemotherapeutic agents are known in the art and described in further detail herein. Examples of chemotherapeutic agents are set forth in Table A. As with proteasome inhibition therapy, new classes of cancer therapies may be combined with glucocorticoid therapy regimens as they are developed. Finally, the methods of the invention include combination of proteasome inhibition therapy with glucocorticoid therapy, either alone, or in conjunction with further agents.

In one aspect, one or more of the markers listed in any one of Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3, can be used to identify candidate agents for use in a treatment regimen which will produce a response in a patient. For example, the method can identify an agent or a combination of agents useful as a proteasome inhibitor. In another example, the method can identify an agent or combination of glucocorticoids. In another example, the method can identify a set of patients likely to be non-responsive to current therapies, and therefore good candidates for inclusion in a clinical trial of a drug aimed at meeting the unmet need of non-responsive patients. For example, a marker or marker set associated with non-response to bortezomib can identify a patient or a test system comprising the capacity to express the marker or marker set. The method can identify a candidate agent which achieves a response in such a patient or test system. In the method, an assay composition comprising a cell, e.g. a tumor cell, capable of expressing a marker or a plurality of markers listed in any one of Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3 is contacted with the test agent, e.g. for an amount of time for the test agent to affect the level of marker, detecting the level of the marker and comparing the level to the level in a reference cell, e.g., a cell contacted with a known proteasome inhibitor (e.g., bortezomib) or glucocorticoid (e.g., dexamethasone) or a normal cell, and identifying the agent as a candidate proteasome inhibitor or glucocorticoid if the test agent produces an informative expression level of the marker or markers typical of a responsive patient. Conversely, the test agent may not be identified as a candidate agent if it is used in the method and produces an informative expression level typical of a non-responsive patient. The assay composition can comprise a tumor cell isolated from a patient with cancer, e.g. a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or cancer from a solid tumor (e.g., in lung, breast, prostate, ovary, colon, kidney or liver). Alternatively, the assay composition can comprise a tumor cell line. The composition comprising the cell can be an in vivo tumor model, e.g. an immunocompromised mouse or a rat with an ectopic, e.g. subcutaneous or ascites, tumor, e.g. a human tumor. The assay composition can be a human subject.

Further to the above, the language, proteasome inhibition therapy regimen and/or glucocorticoid therapy regimen can include additional agents in addition to proteasome inhibition agents, including chemotherapeutic agents. A “chemotherapeutic agent” is intended to include chemical reagents which inhibit the growth of proliferating cells or tissues wherein the growth of such cells or tissues is undesirable. Chemotherapeutic agents such as anti-metabolic agents, e.g., Ara AC, 5-FU and methotrexate, antimitotic agents, e.g., taxane, vinblastine and vincristine, alkylating agents, e.g., melphanlan, BCNU and nitrogen mustard, Topoisomerase II inhibitors, e.g., VW-26, topotecan and Bleomycin, strand-breaking agents, e.g., doxorubicin and DHAD, cross-linking agents, e.g., cisplatin and CBDCA, radiation and ultraviolet light. In a preferred embodiment, the agent is a proteasome inhibitor (e.g., bortezomib or other related compounds). are well known in the art (see e.g., Gilman A. G., et al., The Pharmacological Basis of Therapeutics, 8th Ed., Sec 12:1202-1263 (1990)), and are typically used to treat neoplastic diseases. The chemotherapeutic agents generally employed in chemotherapy treatments are listed below in Table A.

The agents tested in the present methods can be a single agent or a combination of agents. For example, the present methods can be used to determine whether a single chemotherapeutic agent, such as methotrexate, can be used to treat a cancer or whether a combination of two or more agents can be used in combination with a proteasome inhibitor (e.g., bortezomib) and/or a glucocorticoid agent (e.g., dexamethasone). Preferred combinations will include agents that have different mechanisms of action, e.g., the use of an anti-mitotic agent in combination with an alkylating agent and a proteasome inhibitor.

The agents disclosed herein may be administered by any route, including intradermally, subcutaneously, orally, intraarterially or intravenously. Preferably, administration will be by the intravenous route. Preferably parenteral administration may be provided in a bolus or by infusion.

The concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. The agent may be administered in a single dose or in repeat doses. Treatments may be administered daily or more frequently depending upon a number of factors, including the overall health of a patient, and the formulation and route of administration of the selected compound(s).

TABLE A Chemotherapeutic Agents TYPE OF NONPROPRIETARY NAMES CLASS AGENT (OTHER NAMES) Alkylating Nitrogen Mechlorethamine (HN₂) Mustards Cyclophosphamide Ifosfamide Melphalan (L-sarcolysin) Chlorambucil Ethylenimines Hexamethylmelamine And Thiotepa Methylmelamines Alkyl Sulfonates Busulfan Alkylating Nitrosoureas Carmustine (BCNU) Lomustine (CCNU) Semustine (methyl-CCNU) Streptozocin (streptozotocin) Alkylating Triazenes Decarbazine (DTIC; dimethyltriazenoimi- dazolecarboxamide) Alkylator cis-diamminedichloroplatinum II (CDDP) Antimetab- Folic Acid Methotrexate (amethopterin) olites Analogs Pyrimidine Fluorouracil (′5-fluorouracil; 5-FU) Analogs Floxuridine (fluorode-oxyuridine; FUdR) Cytarabine (cytosine arabinoside) Purine Analogs Mercaptopuine (6-mercaptopurine; 6-MP) and Related Thioguanine (6-thioguanine; TG) Inhibitors Pentostatin (2′-deoxycoformycin) Vinca Alkaloids Vinblastin (VLB) Vincristine Topoisomerase Etoposide Inhibitors Teniposide Camptothecin Topotecan 9-amino-campotothecin CPT-11 Natural Antibiotics Dactinomycin (actinomycin D) Products Adriamycin Daunorubicin (daunomycin; rubindomycin) Doxorubicin Bleomycin Plicamycin (mithramycin) Mitomycin (mitomycin C) TAXOL Taxotere Enzymes L-Asparaginase Natural Biological Interfon alfa Products Response Interleukin 2 Modifiers Platinum cis-diamminedichloroplatinum II (CDDP) Coordination Carboplatin Complexes Anthracendione Mitoxantrone Substituted Urea Hydroxyurea Miscellaneous Methyl Hydraxzine Procarbazine Agents Derivative (N-methylhydrazine, (MIH) Adrenocortical Mitotane (o,p′-DDD) Suppressant Aminoglutethimide Hormones and Progestins Hydroxyprogesterone caproate Antagonists Medroxyprogesterone acetate Megestrol acetate Estrogens Diethylstilbestrol Ethinyl estradiol Antiestrogen Tamoxifen Androgens Testosterone propionate Fluoxymesterone Antiandrogen Flutamide Gonadotropin- Leuprolide releasing Hormone analog Isolated Nucleic Acid Molecules, Vectors and Host Cells

One aspect of the invention pertains to isolated nucleic acid molecules that correspond to a predictive marker of the invention, including nucleic acids which encode a polypeptide corresponding to a predictive marker of the invention or a portion of such a polypeptide. Isolated nucleic acids of the invention also include nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules that correspond to a predictive marker of the invention, including nucleic acids which encode a polypeptide corresponding to a predictive marker of the invention, and fragments of such nucleic acid molecules, e.g., those suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

A nucleic acid molecule of the present invention, e.g., a nucleic acid encoding a protein corresponding to a marker listed in any one of Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3, can be isolated and manipulated (e.g., amplified, cloned, synthesized, etc.) using standard molecular biology techniques and the sequence information in the database records described herein. (e.g., described in Sambrook et al., ed., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence, wherein the full length nucleic acid sequence comprises a predictive marker of the invention or which encodes a polypeptide corresponding to a marker of the invention. Such nucleic acids can be used, for example, as a probe or primer. The probe/primer typically is used as one or more substantially purified oligonucleotides. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of a nucleic acid of the invention.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences corresponding to one or more predictive markers of the invention. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

In addition to the nucleotide sequences described in the database records described herein, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to naturally occurring allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation).

As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide corresponding to a marker of the invention, including, e.g., sequences which differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a protein which corresponds to a marker of the invention, and thus encode the same protein.

As used herein, the phrase “allelic variant” refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence. Such naturally occurring allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of naturally occurring allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

The present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid of the invention, e.g., complementary to the coding strand of a double-stranded cDNA molecule corresponding to a marker of the invention or complementary to an mRNA sequence corresponding to a marker of the invention. Accordingly, an antisense nucleic acid of the invention can hydrogen bond to (i.e. anneal with) a sense nucleic acid of the invention. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can also be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions (“5′ and 3′ untranslated regions”) are the 5′ and 3′ sequences which flank the coding region and are not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al., 1996, Bioorganic & Medicinal Chemistry 4(1): 5-23). As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93:14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), supra; or as probes or primers for DNA sequence and hybridization (Hyrup, 1996, supra; Perry-O'Keefe et al., 1996, Proc. Natl. Acad. Sci. USA 93:14670-675).

In another aspect, PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNASE H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup, 1996, supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), supra, and Finn et al. (1996) Nucleic Acids Res. 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5′ end of DNA (Mag et al., 1989, Nucleic Acids Res. 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment (Finn et al., 1996, Nucleic Acids Res. 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment (Peterser et al., 1975, Bioorganic Med. Chem. Lett. 5:1119-11124).

The oligonucleotide can include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The invention also includes molecular beacon nucleic acids having at least one region which is complementary to a marker of the invention, such that the molecular beacon is useful for quantitating the presence of the predictive marker of the invention in a sample. A “molecular beacon” nucleic acid is a nucleic acid comprising a pair of complementary regions and having a fluorophore and a fluorescent quencher associated therewith. The fluorophore and quencher are associated with different portions of the nucleic acid in such an orientation that when the complementary regions are annealed with one another, fluorescence of the fluorophore is quenched by the quencher. When the complementary regions of the nucleic acid are not annealed with one another, fluorescence of the fluorophore is quenched to a lesser degree. Molecular beacon nucleic acids are described, for example, in U.S. Pat. No. 5,876,930.

Vectors, including expression vectors, containing a nucleic acid encoding a polypeptide corresponding to a predictive marker of the invention can be used for production of nucleic acid and proteins corresponding to predictive markers of the invention; as well as for production of compositions relating to the predictive markers. Useful vectors further comprise promoter and/or regulatory sequences for effective expression of the nucleic acid and/or protein corresponding to the predictive marker of interest. In certain instances, promoters can include constitutive promoter/regulatory sequences, inducible promoter/regulatory sequences, tissue specific promoter/regulatory sequences, or the naturally occurring endogenous promoter/regulatory sequences corresponding to the predictive marker of interest, as required. Various expression vectors are well known in the art and can be adapted to suit the particular system for expression. For example, recombinant expression vectors of the invention can be designed for expression of a polypeptide corresponding to a marker of the invention in prokaryotic (e.g., E. coli) or eukaryotic cells (e.g., insect cells {using baculovirus expression vectors}, yeast cells or mammalian cells). Suitable host cells are known in the art and include those discussed in Goeddel, supra. Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase. Vectors and host cells can be produced using routine methodology known in the art. Furthermore, use of vectors and host cells can be utilized for production of nucleic acids, polypeptides and fragments thereof corresponding to markers of the invention.

Isolated Proteins and Antibodies

One aspect of the invention pertains to isolated proteins which correspond to predictive markers of the invention, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide corresponding to a predictive marker of the invention. Polypeptides for use in the invention can be isolated, purified, or produced using the gene identification information provided herein in combination with routine molecular biology, protein purification and recombinant DNA techniques well known in the art.

Preferred polypeptides have the amino acid sequence listed in the one of the GenBank and Entrez database records described herein. Other useful proteins are substantially identical (e.g., at least about 70%, preferably 80%, 90%, 95%, or 99%) to one of these sequences and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm determining the number of identical positions shared between two sequences. Determination can be carried out using any known method in the art for comparison of identity and similarity. Examples of methods used can include for example, a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and)(BLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (accessible at the website maintained by National Center for Biotechnology Information, Bethesda, Md., USA. Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448. When using the FASTA algorithm for comparing nucleotide or amino acid sequences, a PAM120 weight residue table can, for example, be used with a k-tuple value of 2. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

The invention also provides chimeric or fusion proteins corresponding to a marker of the invention. As used herein, a “chimeric protein” or “fusion protein” comprises all or part (preferably a biologically active part) of a polypeptide corresponding to a marker of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the polypeptide corresponding to the marker). Within the fusion protein, the term “operably linked” is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention. Useful fusion proteins can include GST, c-myc, FLAG, HA, and any other well known heterologous tag for use in fusion protein production. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

In addition, fusion proteins can include a signal sequence from another protein such as gp67, melittin, human placental alkaline phosphatase, and phoA. In yet another aspect, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide corresponding to a predictive marker of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

An isolated polypeptide corresponding to a predictive marker of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. For example, an immunogen typically is used to prepare antibodies by immunizing a suitable (i e immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The terms “antibody” and “antibody substance” as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention, e.g., an epitope of a polypeptide of the invention. A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab′)₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies. Synthetic and genetically engineered variants (See U.S. Pat. No. 6,331,415) of any of the foregoing are also contemplated by the present invention. Polyclonal and monoclonal antibodies can be produced by a variety of techniques, including conventional murine monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975) the human B cell hybridoma technique (see Kozbor et al., 1983, Immunol. Today 4:72), the EBV-hybridoma technique (see Cole et al., pp. 77-96 In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985) or trioma techniques. See generally, Harlow, E. and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; and Current Protocols in Immunology, Coligan et al. ed., John Wiley & Sons, New York, 1994. Preferably, for diagnostic applications, the antibodies are monoclonal antibodies. Additionally, for use in in vivo applications the antibodies of the present invention are preferably human or humanized antibodies. Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.

If desired, the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies specific for a protein or polypeptide of the invention can be selected or (e.g., partially purified) or purified by, e.g., affinity chromatography to obtain substantially purified and purified antibody. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein or polypeptide of the invention, and preferably at most 20%, yet more preferably at most 10%, and most preferably at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; and Boss et al., U.S. Pat. No. 4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Pat. No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Cancer Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison (1985) Science 229:1202-1207; Oi et al. (1986) Bio/Techniques 4:214; U.S. Pat. No. 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.

Methods for making human antibodies are known in the art. One method for making human antibodies employs the use of transgenic animals, such as a transgenic mouse. These transgenic animals contain a substantial portion of the human antibody producing genome inserted into their own genome and the animal's own endogenous antibody production is rendered deficient in the production of antibodies. Methods for making such transgenic animals are known in the art. Such transgenic animals can be made using XENOMOUSE™ technology or by using a “minilocus” approach. Methods for making XENOMICE™ are described in U.S. Pat. Nos. 6,162,963, 6,150,584, 6,114,598 and 6,075,181, which are incorporated herein by reference. Methods for making transgenic animals using the “minilocus” approach are described in U.S. Pat. Nos. 5,545,807, 5,545,806 and 5,625,825; also see International Publication No. WO93/12227, which are each incorporated herein by reference.

Antibody fragments may be derived from any of the antibodies described above. For example, antigen-binding fragments, as well as full-length monomeric, dimeric or trimeric polypeptides derived from the above-described antibodies are themselves useful. Useful antibody homologs of this type include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341:544-546 (1989)), which consists of a VH domain; (vii) a single domain functional heavy chain antibody, which consists of a VHH domain (known as a nanobody) see e.g., Cortez-Retamozo, et al., Cancer Res. 64: 2853-2857(2004), and references cited therein; and (vii) an isolated complementarity determining region (CDR), e.g., one or more isolated CDRs together with sufficient framework to provide an antigen binding fragment. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. Science 242:423-426 (1988); and Huston et al. Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding fragment” of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antibody fragments, such as Fv, F(ab′)₂ and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage.

An antibody directed against a polypeptide corresponding to a predictive marker of the invention (e.g., a monoclonal antibody) can be used to detect the predictive marker (e.g., in a cellular sample) in order to evaluate the level and pattern of expression of the predictive marker. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (e.g. in an tumor sample) as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵ I, ¹³¹ I, ³⁵S or ³H.

Accordingly, in one aspect, the invention provides substantially purified antibodies or fragments thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence encoded by a predictive marker identified herein. The substantially purified antibodies of the invention, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies.

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence which is encoded by a nucleic acid molecule of a predictive marker of the invention. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 15 amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to an amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6×SSC at 45° C. and washing in 0.2×SSC, 0.1% SDS at 65° C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

The substantially purified antibodies or fragments thereof may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic membrane of a polypeptide of the invention. The substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of the present invention.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a diagnostic composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In certain aspects, the diagnostic composition contains an antibody of the invention, a detectable moiety, and a pharmaceutically acceptable carrier.

Sensitivity Assays

A sample of cancerous cells is obtained from a patient. An expression level is measured in the sample for a marker corresponding to at least one of the predictive markers set forth in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3. Preferably a marker set is utilized comprising markers identified in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3, and put together in a marker set using the methods described herein. For example, marker sets can comprise the marker sets identified in Table 4, or any marker set prepared by similar methods. Such analysis is used to obtain an expression profile of the tumor in the patient. Evaluation of the expression profile is then used to determine whether the patient is a responsive patient and would benefit from proteasome inhibition therapy (e.g., treatment with a proteasome inhibitor (e.g., bortezomib) alone, or in combination with additional agents) and/or glucocorticoid therapy (e.g., treatment with a glucocorticoid (e.g., dexamethasone) alone, or in combination with additional agents). Evaluation can include use of one marker set prepared using any of the methods provided or other similar scoring methods known in the art (e.g., weighted voting, CTF). Still further, evaluation can comprise use of more than one prepared marker set. A proteasome inhibition therapy and/or glucocorticoid therapy will be identified as appropriate to treat the cancer when the outcome of the evaluation demonstrates decreased non-responsiveness or increased responsiveness in the presence of the agent.

In one aspect, the invention features a method of evaluating a patient, e.g., a patient with cancer, e.g. a hematological cancer (e.g., multiple myeloma, leukemias, lymphoma, etc) or cancer from a solid tumor (e.g., in lung, breast, prostate, ovary, colon, kidney, or liver) for responsiveness or non-responsiveness to treatment with a proteasome inhibition and/or a glucocorticoid therapy regimen The method includes providing an evaluation of the expression of the markers in a predictive marker set of markers in the patient, wherein the predictive marker set has the following properties: it includes a plurality of genes, each of which is differentially expressed as between patients responsive or non-responsive to treatment with a proteasome inhibition and/or a glucocorticoid therapy regimen and non-afflicted subjects and it contains a sufficient number of differentially expressed markers such that differential expression (e.g., as compared to a level in a non-afflicted reference sample) of each of the markers in the predictive marker set in a subject is predictive of responsiveness or nonresponsiveness with no more than about 15%, about 10%, about 5%, about 2.5%, or about 1% false positives (wherein false positive means predicting that a patient as responsive or non-responsive when the subject is not); and providing a comparison of the expression of each of the markers in the set from the patient with a reference value, thereby evaluating the patient.

Examining the expression of one or more of the identified markers or marker sets in a tumor sample taken from a patient during the course of proteasome inhibition therapy and/or glucocorticoid treatment, it is also possible to determine whether the therapeutic agent is continuing to work or whether the cancer has become non-responsive (refractory) to the treatment protocol. For example, a patient receiving a treatment of bortezomib would have tumor cells removed and monitored for the expression of a marker or marker set. If the expression profile of one or more marker sets identified in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3 demonstrates increased responsiveness in the presence of the agent, the treatment with proteasome inhibitor would continue. However, if the expression profile of one or more marker sets identified in Table 1A, Table 1B, Table 2A, Table 2B, and/or Table 3 demonstrates increased non-responsiveness in the presence of the agent, then the cancer may have become resistant to proteasome inhibition therapy and/or glucocorticoid therapy, and another treatment protocol should be initiated to treat the patient.

Importantly, these determinations can be made on a patient by patient basis or on an agent by agent (or combinations of agents). Thus, one can determine whether or not a particular proteasome inhibition therapy and/or glucocorticoid therapy is likely to benefit a particular patient or group/class of patients, or whether a particular treatment should be continued.

Use of Information

In one method, information, e.g., about the patient's marker expression levels (e.g., the result of evaluating a predictive marker or predictive marker set described herein), or about whether a patient will be responsive or non-responsive to a proteasome inhibition therapy and/or glucocorticoid therapy, is provided (e.g., communicated, e.g., electronically communicated) to a third party, e.g., a hospital, clinic, a government entity, reimbursing party or insurance company (e.g., a life insurance company). For example, choice of medical procedure, payment for a medical procedure, payment by a reimbursing party, or cost for a service or insurance can be function of the information. E.g., the third party receives the information, makes a determination based at least in part on the information, and optionally communicates the information or makes a choice of procedure, payment, level of payment, coverage, etc. based on the information. In the method, informative expression level of a predictive marker or a predictive marker set selected from or derived from Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is determined.

In one embodiment, a premium for insurance (e.g., life or medical) is evaluated as a function of information about one or more marker expression levels, e.g., a predictive marker or predictive marker set, e.g., a level of expression associated with responsiveness or non-responsiveness to a proteasome inhibition therapy and/or glucocorticoid therapy (e.g., the informative expression level). For example, premiums can be increased (e.g., by a certain percentage) if the markers of a patient or a patient's predictive marker set described herein are differentially expressed between an insured candidate (or a candidate seeking insurance coverage) and a reference value (e.g., a non-afflicted person). As another example, premiums can be decreased if levels of a predictive marker or predictive marker set are sustained (as described herein) after treatment with a proteasome inhibitor or a glucocorticoid. Premiums can also be scaled depending on marker expression levels, e.g., the result of evaluating a predictive marker or predictive marker set described herein. For example, premiums can be assessed to distribute risk, e.g., as a function of marker expression levels, e.g., the result of evaluating a predictive marker or predictive marker set described herein. In another example, premiums are assessed as a function of actuarial data that is obtained from patients that are enhanced or non-enhanced responders.

Information about marker expression levels, e.g., the result of evaluating a predictive marker or predictive marker set described herein (e.g., the informative expression level), can be used, e.g., in an underwriting process for life insurance. The information can be incorporated into a profile about a subject. Other information in the profile can include, for example, date of birth, gender, marital status, banking information, credit information, children, and so forth. An insurance policy can be recommended as a function of the information on marker expression levels, e.g., the result of evaluating a predictive marker or predictive marker set described herein, along with one or more other items of information in the profile. An insurance premium or risk assessment can also be evaluated as function of the predictive marker or predictive marker set information. In one implementation, points are assigned on the basis of being responsive or non-responsive to a proteasome inhibition therapy and/or glucocorticoid therapy.

In one embodiment, information about marker expression levels, e.g., the result of evaluating a predictive marker or predictive marker set described herein, is analyzed by a function that determines whether to authorize the transfer of funds to pay for a service or treatment provided to a subject (or make another decision referred to herein). For example, the results of analyzing a expression of a predictive marker or predictive marker set described herein may indicate that a subject is responsive or non-responsive to a proteasome inhibition therapy and/or glucocorticoid therapy, suggesting that a treatment course is needed, thereby triggering an outcome that indicates or causes authorization to pay for a service or treatment provided to a subject. In one example, informative expression level of a predictive marker or a predictive marker set selected from or derived from Table 1A, Table 1B, Table 2A, Table 2B, and Table 3 is determined and payment is authorized if the informative expression level identifies a responsive patient. For example, an entity, e.g., a hospital, care giver, government entity, or an insurance company or other entity which pays for, or reimburses medical expenses, can use the outcome of a method described herein to determine whether a party, e.g., a party other than the subject patient, will pay for services (e.g., a particular therapy) or treatment provided to the patient. For example, a first entity, e.g., an insurance company, can use the outcome of a method described herein to determine whether to provide financial payment to, or on behalf of, a patient, e.g., whether to reimburse a third party, e.g., a vendor of goods or services, a hospital, physician, or other care-giver, for a service or treatment provided to a patient. For example, a first entity, e.g., an insurance company, can use the outcome of a method described herein to determine whether to continue, discontinue, enroll an individual in an insurance plan or program, e.g., a health insurance or life insurance plan or program.

In one aspect, the disclosure features a method of providing data. The method includes providing data described herein, e.g., generated by a method described herein, to provide a record, e.g., a record described herein, for determining if a payment will be provided. In some embodiments, the data is provided by computer, compact disc, telephone, facsimile, email, or letter. In some embodiments, the data is provided by a first party to a second party. In some embodiments, the first party is selected from the subject, a healthcare provider, a treating physician, a health maintenance organization (HMO), a hospital, a governmental entity, or an entity which sells or supplies the drug. In some embodiments, the second party is a third party payor, an insurance company, employer, employer sponsored health plan, HMO, or governmental entity. In some embodiments, the first party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug and the second party is a governmental entity. In some embodiments, the first party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug and the second party is an insurance company.

In another aspect, the disclosure features a record (e.g., computer readable record) which includes a list and value of expression for the predictive marker or predictive marker set for a patient. In some embodiments, the record includes more than one value for each marker.

Exemplification

Based on positive findings in multiple myeloma in Phase 1 clinical trials (Orlowski, J Clin Oncol. 2002 Nov. 15; 20(22):4420-7., Aghajanian, Clin Cancer Res. 2002 August; 8(8):2505-11,) Phase 2 myeloma studies were conducted in order to better to allow a more precise estimate of antitumor activity of bortezomib in a more homogeneous population of patients. The safety and efficacy of bortezomib in subjects with multiple myeloma was investigated in two phase 2 clinical studies, M34100-024 (subjects with first relapse) and M34100-025 (subjects with second or greater relapse and refractory to their last prior therapy). In Study M34100-025, the CR+PR rate to bortezomib alone was 27% (53 of 193 patients), and the overall response rate (CR+PR+MR) to bortezomib alone was 35% (67 of 193 patients). See Richardson P G, et al. N Engl J Med., 348:2609-17 (2003). In Study M34100-024 CR+PR rates of were 30% and 38% were seen among patients with relapsed multiple myeloma treated with bortezomib 1.0 mg/m² and 1.3 mg/m², respectively. See Jagannath, Br J Haematol. 127:165-72 (2004). Patient samples and response criteria from patients participating in these studies, as well as the following additional studies described below were sought for use in pharmacogenomic analyses to identify markers associated with patient response to treatments.

An Open-Label Study Comparison of Bortezomib Versus High Dose Dexamethasone in Patients with Relapsed and Refractory Myeloma

A multicenter, open-label, randomized study was conducted, comprising 627 enrolled patients with relapsed or refractory multiple myeloma (Protocol M34101-039). See Richardson et. al., N. Engl. J Med., 352:2487-2498 (2005). Patients were treated with either bortezomib (315 patients) or high-dose dexamethasone (312 patients).

Treatment Dosage and Administration

Drug Supply and Storage

Bortezomib for injection (VELCADE™ Millennium Pharmaceuticals, Inc., Cambridge, Mass.), a sterile lyophilized powder for reconstitution, was supplied in vials containing 2.5 mg bortezomib and 25 mg mannitol USP. Each vial was reconstituted with 2.5 mL of normal (0.9%) saline, Sodium Chloride Injection USP, such that the reconstituted solution contained bortezomib at a concentration of 1 mg/mL. The reconstituted solution was clear and colorless with a final pH between 5 and 6.

Dexamethasome tablets (DECADRON® Merck & Co., Inc.).

TABLE B Drug Information Chemical Name N-Pyrazinecarbonyl-L- phenylalanine- L-leucineboronic acid Research Name MLN341 or PS-341 Generic Name bortezomib dexamethasone Proprietary Name VELCADE ™ Decadron ® CAS Registry No. 179324-69-7 312-93-6 U.S. Pat. No. 5,780,454 Classification Proteasome Inhibitor Steroid Molecular Formula C₁₉H₂₅BN₄O₄ C₂₂H₂₉FO₅ Molecular Weight 384.25 392.47 Structure Boronic acid derivative Synthetic of a leucine adrenocorticosteroid phenylalanine dipeptide

Patients were assigned to receive bortezomib or high-dose dexamethasone by random allocation at a 1:1 ratio. Randomization was to be stratified, based on the number of lines of prior therapy (one prior line versus more than one prior line of therapy), time of progression relative to treatment (progression while on their most recent therapy or within 6 months of stopping their most recent therapy, or relapse >6 months after receiving their most recent therapy), and screening β₂-microglobulin levels (>2.5 mg/L versus ≤2.5 mg/L).

Patients assigned to the bortezomib group received treatment for a maximum of 273 days. Patients in this treatment group received up to eight 3-week treatment cycles followed by up to three 5-week treatment cycles of bortezomib. Within each 3-week treatment cycle, the patient received bortezomib 1.3 mg/m²/dose alone as a bolus intravenous (IV) injection twice weekly for two weeks (on Days 1, 4, 8, and 11) of a 21-day cycle. Within each 5-week treatment cycle, the patient received bortezomib 1.3 mg/m²/dose alone as a bolus IV injection once weekly (on Days 1, 8, 15, and 22) of a 35-day cycle.

Patients assigned to the high-dose dexamethasone group received treatment for a maximum of 280 days. Patients in this treatment group received up to four 5-week treatment cycles, followed by up to five 4-week treatment cycles. Within each 5-week treatment cycle, the patient received dexamethasone 40 mg/day PO, once daily on Days 1 to 4, 9 to 12, and 17 to 20 of a 35-day cycle. Within each 4-week treatment cycle, the patient received dexamethasone 40 mg/day PO once daily on Days 1 to 4 of a 28 day cycle. The protocol provided for patients in the dexamethasone group who experienced confirmed progressive disease (PD) to receive bortezomib on a companion study (An International, Non-Comparative, Open-Label Study of PS-341 Administered to Patients with Multiple Myeloma Who Received High-dose Dexamethasone or Experienced Progressive Disease after Receiving at Least Four Previous Therapies, (Protocol M34101-040). An additional 240 patients who did not participate in this study, enrolled in the companion study and according to the protocol would have received at least four prior therapies. Pharmacogenomic samples were also sought for these 240 patients.

During the study, disease response was assessed according to the European Group for Blood and Marrow Transplant (EBMT) criteria as presented in Table C.

TABLE C Disease Response Criteria Table C Disease Response Criteria¹ Response Criteria for response Complete Requires all of the following: response (CR)² Disappearance of the original monoclonal protein from the blood and urine on at least two determinations for a minimum of six weeks by immunofixation studies. <5% plasma cells in the bone marrow³. No increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response). Disappearance of soft tissue plasmacytomas for at least six weeks. Partial PR includes patients in whom some, but not all, criteria for CR are response fulfilled providing the remaining criteria satisfy the requirements for (PR) PR. Requires all of the following: ≥50% reduction in the level of serum monoclonal protein for at least two determinations six weeks apart. If present, reduction in 24-hour urinary light chain excretion by either ≥90% or to <200 mg for at least two determinations six weeks apart. ≥50% reduction in the size of soft tissue plasmacytomas (by clinical or radiographic examination) for at least six weeks. No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response). Minimal MR includes patients in whom some, but not all, criteria for PR are response fulfilled providing the remaining criteria satisfy the requirements for (MR) MR. Requires all of the following: ≥25% to ≤50% reduction in the level of serum monoclonal protein for at least two determinations six weeks apart. If present, a 50 to 89% reduction in 24-hour light chain excretion, which still exceeds 200 mg/24 h, for at least two determinations six weeks apart. 25-49% reduction in the size of plasmacytomas (by clinical or radiographic examination (e.g., 2D MRI, CT scan). No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response). No change (NC) Not meeting the criteria for MR or PD. Progressive Requires one or more of the following: disease (PD) >25% increase in the level of serum monoclonal paraprotein, which (for patients must also be an absolute increase of at least 5 g/L and confirmed on a not in CR) repeat investigation one to three weeks later^(4, 5). >25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation one to three weeks later^(4, 5). >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%. Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas. Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture). Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause)⁴. Relapse Requires at least one of the following: from CR Reappearance of serum or urine monoclonal paraprotein on immunofixation or routine electrophoresis to an absolute value of >5 g/L for serum and >200 mg/24 hours for urine, and excluding oligoclonal immune reconstitution. Reappearance of monoclonal paraprotein must be confirmed by at least one follow-up. ≥5% plasma cells in the bone marrow aspirate or biopsy. Development of new lytic bone lesions or soft tissue plasmacytomas or definite increase in the size of residual bone lesions (not including compression fracture). Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). ¹Based on the EBMT criteria. See, Blade J, et al. Br J Haematol; 102(5): 1115-23 (1998). ²For proper evaluation of CR, bone marrow should be ≥20% cellular and serum calcium should be within normal limits. ³A bone marrow collection and evaluation is required to document CR. Repeat collection and evaluation of bone marrow is not required to confirm CR for patients with secretory myeloma who have a sustained absence of monoclonal protein on immunofixation for a minimum of 6 weeks; however, repeat collection and evaluation of bone marrow is required at the Response Confirmation visit for patients with non-secretory myeloma. ⁴The need for urgent therapy may require repeating these tests earlier or eliminating a repeat examination. ⁵For determination of PD, increase in paraprotein is relative to the nadir.

Patients were evaluable for response if they had received at least one dose of study drug and had measurable disease at baseline (627 total patients: 315 in the bortezomib group and 312 in the dexamethasone group). The evaluation of confirmed response to treatment with bortezomib or dexamethasone according to the European Group for Blood and Marrow Transplant (EBMT) criteria is provided in Table D. Response and date of disease progression was determined by computer algorithm that integrated data from a central laboratory and case report forms from each clinical site, according to the Blade criteria (Table C). The response rate (complete plus partial response (CR+PR)) in the bortezomib group was 38 percent; and in the dexamethasone group was 18 percent (P<0.0001). Complete response was achieved in 20 patients (6 percent) who received bortezomib, and in 2 patients (<1 percent) who received dexamethasone (P<0.001), with complete response plus near-complete response in 13 and 2 percent (P<0.0001) in patients receiving bortezomib and dexamethasone, respectively. These data have been submitted for publication. See Richardson P G, et al. [submitted NEJM].

TABLE D Summary of Best Confirmed Response to Treatment^(1, 2) (Population, N = 627) bortezomib dexamethasone Best Confirmed n (%) n (%) Difference Response (n = 315) (n = 312) (95% CI)^(a) p-value^(b) Overall Response Rate 121 (38) 56 (18) 0.20 (0.14, 0.27) <0.0001 (CR + PR) Complete Response 20 (6) 2 (<1) 0.06 (0.03, 0.09) 0.0001 Partial Response 101 (32) 54 (17) 0.15 (0.08, 0.21) <0.0001 Near CR: IF+ 21 (7) 3 (<1) 0.06 (0.03, 0.09) SWOG Remission 46 (15) 17 (5) 0.09 (0.05, 0.14) Minor Response 25 (8) 52 (17) −0.09 (−0.14, −0.04) CR + PR + MR 146 (46) 108 (35) 0.12 (0.04, 0.19) No Change 137 (43) 149 (48) −0.04 (−0.12, 0.04) Progressive Disease 22 (7) 41 (13) −0.06 (−0.11, −0.01) Not Evaluable 10 (3) 14 (4) −0.01 (−0.04, 0.02) ¹Response based on computer algorithm using the protocol-specified EBMT criteria. ²Percents calculated for the statistical output in section 14 are ‘rounded’ to the nearest integer including percents ≥0.5% but <1% rounding to 1%; these are reported in the in-text tables as <1%. ^(a)Asymptotic confidence interval for the difference in response rates. ^(b)P-value from the Cochran-Mantel-Haenszel chi-square test adjusted for the actual randomization stratification factors.

Disease progression was determined by Blade criteria as described in Table C and above. The median time to disease progression in the bortezomib group was 6.2 month (189 days); and the in the dexamethasone group was 3.5 months (106 days) (hazard ratio 0.55, P<0.0001). The date of progression was determined by computer algorithm. P-value from log-rank test adjusted by actual randomization factors. See, Richardson et al., New Engl J Med., submitted.

Median time to response was 43 days for patients in both groups. Median duration of response was 8 months in the bortezomib group and 5.6 months in the dexamethasone group.

Patients given bortezomib had a superior overall survival. One-year survival was 80% on bortezomib and 66% on dexamethasone (P<0.0030). This represents a 41% decrease in risk of death in the bortezomib group during the first year after enrollment. The hazard ratio for overall survival was 0.57 (P<0.0013), favoring bortezomib. The analysis of overall survival includes data from 147 patients (44 percent) in the dexamethasone group who had disease progression and subsequently crossed over to receive bortezomib in a companion study.

Quality of Life assessment can be analyzed to determine if response to therapy was accompanied by measurable improvement in quality of life. Analysis is performed on summary scores as well as individual items, with specific analytical methods outlined in a formal statistical analysis plan developed prior to database lock.

Pharmacogenomic Samples Collected

Pharmacogenomic tumor samples (bone marrow aspirate) were collected from patients for evaluation of the expression of global mRNA levels.

Statistical Procedures

Summary tabulations were presented that displayed the number of observations, mean, standard deviation, median, minimum, and maximum for continuous variables, and the number and percent per category for categorical data. The categories for summarization were the two assigned treatment groups.

A formal statistical analysis plan was developed and finalized prior to database lock. The primary efficacy analyses were performed on the intent-to-treat (ITT) population. The primary efficacy analysis was performed on the rates of responders, where a responder was defined as a CR, PR, or MR using the criteria prospectively established in Table C. Two-sided 90% confidence limits on proportions of responders in each dose group were established, corresponding to a 95% one-sided lower limit.

For those patients who participated in the pharmacogenomic portion of the study, correlation between RNA expression levels and response to therapy were evaluated descriptively. In addition, duration of response, time to disease progression, quality of life, and overall patient survival may be analyzed using RNA expression as a factor.

TABLE E Summary of Pharmacogenomic Patient Response TOTAL with evaluable Study CR PR MR NC PD IE response all 10 69 25 59 61 22 224 024 1 1 0 1 4 0 7 025 2 10 3 10 14 5 39 040 1 20 6 13 8 2 48 039 341 5 25 5 19 13 9 67 039 Dex 1 13 11 16 22 6 62

A total of 224 patient samples were assessed for pharmacogenomic analyses. These patient samples were collected from the clinical trials of bortezomib for the treatment of multiple myeloma See Table E. The overall response rate to bortezomib in this set of patients was 46.4% (CR+PR rate of 35%). The overall response rate to dexamethasone was 39.7% (CR+PR rate of 22.2%). All pharmacogenomic analyses relied on the European Group for Blood and Marrow Transplant (EBMT) criteria of response category.

Identification of Responsive and Non-Predictive Markers

Biopsies from 224 multiple myeloma patients resulted in generation of high quality gene expression data which was used to identify predictive markers. Candidate markers that are correlated with the outcome of multiple myeloma patients to proteasome inhibition (e.g., bortezomib) therapy or glucocorticoid (e.g., dexamethasone) therapy were selected by using a combination of marker ranking algorithms. Supervised learning and feature selection algorithms were then used to identify the markers of the present invention.

A data set comprising 224 discovery samples, time to progression data and short-term response categorization was used to identify genes associated with patient outcome to one of two treatments (bortezomib or dexamethasone). The data set consisted of discovery samples matched with the patient's outcome as measured by best response and time to disease progression. For best response, each patient was classified as responder (N_(R)), stable disease (N_(S)), or progression (N_(P)). For marker identification, the three response classes were further grouped into responders vs. non-responders (stable and progression) (N_(P+S)), responders vs. progression, or progression vs. others (stable and responders) (N_(R+S)). The analyses further separated the patients based on the treatment they received. For bortezomib analyses N_(R)=79, N_(S)=43, and N_(P)=41. Thus, the responder vs. non-responder analysis utilizes 79 vs. 84 samples. The responder vs. progression analysis utilizes 79 vs. 41 and the progression vs. other analysis utilizes 41 vs. 122 samples. For the dexamethasone analysis N_(R) 25, N_(S)=16, and N_(P)=21. Accordingly, the responder vs. non-responder analysis utilizes 25 vs. 37 samples. The responder vs. progression analysis utilizes 25 vs. 21 and the progression vs. other analysis utilizes 21 vs. 41 samples.

44,928 gene transcripts (Affymetrix probe sets) were profiled for each sample on the two Affymetrix U133 microarrays (A and B) according to manufacturer's directions. Total RNA was isolated from homogenized patient tumor tissue by Triazol™ (Life Technologies, Inc.) and stored at 80° C., following the manufacturer's recommendations. Detailed methods for labeling the samples and subsequent hybridization to the arrays are available from Affymetrix (Santa Clara, Calif.). Briefly, 1.5 μg of total RNA was converted to double-stranded cDNA (Superscript; Life Technologies, Inc.) priming the first-strand synthesis with a T7-(dT)24 primer containing a T7 polymerase promoter (Affymetrix Inc.). All of the double-stranded cDNA was subsequently used as a template to generate biotinylated cRNA using the incorporated T7 promoter sequence in an in vitro transcription system (Megascript kit; Ambion and Bio-11-CTP and Bio-16-UTP; Enzo). Reference oligonucleotides and spikes were added to 6-10 μg of cRNA, which was then hybridized to U133 A and B oligonucleotide arrays for 16 h at 45° C. with constant rotation. The arrays were then washed and stained on an Affymetrix fluidics station using the EUKGE-WS 1 protocol and scanned on an Affymetrix GeneArray scanner.

Normalization and Logarithmic Transformation.

Expression values for all markers on each microarray were normalized to a trimmed mean of 150. Expression values were determined using MASS gene expression analysis data processing software (Affymetrix, Santa Clara, Calif.). These values will be referred to as the “normalized expression” in the remainder of this section. In a further processing step, the number 1 was added to each normalized expression value. The logarithm base 2 was taken of the resulting number, and this value will be referred to as the “log expression” in the remainder of this section.

Variance Components Analysis.

There were up to six replicate hybridizations for each patient: three replicate hybridizations for each of two T7 RNA labelings. To summarize replicates into a single estimate of intensity for each patient, a mixed effects linear model was used. For each probe set, a model was fit which included terms the patient sample specific random effect representing the deviation from the overall mean intensity, and the replicate hybridization random effect. These random effects are referred to as the variance components of the model. Model fitting includes assessing the variance due to these two random effects, resulting in estimates of patient sample variance and replicate variance.

Summarizing Expression Across Replicates.

The final summary expression value, for each sample on each probe set, was obtained by estimating the best linear unbiased predictor (BLUP). The BLUP can be viewed as a weighted average of each subject's replicates with weights inversely proportional to the linear combination of the variance components. The weights influence how much each subject's estimate of intensity deviates away from the overall mean. Details on mixed effects models and calculating BLUP estimates can be found in most texts which discuss linear mixed effects models and variance components. See, for example, “Variance Components” by Searle, Casella, and McCulloch. Wiley Series in Probability and Mathematical Statistics, 1992 John Wiley & Sons.

Removal of Genes with Low Inter-Patient Variance.

The probe sets were reduced in number to include only those having more than 75% of their variance due to patient sample variance. Of 44,928 probe sets, 7,017 passed this filter and were carried on to further analysis.

Optional Reverse Log Transformation.

The BLUP expression value was used for differential expression analysis with the t-test. For computing the digital differential expression scores, the final summary value, x, was transformed back to the original scale by exponentiating, thus reversing the log transformation: y=2^(x)−1 Single Marker Selection.

Single gene transcripts that appear associated with patient response categories or with patient time to progression can be identified using the feature ranking and filtering methodology described below. Single marker identification of predictive markers using the methodology described herein are set forth in Table 1 (Table 1A and Table 1B), Table 2 (Table 2A and Table 2B), and Table 3.

Model Selection.

A set of one or more gene transcripts that together classify samples into sensitive and resistant groups (or responsive and non-responsive) or predict TTP, in the context if a particular classifier algorithm, is referred to as a “model.” The gene transcripts are referred to as “features.” Determining which combination of gene transcript(s) best classifies samples into sensitive and resistant groups is referred to as “model selection.” The following section describes the process of how the models of the present invention were identified. An exemplary model is set forth in Table 4. The methods provided herein along with the single marker identification or predictive markers can be used to identify additional models comprising markers of the invention.

Feature Ranking and Filtering

The first step in predictive model selection is to filter the 7,017 features down to a smaller number which show a correspondence with the sample classifications. Filtering involves first ranking the features by a scoring method, and then taking only the highest ranking features for further analysis. The filtering algorithms used in the present invention were: (1) t-test, and (2) Pooled Fold Change (“PFC). In certain aspects, the t-test was used to identify genes showing a small but consistent change in levels, and PFC was used to identify genes that were “off” in one class, but “on” in a fraction of the other class. For time to progression data, Cox proportional hazards modeling was used to determine a p-value for the association of a feature with time to progression.

The t-test is a standard statistical method to test for significant difference of means between two sets of points presumed to have normal distribution. It is closely related to the more ad hoc measure of differential expression SNR (signal to noise ratio), which is the difference of the class means divided by the sum of the class standard deviations, and has been used to analyze expression data before; for example, see the definition of P(g,c), a measure of correlation between expression of gene g and class vector c, in Golub et al., “Molecular Classification of Cancer: Class discovery and class prediction by marker expression monitoring,” Science, 286:531-537 (1999), the contents of which are incorporated herein by reference.

The Pooled Fold Change (“PFC”) method is a measure of differential expression between two groups of samples, arbitrarily designated “control” and “tester.” PFC finds genes with higher expression in the tester than in the control samples. For the two-class comparisons described in this invention, each class was used in turn as the tester. To qualify as having higher expression, tester samples must be above the k^(th) percentile of the control sample. The fold-change values of tester samples are subjected to a nonlinear transformation that rises to a user-specified asymptote, in order to distinguish moderate levels of fold-change, but not make distinctions between very large fold-changes. The squashed fold-change values of the over-expressed tester samples are averaged to get the POOF score. In particular, PFC for a given tester sample, s, and gene, g, is computed as the average across tester samples of the compressed tester:control ratio R(s,g): R(s,g)=C(x_(gs)/(k+x_(g) ^(Q))), where C(x) is the compression function C(z)=A(1−e^(−z/A)) for z≥T, and C(z)=0 for z<T, where T is a threshold value no less than 1.0. A is an upper asymptote on the fold-change value, k is a constant reflecting the additive noise in the data, i.e., the fixed component of the variance in repeated measurements. x_(gs) is the expression value of gene g in sample s, x_(g) ^(Q) is the Qth percentile of the control samples' expression value.

A minimum fraction f of the tester samples must have R(s,g) greater than 0; if this does not hold true, then the value of R(s,g) is set to 0.

We used the following parameters in our application of this algorithm:

Parameter Q f T A k Value in run 1 0.9 0.3 1.2 5 0.25

Markers using the 7,017 probe sets were analyzed for differential expression across the 224 patient samples using the t-test and PFC methods described above. Probe sets found to be significant by t-test with a p-value less than 0.01, or having a PFC score other than 0, are reported in Table 1A, Table 1B, Table 2A, Table 2B and Table 3. These probe sets can be used in building marker sets as exemplified below.

A Cox proportional hazard analysis was performed to determine predictors of time until disease progression (TTP) in patients with relapsed and refractory multiple myeloma after treatment. This methodology is designed to analyze time to event data where some of the data may be censored (see E. T. Lee, Statistical Methods for Survival Data Analysis, 2^(nd) ed. 1992, John Wiley& Sons, Inc.). The median time to disease progression in the bortezomib group was 6.2 month (189 days); and the in the dexamethasone group was 3.5 months (106 days) (hazard ratio 0.55, P<0.0001). The date of progression was determined by computer algorithm. The statistical package SAS was used to perform the analysis; what parameters used to assess, etc.

We estimated Cox proportional hazard models for each of the 7017 transcripts passing the variance filter. That is, 7,017 models were estimated where each model contained 1 transcript. From each model, we obtained estimates of relative risk, 95% confidence intervals and p-values for the association of each transcript to TTP. From the 7017 models, we found 294 transcripts which had p-values of less than 0.01 in analyzing the 162 patients treated with bortezomib. We found 187 transcripts which had p-values of less than 0.01 in analyzing the 63 patients treated with dexamethasone. That is, these transcripts were significantly associated with TTP. These probe sets are listed in Table 1A, Table 1B, Table 2A, Table 2B and Table 3.

The rank reported in Tables 1A, 1B, 2A, 2B and 3 is determined by independently ranking the different scores of the markers. Ranks are generated for TTP, for PD vs R, for PD vs NC+R, for NR vs R. For the response comparisons, both T-test and digital scores are ranked. Thus there can be up to 7 different #1 ranks for proteasome inhibitor-specific predictive markers of treatment outcome.

Summary of the Data Provided in the Tables

The following terms are used throughout the Tables:

-   “No.” or “Number” corresponds to an identification number for the     predictive markers. -   “Probeset ID” corresponds to the Affymetrix (Santa Clara, Calif.)     identifier from the Human Genome U133A, B set oligonucleotide arrays     which were used; -   “Rep Public ID” refers to a Representative Public identifier for the     gene corresponding to the probe set, and was taken from HG-U133A and     HG-U133B annotation files, dated Apr. 12, 2005 which was available     and downloaded from the GeneChip support area of the Affymetrix web     site (accessible in the Human Genome U133 Set-Support Materials in     the Support section of the website maintained by Affymetrix, Inc.,     Santa Clara, Calif.); -   “SEQ ID NO” is the identification number in the sequence listing of     the sequence corresponding to the sequence in the GenBank record     identified by the Representative Public Identifier. -   “Title” corresponds to a common description, where available, and     was also taken from the Affymetrix annotation files; -   “Gene symbol” corresponds to a symbol the gene is commonly known by,     and was also taken from the Affymetrix annotation files; -   “Entrez Gene ID” corresponds to the NCBI Unigene unique gene     identifier; -   “TTP Marker” represents indication of predictive marker which is     significantly upregulated in samples with a correlation to longer     time to progression (+), or are significantly upregulated in samples     with a correlation to shorter time to progression (−); -   “Response Marker” represents indication of predictive marker which     is significantly upregulated in samples which are responsive to     therapy (+), or are significantly upregulated in samples which are     non-responsive to therapy (−); -   “Type of Specificity” indicates the significance of TTP and/or     response indicator as significant indicator of the predictive     marker; -   “Rank” corresponds to the process of determining which individual     markers may be used in combination to group or classify a sample,     for example, as responsive or non-responsive. Rank is indicated as     the lowest rank score identified among all the methods for each of     the predictive markers. In Table 3 where predictive markers are     indicative of responsive or non-responsive for proteasome inhibition     or glucocorticoid therapy, the rank indicates the lowest rank across     various methods for bortezomib or dexamethasone treated samples.     Three different feature selection methods were utilized for     determining the best classifier, and rank determination: (1)     t-test, (2) Pooled Fold Change (“PFC”), and (3) the Wilcoxon     Rank-Sum Test.

Predictive markers of the invention are provided in Tables 1A, 1B, 2A, 2B, and 3. Table 1 sets forth predictive markers identified which are specific identifiers of response or non-response to proteasome inhibition therapy (e.g., bortezomib). Table 1A provides predictive markers which are upregulated indicators of non-response and/or correlate with shorter time to progression. Marker nos. 1-547 in Table 1A are newly associated predictive markers, and predictive markers no. 548-657 have been previously identified as associated markers predictive of non-response and/or correlation with shorter time to progression. See, International Patent Publication No. WO04053066, published Jun. 24, 2004. Table 1B provides predictive markers which are upregulated indicators of response and/or correlate with longer time to progression. Marker nos. 658-876 in Table 1B are newly associated predictive markers, and predictive markers no. 877-911 have been previously identified as associated markers predictive of response and/or correlation with longer time to progression. See, International Patent Publication No. WO04053066, published Jun. 24, 2004. Table 2 sets forth predictive markers identified which are specific identifiers of response or non-response to glucocorticoid therapy (e.g., dexamethasone). Table 2A provides predictive markers which are upregulated indicators of non-response and/or correlate with shorter time to progression. Marker nos. 912-1062 in Table 2A are newly associated predictive markers, and predictive markers no. 1063-1070 have been previously identified as associated markers predictive of non-response and/or correlation with shorter time to progression related to advanced stage patient's non-response to bortezomib treatment. See, International Patent Publication No. WO04053066, published Jun. 24, 2004. Table 2B provides predictive markers which are upregulated indicators of response and/or correlate with longer time to progression. Marker nos. 1071-1185 in Table 2B are newly associated predictive markers, and predictive markers no. 1186-1202 have been previously identified as associated markers predictive of response and/or correlation with longer time to progression related to advanced stage patient's response to bortezomib treatment. See, International Patent Publication No. WO04053066, published Jun. 24, 2004. Table 3 sets forth predictive markers identified which are not specific to proteasome inhibition therapy or glucocorticoid therapy, rather are indicator predictive markers of response/longer time to progression (+) or non-response/shorter time to progression (−) with regard to either therapy, and are indicators of general disease aggressiveness. Marker nos. 1203-1423 in Table 3 are newly associated predictive markers, and predictive markers no. 1424-1474 have been previously identified as associated markers predictive of non-response/correlation with shorter time to progression and/or response/correlation with longer time to progression related to advanced stage patient's response to bortezomib treatment. See, International Patent Publication No. WO04053066, published Jun. 24, 2004.

TABLE 1 PROTEASOME INHIBITOR PREDICTIVE MARKER IDENTIFICATION 1A Predictive Markers Upregulated Indicators of Non-Response and/or Short Time to Progression SEQ Rep Public ID Gene Entrez No. ProbeSet ID chip ID NO: Title Symbol Gene ID TTP marker Response marker Type of specificity Rank 1 220960_x_at HG-U133A NM_000983 1 ribosomal protein L22 RPL22 6146 — resp 1 2 213941_x_at HG-U133A AI970731 2 ribosomal protein S7 RPS7 6201 — resp 3 3 208752_x_at HG-U133A AI888672 3 nucleosome assembly protein 1-like 1 NAP1L1 4673 — resp 7 4 200017_at HG-U133A NM_002954 4 ribosomal protein S27a RPS27A 6233 — resp 8 5 218589_at HG-U133A NM_005767 5 purinergic receptor P2Y, G-protein coupled, 5 P2RY5 10161 — resp 8 6 200971_s_at HG-U133A NM_014445 6 stress-associated endoplasmic reticulum SERP1 27230 — resp 9 protein 1 7 201094_at HG-U133A NM_001032 7 ribosomal protein S29 RPS29 6235 — resp 10 8 201256_at HG-U133A NM_004718 8 cytochrome c oxidase subunit VIIa COX7A2L 9167 — resp 11 polypeptide 2 like 9 233252_s_at HG-U133B AK024960 9 spermatid perinuclear RNA binding protein STRBP 55342 — resp 13 10 208517_x_at HG-U133A NM_001207 10 basic transcription factor 3 BTF3 689 — resp 15 11 211939_x_at HG-U133A X74070 11 basic transcription factor 3 BTF3 689 — resp 16 12 201592_at HG-U133A NM_003756 12 eukaryotic translation initiation factor 3, EIF3S3 8667 — resp 19 subunit 3 gamma, 40 kDa 13 200018_at HG-U133A NM_001017 13 ribosomal protein S13 RPS13 6207 — resp 20 14 224468_s_at HG-U133B BC006151 14 multidrug resistance-related protein MGC13170 84798 — resp 21 15 200074_s_at HG-U133B U16738 15 ribosomal protein L14 RPL14 9045 — resp 22 16 201516_at HG-U133A NM_003132 16 spermidine synthase SRM 6723 — resp 22 17 213687_s_at HG-U133A BE968801 17 ribosomal protein L35a RPL35A 6165 — resp 22 18 200781_s_at HG-U133A NM_001019 18 ribosomal protein S15a /// ADP-ribosylation RPS15A 23204 /// — resp 23 factor-like 6 interacting protein /// ARL6IP 6210 19 225794_s_at HG-U133B AV751709 19 hypothetical gene supported by AL449243 LOC91689 91689 — resp 24 20 200036_s_at HG-U133B NM_007104 20 ribosomal protein L10a RPL10A 4736 — resp 25 21 217491_x_at HG-U133A AF042165 21 cytochrome c oxidase subunit VIIc COX7C 1350 — resp 25 22 204118_at HG-U133A NM_001778 22 CD48 antigen (B-cell membrane protein) CD48 962 — resp 26 23 221775_x_at HG-U133A BG152979 23 ribosomal protein L22 RPL22 6146 — resp 26 24 200091_s_at HG-U133A AA888388 24 ribosomal protein S25 RPS25 6230 — resp 27 25 200088_x_at HG-U133B AK026491 25 ribosomal protein L12 RPL12 6136 — resp 28 26 208768_x_at HG-U133A D17652 26 ribosomal protein L22 RPL22 6146 — resp 28 27 200010_at HG-U133A NM_000975 27 ribosomal protein L11 RPL11 6135 — resp 29 28 213846_at HG-U133A AA382702 28 cytochrome c oxidase subunit VIIc COX7C 1350 — resp 30 29 225795_at HG-U133B AV751709 19 hypothetical gene supported by AL449243 LOC91689 91689 — resp 30 30 200036_s_at HG-U133A NM_007104 20 ribosomal protein L10a RPL10A 4736 — resp 31 31 200034_s_at HG-U133B NM_000970 29 ribosomal protein L6 RPL6 6128 — resp 32 32 211938_at HG-U133A BF247371 30 eukaryotic translation initiation factor 4B EIF4B 1975 — resp 32 33 227141_at HG-U133B AW205739 31 hypothetical protein BC009514 LOC127253 127253 — resp 34 34 225230_at HG-U133B AI735261 32 hypothetical protein MGC54289 MGC54289 128338 — resp 35 35 208697_s_at HG-U133A BC000734 33 eukaryotic translation initiation factor 3, EIF3S6 3646 — resp 36 subunit 6 48 kDa 36 200005_at HG-U133A NM_003753 34 eukaryotic translation initiation factor 3, EIF3S7 8664 — resp 44 subunit 7 zeta, 66/67 kDa 37 209058_at HG-U133A AB002282 35 endothelial differentiation-related factor 1 EDF1 8721 — resp 47 38 201134_x_at HG-U133A NM_001867 36 cytochrome c oxidase subunit VIIc COX7C 1350 — resp 48 39 225951_s_at HG-U133B AV756026 37 LOC440309 440309 — resp 49 40 216342_x_at HG-U133A AL121916 38 — resp 50 41 221475_s_at HG-U133A NM_002948 39 ribosomal protein L15 RPL15 6138 — resp 50 42 200029_at HG-U133B NM_000981 40 ribosomal protein L19 RPL19 6143 — resp 55 43 201773_at HG-U133A NM_015339 41 activity-dependent neuroprotector ADNP 23394 — resp 56 44 200858_s_at HG-U133A NM_001012 42 ribosomal protein S8 RPS8 6202 — resp 57 45 200005_at HG-U133B NM_003753 34 eukaryotic translation initiation factor 3, EIF3S7 8664 — resp 58 subunit 7 zeta, 66/67 kDa 46 200981_x_at HG-U133A NM_016592 43 GNAS complex locus GNAS 2778 — resp 59 47 203484_at HG-U133A NM_014302 44 Sec61 gamma subunit SEC61G 23480 — resp 60 48 200074_s_at HG-U133A U16738 15 ribosomal protein L14 RPL14 9045 — resp 61 49 224196_x_at HG-U133B AF161492 45 CGI-30 protein CGI-30 51611 — resp 61 50 228622_s_at HG-U133B AW071239 46 DnaJ (Hsp40) homolog, subfamily C, DNAJC4 3338 — resp 61 member 4 51 208635_x_at HG-U133A BF976260 47 nascent-polypeptide-associated complex NACA 4666 — resp 62 alpha polypeptide 52 200705_s_at HG-U133A NM_001959 48 eukaryotic translation elongation factor 1 beta 2 EEF1B2 1933 — resp 66 53 200010_at HG-U133B NM_000975 27 ribosomal protein L11 RPL11 6135 — resp 67 54 200013_at HG-U133A NM_000986 49 ribosomal protein L24 RPL24 6152 — resp 69 55 200099_s_at HG-U133B AL356115 50 ribosomal protein S3A RPS3A 6189 — resp 71 56 200025_s_at HG-U133B NM_000988 51 ribosomal protein L27 RPL27 6155 — resp 74 57 200091_s_at HG-U133B AA888388 24 ribosomal protein S25 RPS25 6230 — resp 75 58 202231_at HG-U133A NM_006360 52 dendritic cell protein GA17 10480 — resp 76 59 217408_at HG-U133A AL050361 53 mitochondrial ribosomal protein S18B MRPS18B 28973 — resp 76 60 200626_s_at HG-U133A NM_018834 54 matrin 3 MATR3 9782 — resp 78 61 213762_x_at HG-U133A AI452524 55 RNA binding motif protein, X-linked RBMX 27316 — resp 80 62 200081_s_at HG-U133B BE741754 56 ribosomal protein S6 RPS6 6194 — resp 81 63 213890_x_at HG-U133A AI200589 57 ribosomal protein S16 RPS16 6217 — resp 81 64 200099_s_at HG-U133A AL356115 50 ribosomal protein S3A RPS3A 6189 — resp 83 65 200002_at HG-U133B NM_007209 58 ribosomal protein L35 RPL35 11224 — resp 87 66 200062_s_at HG-U133A L05095 59 ribosomal protein L30 RPL30 6156 — resp 87 67 200013_at HG-U133B NM_000986 49 ribosomal protein L24 RPL24 6152 — resp 88 68 200018_at HG-U133B NM_001017 13 ribosomal protein S13 RPS13 6207 — resp 91 69 201622_at HG-U133A NM_014390 60 staphylococcal nuclease domain containing 1 SND1 27044 — resp 92 70 200029_at HG-U133A NM_000981 40 ribosomal protein L19 RPL19 6143 — resp 93 71 223015_at HG-U133B AF212241 61 eukaryotic translation initiation factor (eIF) eIF2A 83939 — resp 94 2A 72 200624_s_at HG-U133A AA577695 62 matrin 3 MATR3 9782 — resp 96 73 212600_s_at HG-U133A AV727381 63 ubiquinol-cytochrome c reductase core UQCRC2 7385 — resp 97 protein II 74 200034_s_at HG-U133A NM_000970 29 ribosomal protein L6 RPL6 6128 — resp 99 75 212042_x_at HG-U133A BG389744 64 ribosomal protein L7 RPL7 6129 — resp 99 76 208319_s_at HG-U133A NM_006743 65 RNA binding motif (RNP1, RRM) protein 3 RBM3 5935 — resp 100 77 226296_s_at HG-U133B AK021626 66 mitochondrial ribosomal protein S15 MRPS15 64960 — resp 101 78 223245_at HG-U133B AK024285 67 spermatid perinuclear RNA binding protein STRBP 55342 — resp 102 79 200735_x_at HG-U133A NM_005594 68 nascent-polypeptide-associated complex NACA 4666 — resp 103 alpha polypeptide 80 201600_at HG-U133A NM_007273 69 repressor of estrogen receptor activity REA 11331 — resp 109 81 203857_s_at HG-U133A NM_006810 70 for protein disulfide isomerase-related PDIR 10954 — resp 109 82 212826_s_at HG-U133A AI961224 71 solute carrier family 25 (mitochondrial SLC25A6 293 — resp 111 carrier; adenine nucleotide translocator), member 6 83 203621_at HG-U133A NM_002492 72 NADH dehydrogenase (ubiquinone) 1 beta NDUFB5 4711 — resp 112 subcomplex, 5, 16 kDa 84 200963_x_at HG-U133A NM_000993 73 ribosomal protein L31 RPL31 6160 — resp 113 85 200909_s_at HG-U133A NM_001004 74 ribosomal protein, large P2 RPLP2 6181 — resp 114 86 217768_at HG-U133A NM_016039 75 chromosome 14 open reading frame 166 C14orf166 51637 — resp 115 87 200936_at HG-U133A NM_000973 76 ribosomal protein L8 RPL8 6132 — resp 117 88 214800_x_at HG-U133A R83000 77 basic transcription factor 3 BTF3 689 — resp 119 89 224935_at HG-U133B BG165815 78 Eukaryotic translation initiation factor 2, EIF2S3 1968 — resp 123 subunit 3 gamma, 52 kDa 90 200823_x_at HG-U133A NM_000992 79 ribosomal protein L29 RPL29 6159 — resp 125 91 216520_s_at HG-U133A AF072098 80 tumor protein, translationally-controlled 1 TPT1 7178 — resp 126 92 207040_s_at HG-U133A NM_003932 81 suppression of tumorigenicity 13 (colon ST13 6767 — resp 127 carcinoma) (Hsp70 interacting protein) 93 222993_at HG-U133B AF325707 82 mitochondrial ribosomal protein L37 MRPL37 51253 — resp 127 94 200016_x_at HG-U133B NM_002136 83 heterogeneous nuclear ribonucleoprotein A1 HNRPA1 3178 — resp 128 95 202233_s_at HG-U133A NM_006004 84 ubiquinol-cytochrome c reductase hinge UQCRH 7388 — resp 128 protein 96 217673_x_at HG-U133A AA650558 85 GNAS complex locus GNAS 2778 — resp 130 97 202515_at HG-U133A BG251175 86 discs, large homolog 1 (Drosophila) DLG1 1739 — resp 131 98 212967_x_at HG-U133A AW148801 87 nucleosome assembly protein 1-like 1 NAP1L1 4673 — resp 131 99 218213_s_at HG-U133A NM_014206 88 chromosome 11 open reading frame 10 C11orf10 746 — resp 133 100 228095_at HG-U133B AA608749 89 — resp 133 101 200062_s_at HG-U133B L05095 59 ribosomal protein L30 RPL30 6156 — resp 134 102 212273_x_at HG-U133A AI591100 90 GNAS complex locus GNAS 2778 — resp 135 103 200055_at HG-U133B NM_006284 91 TAF10 RNA polymerase II, TATA box TAF10 6881 — resp 136 binding protein (TBP)-associated factor, 30 kDa 104 222832_s_at HG-U133B AA746206 92 chromosome 2 open reading frame 33 C2orf33 56947 — resp 136 105 218147_s_at HG-U133A NM_018446 93 glycosyltransferase 8 domain containing 1 GLT8D1 55830 — resp 137 106 217927_at HG-U133A NM_014041 94 signal peptidase complex subunit 1 homolog SPCS1 28972 — resp 139 (S. cerevisiae) 107 200651_at HG-U133A NM_006098 95 guanine nucleotide binding protein (G GNB2L1 10399 — resp 140 protein), beta polypeptide 2-like 1 108 201894_s_at HG-U133A NM_001920 96 signal sequence receptor, alpha (translocon- SSR1 6745 — resp 140 associated protein alpha) 109 201812_s_at HG-U133A NM_019059 97 translocase of outer mitochondrial membrane TOMM7 201725 — resp 141 7 homolog (yeast) /// hypothetical protein /// /// 54543 LOC201725 LOC201725 110 208717_at HG-U133A BC001669 98 oxidase (cytochrome c) assembly 1-like OXA1L 5018 — resp 144 111 212995_x_at HG-U133A BG255188 99 hypothetical protein FLJ14346 FLJ14346 80097 — resp 145 112 203113_s_at HG-U133A NM_001960 100 eukaryotic translation elongation factor 1 EEF1D 1936 — resp 147 delta (guanine nucleotide exchange protein) 113 213041_s_at HG-U133A BE798517 101 ATP synthase, H+ transporting, ATP5D 513 — resp 147 mitochondrial F1 complex, delta subunit 114 204944_at HG-U133A NM_002841 102 protein tyrosine phosphatase, receptor type, G PTPRG 5793 — resp 149 115 224615_x_at HG-U133B AL110115 103 histocompatibility (minor) 13 HM13 81502 — resp 149 116 225547_at HG-U133B BG169443 104 U87HG mRNA, complete sequence — resp 150 117 223671_x_at HG-U133B AF248965 105 CGI-30 protein CGI-30 51611 — resp 151 118 214042_s_at HG-U133A AW071997 106 ribosomal protein L22 RPL22 6146 — resp 152 119 200094_s_at HG-U133B AI004246 107 eukaryotic translation elongation factor 2 EEF2 1938 — resp 153 120 200017_at HG-U133B NM_002954 4 ribosomal protein S27a RPS27A 6233 — resp 154 121 200012_x_at HG-U133B NM_000982 108 ribosomal protein L21 RPL21 6144 — resp 156 122 200016_x_at HG-U133A NM_002136 83 heterogeneous nuclear ribonucleoprotein A1 HNRPA1 3178 — resp 157 123 224523_s_at HG-U133B BC006475 109 hypothetical protein MGC4308 MGC4308 84319 — resp 157 124 204102_s_at HG-U133A NM_001961 110 eukaryotic translation elongation factor 2 EEF2 1938 — resp 161 125 200025_s_at HG-U133A NM_000988 51 ribosomal protein L27 RPL27 6155 — resp 162 126 221263_s_at HG-U133A NM_031287 111 splicing factor 3b, subunit 5, 10 kDa SF3B5 83443 — resp 163 127 210027_s_at HG-U133A M80261 112 APEX nuclease (multifunctional DNA repair APEX1 328 — resp 164 enzyme) 1 128 220994_s_at HG-U133A NM_014178 113 syntaxin binding protein 6 (amisyn) STXBP6 29091 — resp 166 129 209397_at HG-U133A BC000147 114 malic enzyme 2, NAD(+)-dependent, ME2 4200 — resp 167 mitochondrial 130 223847_s_at HG-U133B AF267855 115 endoplasmic reticulum-golgi intermediate KIAA1181 57222 — resp 168 compartment 32 kDa protein 131 223246_s_at HG-U133B BC002693 116 spermatid perinuclear RNA binding protein STRBP 55342 — resp 169 132 224439_x_at HG-U133B BC005966 117 ring finger protein 7 RNF7 9616 — resp 169 133 211666_x_at HG-U133A L22453 118 ribosomal protein L3 RPL3 6122 — resp 171 134 218101_s_at HG-U133A NM_004549 119 NADH dehydrogenase (ubiquinone) 1, NDUFC2 4718 — resp 172 subcomplex unknown, 2, 14.5 kDa 135 207628_s_at HG-U133A NM_017528 120 Williams Beuren syndrome chromosome WBSCR22 114049 — resp 173 region 22 136 200093_s_at HG-U133B N32864 121 histidine triad nucleotide binding protein 1 HINT1 3094 — resp 174 137 201106_at HG-U133A NM_002085 122 glutathione peroxidase 4 (phospholipid GPX4 2879 — resp 174 hydroperoxidase) 138 201593_s_at HG-U133A AV716798 123 likely ortholog of mouse immediate early LEREPO4 55854 — resp 175 response, erythropoietin 4 139 211971_s_at HG-U133A AI653608 124 leucine-rich PPR-motif containing LRPPRC 10128 — resp 178 140 214173_x_at HG-U133A AW514900 125 chromosome 19 open reading frame 2 C19orf2 8725 — resp 178 141 208887_at HG-U133A BC000733 126 eukaryotic translation initiation factor 3, EIF3S4 8666 — resp 180 subunit 4 delta, 44 kDa 142 216570_x_at HG-U133A AL096829 127 — resp 181 143 212085_at HG-U133A AA916851 128 solute carrier family 25 (mitochondrial SLC25A6 293 — resp 182 carrier; adenine nucleotide translocator), member 6 144 218927_s_at HG-U133A NM_018641 129 carbohydrate (chondroitin 4) sulfotransferase CHST12 55501 — resp 183 12 145 235721_at HG-U133B N62126 130 deltex 3 homolog (Drosophila) DTX3 196403 — resp 184 146 218146_at HG-U133A NM_018446 93 glycosyltransferase 8 domain containing 1 GLT8D1 55830 — resp 185 147 200094_s_at HG-U133A AI004246 107 eukaryotic translation elongation factor 2 EEF2 1938 — resp 186 148 211662_s_at HG-U133A L08666 131 voltage-dependent anion channel 2 VDAC2 7417 — resp 186 149 218774_at HG-U133A NM_014026 132 decapping enzyme, scavenger DCPS 28960 — resp 188 150 227558_at HG-U133B AI570531 133 chromobox homolog 4 (Pc class homolog, CBX4 8535 — resp 190 Drosophila) 151 209059_s_at HG-U133A AB002282 35 endothelial differentiation-related factor 1 EDF1 8721 — resp 191 152 201784_s_at HG-U133A NM_014267 134 small acidic protein SMAP 10944 — resp 192 153 218495_at HG-U133A NM_004182 135 ubiquitously-expressed transcript UXT 8409 — resp 193 154 218684_at HG-U133A NM_018103 136 leucine rich repeat containing 5 LRRC5 55144 — resp 194 155 200967_at HG-U133A NM_000942 137 peptidylprolyl isomerase B (cyclophilin B) PPIB 5479 — resp 196 156 219293_s_at HG-U133A NM_013341 138 GTP-binding protein PTD004 PTD004 29789 — resp 200 157 213864_s_at HG-U133A AI985751 139 nucleosome assembly protein 1-like 1 NAP1L1 4673 — resp 202 158 217926_at HG-U133A NM_014047 140 HSPC023 protein HSPC023 28974 — resp 205 159 208746_x_at HG-U133A AF070655 141 ATP synthase, H+ transporting, ATP5L 10632 — resp 207 mitochondrial F0 complex, subunit g 160 229742_at HG-U133B AA420989 142 hypothetical LOC145853 LOC145853 145853 — resp 207 161 207585_s_at HG-U133A NM_001001 143 ribosomal protein L36a-like RPL36AL 6166 — resp 208 162 214271_x_at HG-U133A AA281332 144 ribosomal protein L12 RPL12 6136 — resp 210 163 213080_x_at HG-U133A BF214492 145 ribosomal protein L5 RPL5 6125 — resp 213 164 222229_x_at HG-U133A AL121871 146 ribosomal protein L26 /// similar to 60S RPL26 /// 400055 — resp 213 ribosomal protein L26 LOC400055 /// /// 441073 LOC441073 /// 6154 165 224932_at HG-U133B AI814909 147 chromosome 22 open reading frame 16 C22orf16 400916 — resp 214 166 200055_at HG-U133A NM_006284 91 TAF10 RNA polymerase II, TATA box TAF10 6881 — resp 215 binding protein (TBP)-associated factor, 30 kDa 167 225220_at HG-U133B BF340290 148 CDNA clone IMAGE: 4184613, partial cds — resp 218 168 221476_s_at HG-U133A AF279903 149 ribosomal protein L15 RPL15 6138 — resp 219 169 223165_s_at HG-U133B BC004469 150 inositol hexaphosphate kinase 2 IHPK2 51447 — resp 221 170 229803_s_at HG-U133B AI347000 151 Nudix (nucleoside diphosphate linked moiety NUDT3 11165 — resp 223 X)-type motif 3 171 200048_s_at HG-U133B NM_006694 152 jumping translocation breakpoint JTB 10899 — resp 228 172 209330_s_at HG-U133A D55674 153 heterogeneous nuclear ribonucleoprotein D HNRPD 3184 — resp 230 (AU-rich element RNA binding protein 1, 37 kDa) 173 213860_x_at HG-U133A AW268585 154 casein kinase 1, alpha 1 CSNK1A1 1452 — resp 231 174 200006_at HG-U133A NM_007262 155 Parkinson disease (autosomal recessive, early PARK7 11315 — resp 232 onset) 7 175 213086_s_at HG-U133A BF341845 156 casein kinase 1, alpha 1 CSNK1A1 1452 — resp 232 176 226131_s_at HG-U133B AA583817 157 ribosomal protein S16 RPS16 6217 — resp 235 177 200038_s_at HG-U133A NM_000985 158 ribosomal protein L17 RPL17 6139 — resp 237 178 208620_at HG-U133A U24223 159 poly(rC) binding protein 1 PCBP1 5093 — resp 238 179 200811_at HG-U133A NM_001280 160 cold inducible RNA binding protein CIRBP 1153 — resp 239 180 208669_s_at HG-U133A AF109873 161 CREBBP/EP300 inhibitor 1 CRI1 23741 — resp 240 181 215227_x_at HG-U133A BG035989 162 acid phosphatase 1, soluble ACP1 52 — resp 244 182 202961_s_at HG-U133A NM_004889 163 ATP synthase, H+ transporting, ATP5J2 9551 — resp 247 mitochondrial F0 complex, subunit f, isoform 2 183 200048_s_at HG-U133A NM_006694 152 jumping translocation breakpoint JTB 10899 — resp 248 184 200093_s_at HG-U133A N32864 121 histidine triad nucleotide binding protein 1 HINT1 3094 — resp 250 185 209009_at HG-U133A BC001169 164 esterase D/formylglutathione hydrolase ESD 2098 — resp 252 186 202649_x_at HG-U133A NM_001022 165 ribosomal protein S19 RPS19 6223 — resp 254 187 213801_x_at HG-U133A AW304232 166 ribosomal protein SA /// similar to Laminin RPSA /// 388524 — resp 254 receptor 1 LOC388524 /// 3921 188 222580_at HG-U133B AK023596 167 zinc finger protein 644 ZNF644 84146 — resp 256 189 200669_s_at HG-U133A NM_003340 168 ubiquitin-conjugating enzyme E2D 3 UBE2D3 7323 — resp 257 (UBC4/5 homolog, yeast) 190 200038_s_at HG-U133B NM_000985 158 ribosomal protein L17 RPL17 6139 — resp 258 191 222412_s_at HG-U133B AW150923 169 signal sequence receptor, gamma (translocon- SSR3 6747 — resp 259 associated protein gamma) 192 201001_s_at HG-U133A BG164064 170 ubiquitin-conjugating enzyme E2 variant 1 UBE2V1 387522 — resp 260 /// Kua- /// 7335 UEV 193 209150_s_at HG-U133A U94831 171 transmembrane 9 superfamily member 1 TM9SF1 10548 — resp 263 194 216559_x_at HG-U133A AL050348 172 heterogeneous nuclear ribonucleoprotein A1 HNRPA1 3178 — resp 265 195 225063_at HG-U133B BF568780 173 bone marrow stromal cell-derived ubiquitin- BMSC- 84993 — resp 269 like UbP 196 217790_s_at HG-U133A NM_007107 174 signal sequence receptor, gamma (translocon- SSR3 6747 — resp 271 associated protein gamma) 197 211942_x_at HG-U133A BF979419 175 ribosomal protein L13a RPL13A 23521 — resp 275 198 212716_s_at HG-U133A AW083133 176 eukaryotic translation initiation factor 3, EIF3S12 27335 — resp 275 subunit 12 199 200990_at HG-U133A NM_005762 177 tripartite motif-containing 28 TRIM28 10155 — resp 276 200 239082_at HG-U133B BF437161 178 — resp 276 201 224577_at HG-U133B AB033007 179 endoplasmic reticulum-golgi intermediate KIAA1181 57222 — resp 278 compartment 32 kDa protein 202 202785_at HG-U133A NM_005001 180 NADH dehydrogenase (ubiquinone) 1 alpha NDUFA7 4701 — resp 279 subcomplex, 7, 14.5 kDa 203 213356_x_at HG-U133A AL568186 181 heterogeneous nuclear ribonucleoprotein A1 HNRPA1 3178 /// — resp 279 /// similar to Heterogeneous nuclear /// 441507 ribonucleoprotein A1 (Helix-destabilizing LOC441507 protein) (Single-strand binding protein) (hnRNP core protein A1) (HDP) 204 200726_at HG-U133A NM_002710 182 protein phosphatase 1, catalytic subunit, PPP1CC 5501 — resp 280 gamma isoform 205 201781_s_at HG-U133A AL558532 183 aryl hydrocarbon receptor interacting protein AIP 9049 — resp 282 206 227711_at HG-U133B BG150433 184 hypothetical protein FLJ32942 FLJ32942 121355 — resp 283 207 201002_s_at HG-U133A U39361 185 ubiquitin-conjugating enzyme E2 variant 1 UBE2V1 387522 — resp 284 /// Kua- /// 7335 UEV 208 200032_s_at HG-U133B NM_000661 186 ribosomal protein L9 RPL9 6133 — resp 285 209 227134_at HG-U133B AI341537 187 synaptotagmin-like 1 SYTL1 84958 — resp 288 210 213129_s_at HG-U133A AI970157 188 glycine cleavage system protein H GCSH 2653 — resp 292 (aminomethyl carrier) 211 225706_at HG-U133B AI761989 189 glucocorticoid induced transcript 1 GLCCI1 113263 — resp 293 212 200002_at HG-U133A NM_007209 58 ribosomal protein L35 RPL35 11224 — resp 294 213 223193_x_at HG-U133B AF201944 190 growth and transformation-dependent protein E2IG5 26355 — resp 297 214 200022_at HG-U133B NM_000979 191 ribosomal protein L18 RPL18 6141 — resp 298 215 200088_x_at HG-U133A AK026491 25 ribosomal protein L12 RPL12 6136 — resp 299 216 225700_at HG-U133B AC006042 192 glucocorticoid induced transcript 1 GLCCI1 113263 — resp 300 217 209787_s_at HG-U133A BC001282 193 high mobility group nucleosomal binding HMGN4 10473 — resp 301 domain 4 218 200081_s_at HG-U133A BE741754 56 ribosomal protein S6 RPS6 6194 — resp 303 219 224345_x_at HG-U133B AF107495 194 growth and transformation-dependent protein E2IG5 26355 — resp 304 220 209329_x_at HG-U133A BC000587 195 hypothetical protein MGC2198 MGC2198 192286 — resp 307 221 217773_s_at HG-U133A NM_002489 196 NADH dehydrogenase (ubiquinone) 1 alpha NDUFA4 4697 — resp 308 subcomplex, 4, 9 kDa 222 201665_x_at HG-U133A NM_001021 197 ribosomal protein S17 RPS17 6218 — resp 309 223 200674_s_at HG-U133A NM_000994 198 ribosomal protein L32 RPL32 6161 — resp 311 224 202209_at HG-U133A NM_014463 199 LSM3 homolog, U6 small nuclear RNA LSM3 27258 — resp 311 associated (S. cerevisiae) 225 229563_s_at HG-U133B BG231561 200 ribosomal protein L10a RPL10A 4736 — resp 312 226 200057_s_at HG-U133B NM_007363 201 non-POU domain containing, octamer- NONO 4841 — resp 313 binding 227 212352_s_at HG-U133A BE780075 202 transmembrane trafficking protein TMP21 10972 — resp 313 228 221972_s_at HG-U133A AL571362 203 calcium binding protein Cab45 precursor Cab45 51150 — resp 314 229 226386_at HG-U133B BG397444 204 chromosome 7 open reading frame 30 C7orf30 115416 — resp 315 230 200741_s_at HG-U133A NM_001030 205 ribosomal protein S27 (metallopanstimulin 1) RPS27 6232 — resp 317 231 226073_at HG-U133B BE857362 206 hypothetical protein LOC219854 LOC219854 219854 — resp 318 232 238026_at HG-U133B AI458020 207 — resp 318 233 207871_s_at HG-U133A NM_018412 208 suppression of tumorigenicity 7 ST7 7982 — resp 323 234 213376_at HG-U133A AI656706 209 zinc finger and BTB domain containing 1 ZBTB1 22890 — resp 323 235 200891_s_at HG-U133A NM_003144 210 signal sequence receptor, alpha (translocon- SSR1 6745 — resp 324 associated protein alpha) 236 223157_at HG-U133B BC004894 211 chromosome 4 open reading frame 14 C4orf14 84273 — resp 324 237 225606_at HG-U133B AI949179 212 BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 — resp 327 238 200968_s_at HG-U133A NM_000942 137 peptidylprolyl isomerase B (cyclophilin B) PPIB 5479 — resp 328 239 213414_s_at HG-U133A BE259729 213 ribosomal protein S19 RPS19 6223 — resp 330 240 226845_s_at HG-U133B AL036350 214 helicase/primase complex protein LOC150678 150678 — resp 331 241 212460_at HG-U133A BE738425 215 chromosome 14 open reading frame 147 C14orf147 171546 — resp 332 242 231530_s_at HG-U133B BG150085 216 chromosome 11 open reading frame 1 C11orf1 64776 — resp 332 243 219762_s_at HG-U133A NM_015414 217 ribosomal protein L36 RPL36 25873 — resp 333 244 213897_s_at HG-U133A AI832239 218 mitochondrial ribosomal protein L23 MRPL23 6150 — resp 335 245 200682_s_at HG-U133A BG531983 219 ubiquitin-conjugating enzyme E2L 3 UBE2L3 7332 — resp 342 246 203338_at HG-U133A NM_006246 220 protein phosphatase 2, regulatory subunit B PPP2R5E 5529 — resp 343 (B56), epsilon isoform 247 224936_at HG-U133B BE252813 221 eukaryotic translation initiation factor 2, EIF2S3 1968 — resp 343 subunit 3 gamma, 52 kDa 248 228690_s_at HG-U133B AI743115 222 NADH dehydrogenase (ubiquinone) 1 alpha NDUFA11 126328 — resp 344 subcomplex, 11, 14.7 kDa 249 208645_s_at HG-U133A AF116710 223 ribosomal protein S14 RPS14 6208 — resp 345 250 202737_s_at HG-U133A NM_012321 224 LSM4 homolog, U6 small nuclear RNA LSM4 25804 — resp 346 associated (S. cerevisiae) 251 212790_x_at HG-U133A BF942308 225 ribosomal protein L13a RPL13A 23521 — resp 346 252 227126_at HG-U133B AI857788 226 Transcribed locus — resp 347 253 200707_at HG-U133A NM_002743 227 protein kinase C substrate 80K-H PRKCSH 5589 — resp 349 254 226453_at HG-U133B BF982002 228 AYP1 protein AYP1 84153 — resp 350 255 223191_at HG-U133B AF151037 229 chromosome 14 open reading frame 112 C14orf112 51241 — resp 352 256 204246_s_at HG-U133A NM_007234 230 dynactin 3 (p22) DCTN3 11258 — resp 353 257 208907_s_at HG-U133A BC005373 231 mitochondrial ribosomal protein S18B MRPS18B 28973 — resp 353 258 203095_at HG-U133A NM_002453 232 mitochondrial translational initiation factor 2 MTIF2 4528 — resp 356 259 221700_s_at HG-U133A AF348700 233 ubiquitin A-52 residue ribosomal protein UBA52 7311 — resp 356 fusion product 1 260 200095_x_at HG-U133B AA320764 234 ribosomal protein S10 RPS10 6204 — resp 358 261 208826_x_at HG-U133A U27143 235 histidine triad nucleotide binding protein 1 HINT1 3094 — resp 358 262 226236_at HG-U133B BF675218 236 hypothetical gene supported by AF147354 LOC388789 388789 — resp 358 263 217774_s_at HG-U133A NM_016404 237 hypothetical protein HSPC152 HSPC152 51504 — resp 359 264 200089_s_at HG-U133B AI953886 238 ribosomal protein L4 RPL4 6124 — resp 361 265 202300_at HG-U133A NM_006402 239 hepatitis B virus x interacting protein HBXIP 10542 — resp 365 266 210470_x_at HG-U133A BC003129 240 non-POU domain containing, octamer- NONO 4841 — resp 367 binding 267 200092_s_at HG-U133B BF216701 241 ribosomal protein L37 RPL37 6167 — resp 368 268 200716_x_at HG-U133A NM_012423 242 ribosomal protein L13a RPL13A 23521 — resp 369 269 210434_x_at HG-U133A AF151056 243 jumping translocation breakpoint JTB 10899 — resp 372 270 200819_s_at HG-U133A NM_001018 244 ribosomal protein S15 RPS15 6209 — resp 373 271 201049_s_at HG-U133A NM_022551 245 ribosomal protein S18 RPS18 6222 — resp 373 272 201922_at HG-U133A NM_014886 246 TGF beta-inducible nuclear protein 1 TINP1 10412 — resp 374 273 201113_at HG-U133A NM_003321 247 Tu translation elongation factor, TUFM 7284 — resp 375 mitochondrial 274 206174_s_at HG-U133A NM_002721 248 protein phosphatase 6, catalytic subunit PPP6C 5537 — resp 380 275 203720_s_at HG-U133A NM_001983 249 excision repair cross-complementing rodent ERCC1 2067 — resp 381 repair deficiency, complementation group 1 (includes overlapping antisense sequence) 276 223034_s_at HG-U133B BC000152 250 chromosome 1 open reading frame 43 C1orf43 25912 — resp 385 277 200092_s_at HG-U133A BF216701 241 ribosomal protein L37 RPL37 6167 — resp 387 278 217729_s_at HG-U133A NM_001130 251 amino-terminal enhancer of split AES 166 — resp 392 279 202467_s_at HG-U133A NM_004236 252 COP9 constitutive photomorphogenic COPS2 9318 — resp 393 homolog subunit 2 (Arabidopsis) 280 208066_s_at HG-U133A NM_001514 253 general transcription factor IIB GTF2B 2959 — resp 395 281 207721_x_at HG-U133A NM_005340 254 histidine triad nucleotide binding protein 1 HINT1 3094 — resp 397 282 214687_x_at HG-U133A AK026577 255 aldolase A, fructose-bisphosphate ALDOA 226 — resp 398 283 213969_x_at HG-U133A BF683426 256 ribosomal protein L29 RPL29 6159 — resp 400 284 221524_s_at HG-U133A AF272036 257 Ras-related GTP binding D RRAGD 58528 — resp 402 285 223376_s_at HG-U133B AB055977 258 brain protein I3 BRI3 25798 — resp 404 286 203107_x_at HG-U133A NM_002952 259 ribosomal protein S2 RPS2 6187 — resp 405 287 202514_at HG-U133A AW139131 260 discs, large homolog 1 (Drosophila) DLG1 1739 — resp 406 288 208756_at HG-U133A U36764 261 eukaryotic translation initiation factor 3, EIF3S2 8668 — resp 407 subunit 2 beta, 36 kDa 289 227525_at HG-U133B AA058770 262 glucocorticoid induced transcript 1 GLCCI1 113263 — resp 411 290 220261_s_at HG-U133A NM_018106 263 zinc finger, DHHC domain containing 4 ZDHHC4 55146 — resp 412 291 217990_at HG-U133A NM_016576 264 guanosine monophosphate reductase 2 GMPR2 51292 — resp 413 292 212391_x_at HG-U133A AI925635 265 ribosomal protein S3A RPS3A 6189 — resp 414 293 219033_at HG-U133A NM_024615 266 poly (ADP-ribose) polymerase family, PARP8 79668 — resp 416 member 8 294 203034_s_at HG-U133A NM_000990 267 ribosomal protein L27a RPL27A 6157 — resp 418 295 208856_x_at HG-U133A BC003655 268 ribosomal protein, large, P0 RPLP0 6175 — resp 421 296 224767_at HG-U133B AL044126 269 Ribosomal protein L37 RPL37 6167 — resp 422 297 202758_s_at HG-U133A NM_003721 270 regulatory factor X-associated ankyrin- RFXANK 8625 — resp 424 containing protein 298 223436_s_at HG-U133B BC005133 271 tRNA splicing 2′ phosphotransferase 1 MGC11134 83707 — resp 427 299 203190_at HG-U133A NM_002496 272 NADH dehydrogenase (ubiquinone) Fe—S NDUFS8 4728 — resp 428 protein 8, 23 kDa (NADH-coenzyme Q reductase) 300 200818_at HG-U133A NM_001697 273 ATP synthase, H+ transporting, ATP5O 539 — resp 430 mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein) 301 227228_s_at HG-U133B AB040942 274 KIAA1509 KIAA1509 440193 — resp 430 302 234000_s_at HG-U133B AJ271091 275 butyrate-induced transcript 1 HSPC121 51495 — resp 432 303 205849_s_at HG-U133A NM_006294 276 ubiquinol-cytochrome c reductase binding UQCRB 7381 — resp 436 protein 304 226165_at HG-U133B BF674436 277 hypothetical gene supported by BC055092 LOC401466 401466 — resp 438 305 220942_x_at HG-U133A NM_014367 278 growth and transformation-dependent protein E2IG5 26355 — resp 440 306 231870_s_at HG-U133B BG291007 279 CGI-07 protein CGI-07 51068 — resp 440 307 212270_x_at HG-U133A BG168283 280 ribosomal protein L17 RPL17 6139 — resp 443 308 212773_s_at HG-U133A BG165094 281 translocase of outer mitochondrial membrane TOMM20 9804 — resp 443 20 homolog (yeast) 309 222785_x_at HG-U133B AJ250229 282 chromosome 11 open reading frame 1 C11orf1 64776 — resp 443 310 222497_x_at HG-U133B AL520719 283 NMD3 homolog (S. cerevisiae) NMD3 51068 — resp 444 311 200933_x_at HG-U133A NM_001007 284 ribosomal protein S4, X-linked RPS4X 6191 — resp 448 312 226650_at HG-U133B AI984061 285 hypothetical protein LOC90637 LOC90637 90637 — resp 453 313 200031_s_at HG-U133B NM_001015 286 ribosomal protein S11 RPS11 6205 — resp 454 314 217747_s_at HG-U133A NM_001013 287 ribosomal protein S9 RPS9 6203 — resp 454 315 211720_x_at HG-U133A BC005863 288 ribosomal protein, large, P0 RPLP0 6175 — resp 455 316 203403_s_at HG-U133A NM_005977 289 ring finger protein (C3H2C3 type) 6 RNF6 6049 — resp 457 317 215963_x_at HG-U133A Z98200 290 — resp 459 318 218034_at HG-U133A NM_016068 291 tetratricopeptide repeat domain 11 TTC11 51024 — resp 460 319 218258_at HG-U133A NM_015972 292 polymerase (RNA) I polypeptide D, 16 kDa POLR1D 51082 — resp 462 320 201154_x_at HG-U133A NM_000968 293 ribosomal protein L4 RPL4 6124 — resp 463 321 200846_s_at HG-U133A NM_002708 294 protein phosphatase 1, catalytic subunit, PPP1CA 5499 — resp 464 alpha isoform 322 217313_at HG-U133A AC004692 295 — resp 465 323 211061_s_at HG-U133A BC006390 296 mannosyl (alpha-1,6-)-glycoprotein beta-1,2- MGAT2 4247 — resp 467 N-acetylglucosaminyltransferase 324 216383_at HG-U133A U52111 297 ribosomal protein L18a RPL18A 6142 — resp 470 325 222467_s_at HG-U133B AK023950 298 chromosome 11 open reading frame 23 C11orf23 55291 — resp 471 326 202276_at HG-U133A NM_006304 299 split hand/foot malformation (ectrodactyly) SHFM1 7979 — resp 480 type 1 327 65588_at HG-U133A AA827892 300 hypothetical LOC388796 LOC388796 388796 — resp 481 328 234339_s_at HG-U133B AF296124 301 glioma tumor suppressor candidate region GLTSCR2 29997 — resp 484 gene 2 329 211487_x_at HG-U133A BC004886 302 ribosomal protein S17 RPS17 6218 — resp 492 330 201406_at HG-U133A NM_021029 303 ribosomal protein L36a RPL36A 6173 — resp 494 331 212537_x_at HG-U133A BE733979 304 ribosomal protein L17 RPL17 6139 — resp 495 332 220647_s_at HG-U133A NM_016565 305 E2IG2 protein E2IG2 51287 — resp 502 333 200717_x_at HG-U133A NM_000971 306 ribosomal protein L7 RPL7 6129 — resp 504 334 223461_at HG-U133B AF151073 307 TBC1 domain family, member 7 TBC1D7 51256 — resp 506 335 207831_x_at HG-U133A NM_013407 308 deoxyhypusine synthase DHPS 1725 — resp 508 336 201119_s_at HG-U133A NM_004074 309 cytochrome c oxidase subunit 8A COX8A 1351 — resp 509 (ubiquitous) 337 206782_s_at HG-U133A NM_005528 310 DnaJ (Hsp40) homolog, subfamily C, DNAJC4 3338 — resp 509 member 4 338 218836_at HG-U133A NM_024839 311 ribonuclease P 21 kDa subunit RPP21 79897 — resp 510 339 200084_at HG-U133B BE748698 312 small acidic protein SMAP 10944 — resp 513 340 201033_x_at HG-U133A NM_001002 313 ribosomal protein, large, P0 RPLP0 6175 — resp 514 341 222212_s_at HG-U133A AK001105 314 LAG1 longevity assurance homolog 2 (S. cerevisiae) LASS2 29956 — resp 515 342 202029_x_at HG-U133A NM_000999 315 ribosomal protein L38 RPL38 6169 — resp 518 343 208910_s_at HG-U133A L04636 316 complement component 1, q subcomponent C1QBP 708 — resp 520 binding protein 344 217816_s_at HG-U133A NM_020357 317 PEST-containing nuclear protein PCNP 57092 — resp 521 345 210646_x_at HG-U133A BC001675 318 ribosomal protein L13a RPL13A 23521 — resp 527 346 223423_at HG-U133B BC000181 319 G protein-coupled receptor 160 GPR160 26996 — resp 532 347 209091_s_at HG-U133A AF263293 320 SH3-domain GRB2-like endophilin B1 SH3GLB1 51100 — resp 533 348 200809_x_at HG-U133A NM_000976 321 ribosomal protein L12 RPL12 6136 — resp 541 349 224068_x_at HG-U133B U39402 322 RNA binding motif protein 22 RBM22 55696 — resp 541 350 200032_s_at HG-U133A NM_000661 186 ribosomal protein L9 RPL9 6133 — resp 548 351 227990_at HG-U133B AA843238 323 Step II splicing factor SLU7 SLU7 10569 — resp 548 352 223038_s_at HG-U133B BG479856 324 chromosome 12 open reading frame 14 C12orf14 58516 — resp 558 353 224930_x_at HG-U133B BE559788 325 ribosomal protein L7a RPL7A 6130 — resp 558 354 218401_s_at HG-U133A NM_012482 326 zinc finger protein 281 ZNF281 23528 — resp 561 355 213588_x_at HG-U133A AA838274 327 ribosomal protein L14 RPL14 9045 — resp 566 356 226816_s_at HG-U133B AI745170 328 KIAA1143 protein KIAA1143 57456 — resp 566 357 212397_at HG-U133A AL137751 329 radixin RDX 5962 — resp 568 358 200084_at HG-U133A BE748698 312 small acidic protein SMAP 10944 — resp 570 359 202983_at HG-U133A AI760760 330 SWI/SNF related, matrix associated, actin SMARCA3 6596 — resp 571 dependent regulator of chromatin, subfamily a, member 3 360 201338_x_at HG-U133A NM_002097 331 general transcription factor IIIA GTF3A 2971 — resp 573 361 214182_at HG-U133A AA243143 332 — resp 573 362 200689_x_at HG-U133A NM_001404 333 eukaryotic translation elongation factor 1 EEF1G 1937 — resp 577 gamma 363 225002_s_at HG-U133B BE349022 334 sulfatase modifying factor 2 SUMF2 25870 — resp 582 364 210024_s_at HG-U133A AB017644 335 ubiquitin-conjugating enzyme E2E 3 UBE2E3 10477 — resp 588 (UBC4/5 homolog, yeast) 365 200089_s_at HG-U133A AI953886 238 ribosomal protein L4 RPL4 6124 — resp 594 366 217256_x_at HG-U133A Z98950 336 — resp 594 367 200926_at HG-U133A NM_001025 337 ribosomal protein S23 RPS23 6228 — resp 596 368 225237_s_at HG-U133B BF435123 338 musashi homolog 2 (Drosophila) MSI2 124540 — resp 598 369 203517_at HG-U133A NM_006554 339 metaxin 2 MTX2 10651 — resp 602 370 200929_at HG-U133A NM_006827 340 transmembrane trafficking protein TMP21 10972 — resp 614 371 203897_at HG-U133A BE963444 341 hypothetical protein A-211C6.1 LOC57149 57149 — resp 621 372 224479_s_at HG-U133B BC006235 342 mitochondrial ribosomal protein L45 MRPL45 84311 — resp 623 373 223244_s_at HG-U133B AF217092 343 13 kDa differentiation-associated protein DAP13 55967 — resp 625 374 208699_x_at HG-U133A BF696840 344 transketolase (Wernicke-Korsakoff TKT 7086 — resp 626 syndrome) 375 200892_s_at HG-U133A BC000451 345 splicing factor, arginine/serine-rich 10 SFRS10 6434 — resp 636 (transformer 2 homolog, Drosophila) 376 228089_x_at HG-U133B H72927 346 similar to RIKEN cDNA 1810059G22 LOC374395 374395 — resp 637 377 202736_s_at HG-U133A AA112507 347 LSM4 homolog, U6 small nuclear RNA LSM4 25804 — resp 641 associated (S. cerevisiae) 378 217906_at HG-U133A NM_014315 348 kelch domain containing 2 KLHDC2 23588 — resp 644 379 224703_at HG-U133B AI814644 349 — resp 646 380 218930_s_at HG-U133A NM_018374 350 hypothetical protein FLJ11273 FLJ11273 54664 — resp 651 381 200810_s_at HG-U133A NM_001280 160 cold inducible RNA binding protein CIRBP 1153 — resp 652 382 225312_at HG-U133B AV704551 351 COMM domain containing 6 COMMD6 170622 — resp 654 383 210101_x_at HG-U133A AF257318 352 SH3-domain GRB2-like endophilin B1 SH3GLB1 51100 — resp 656 384 222452_s_at HG-U133B AA741071 353 hypothetical protein SP192 SP192 60313 — resp 658 385 202169_s_at HG-U133A AF302110 354 aminoadipate-semialdehyde dehydrogenase- AASDHPPT 60496 — resp 662 phosphopantetheinyl transferase 386 211710_x_at HG-U133A BC005817 355 ribosomal protein L4 RPL4 6124 — resp 663 387 202343_x_at HG-U133A NM_001862 356 cytochrome c oxidase subunit Vb COX5B 1329 — resp 667 388 208097_s_at HG-U133A NM_030755 357 thioredoxin domain containing TXNDC 81542 — resp 680 389 217339_x_at HG-U133A AJ275978 358 cancer/testis antigen 1B CTAG1B 1485 — — resp 4 390 202469_s_at HG-U133A AU149367 359 cleavage and polyadenylation specific factor CPSF6 11052 — — resp 38 6, 68 kDa 391 214548_x_at HG-U133A AF064092 360 GNAS complex locus GNAS 2778 — — resp 138 392 200780_x_at HG-U133A NM_000516 361 GNAS complex locus GNAS 2778 — — resp 190 393 224972_at HG-U133B BF381837 362 Chromosome 20 open reading frame 52 C20orf52 140823 — — resp 198 394 208833_s_at HG-U133A AF119662 363 ataxin 10 ATXN10 25814 — — resp 280 395 202107_s_at HG-U133A NM_004526 364 MCM2 minichromosome maintenance MCM2 4171 — TTP 8 deficient 2, mitotin (S. cerevisiae) 396 210766_s_at HG-U133A AF053640 365 CSE1 chromosome segregation 1-like (yeast) CSE1L 1434 — TTP 9 397 221601_s_at HG-U133A AI084226 366 regulator of Fas-induced apoptosis TOSO 9214 — TTP 15 398 209568_s_at HG-U133A AF186779 367 ral guanine nucleotide dissociation RGL1 23179 — TTP 17 stimulator-like 1 399 201555_at HG-U133A NM_002388 368 MCM3 minichromosome maintenance MCM3 4172 — TTP 21 deficient 3 (S. cerevisiae) 400 212563_at HG-U133A BG491842 369 block of proliferation 1 BOP1 23246 — TTP 23 401 221602_s_at HG-U133A AF057557 370 regulator of Fas-induced apoptosis TOSO 9214 — TTP 25 402 200608_s_at HG-U133A NM_006265 371 RAD21 homolog (S. pombe) RAD21 5885 — TTP 26 403 202589_at HG-U133A NM_001071 372 thymidylate synthetase TYMS 7298 — TTP 33 404 201930_at HG-U133A NM_005915 373 MCM6 minichromosome maintenance MCM6 4175 — TTP 34 deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae) 405 201726_at HG-U133A BC003376 374 ELAV (embryonic lethal, abnormal vision, ELAVL1 1994 — TTP 36 Drosophila)-like 1 (Hu antigen R) 406 217821_s_at HG-U133A AF118023 375 WW domain binding protein 11 WBP11 51729 — TTP 44 407 216237_s_at HG-U133A AA807529 376 MCM5 minichromosome maintenance MCM5 4174 — TTP 45 deficient 5, cell division cycle 46 (S. cerevisiae) 408 201589_at HG-U133A D80000 377 SMC1 structural maintenance of SMC1L1 8243 — TTP 46 chromosomes 1-like 1 (yeast) 409 213911_s_at HG-U133A BF718636 378 H2A histone family, member Z H2AFZ 3015 — TTP 47 410 208766_s_at HG-U133A BC001449 379 heterogeneous nuclear ribonucleoprotein R HNRPR 10236 — TTP 54 411 226547_at HG-U133B AI817830 380 MYST histone acetyltransferase (monocytic MYST3 7994 — TTP 56 leukemia) 3 412 221952_x_at HG-U133A AB037814 381 KIAA1393 KIAA1393 57570 — TTP 60 413 202642_s_at HG-U133A NM_003496 382 transformation/transcription domain- TRRAP 8295 — TTP 64 associated protein 414 218350_s_at HG-U133A NM_015895 383 geminin, DNA replication inhibitor GMNN 51053 — TTP 69 415 225827_at HG-U133B AI832074 384 eukaryotic translation initiation factor 2C, 2 EIF2C2 27161 — TTP 70 416 223024_at HG-U133B AL562950 385 adaptor-related protein complex 1, mu 1 AP1M1 8907 — TTP 72 subunit 417 210983_s_at HG-U133A AF279900 386 MCM7 minichromosome maintenance MCM7 4176 — TTP 75 deficient 7 (S. cerevisiae) 418 200045_at HG-U133B NM_001090 387 ATP-binding cassette, sub-family F ABCF1 23 — TTP 77 (GCN20), member 1 419 212316_at HG-U133A AA502912 388 nucleoporin 210 kDa NUP210 23225 — TTP 79 420 200882_s_at HG-U133A NM_002810 389 proteasome (prosome, macropain) 26S PSMD4 5710 — TTP 80 subunit, non-ATPase, 4 421 201639_s_at HG-U133A NM_013291 390 cleavage and polyadenylation specific factor CPSF1 29894 — TTP 83 1, 160 kDa 422 213893_x_at HG-U133A AA161026 391 postmeiotic segregation increased 2-like 5 PMS2L5 5383 — TTP 84 423 226936_at HG-U133B BG492359 392 CDNA clone IMAGE: 4452583, partial cds C6orf173 — TTP 88 424 228245_s_at HG-U133B AW594320 393 ovostatin /// similar to ovostatin-2 OVOS /// 408186 — TTP 89 LOC440080 /// 440080 425 225655_at HG-U133B AK025578 394 ubiquitin-like, containing PHD and RING UHRF1 29128 — TTP 91 finger domains, 1 426 223516_s_at HG-U133B AF216754 395 chromosome 6 open reading frame 49 C6orf49 29964 — TTP 97 427 201128_s_at HG-U133A NM_001096 396 ATP citrate lyase ACLY 47 — TTP 100 428 208821_at HG-U133A J04564 397 small nuclear ribonucleoprotein polypeptides SNRPB 6628 — TTP 102 B and B1 429 200090_at HG-U133B BG168896 398 farnesyltransferase, CAAX box, alpha FNTA 2339 — TTP 105 430 218437_s_at HG-U133A NM_020347 399 leucine zipper transcription factor-like 1 LZTFL1 54585 — TTP 106 431 225549_at HG-U133B BF129093 400 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 DDX6 1656 — TTP 107 432 201180_s_at HG-U133A J03198 401 guanine nucleotide binding protein (G GNAI3 2773 — TTP 108 protein), alpha inhibiting activity polypeptide 3 433 235242_at HG-U133B BE739287 402 CDNA FLJ41375 fis, clone BRCAN2007700 — TTP 110 434 225834_at HG-U133B AL135396 403 Similar to RIKEN cDNA 2700049P18 gene MGC57827 389835 — TTP 112 435 200098_s_at HG-U133B T33068 404 anaphase promoting complex subunit 5 ANAPC5 51433 — TTP 121 436 210543_s_at HG-U133A U34994 405 protein kinase, DNA-activated, catalytic PRKDC 5591 — TTP 126 polypeptide 437 213378_s_at HG-U133A AI983033 406 DEAD/H (Asp-Glu-Ala-Asp/His) box DDX11 1663 — TTP 131 polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) 438 220448_at HG-U133A NM_022055 407 potassium channel, subfamily K, member 12 KCNK12 56660 — TTP 136 439 228273_at HG-U133B BG165011 408 Hypothetical protein FLJ11029 FLJ11029 55771 — TTP 140 440 222988_s_at HG-U133B AF151020 409 transmembrane protein 9 TMEM9 252839 — TTP 146 441 209773_s_at HG-U133A BC001886 410 ribonucleotide reductase M2 polypeptide RRM2 6241 — TTP 148 442 202715_at HG-U133A NM_004341 411 carbamoyl-phosphate synthetase 2, aspartate CAD 790 — TTP 152 transcarbamylase, and dihydroorotase 443 202171_at HG-U133A AU146275 412 zinc finger protein 161 ZNF161 7716 — TTP 155 444 203999_at HG-U133A AV731490 413 synaptotagmin I SYT1 6857 — TTP 159 445 214526_x_at HG-U133A NM_005394 414 — TTP 160 446 212282_at HG-U133A BF038366 415 hypothetical protein MAC30 MAC30 27346 — TTP 164 447 202779_s_at HG-U133A NM_014501 416 ubiquitin-conjugating enzyme E2S UBE2S 27338 — TTP 166 448 201115_at HG-U133A NM_006230 417 polymerase (DNA directed), delta 2, POLD2 5425 — TTP 174 regulatory subunit 50 kDa 449 214756_x_at HG-U133A AB017004 418 — TTP 180 450 200853_at HG-U133A NM_002106 419 H2A histone family, member Z H2AFZ 3015 — TTP 182 451 200098_s_at HG-U133A T33068 404 anaphase promoting complex subunit 5 ANAPC5 51433 — TTP 184 452 225244_at HG-U133B AA019893 420 SVAP1 protein IMAGE3451454 116841 — TTP 187 453 213122_at HG-U133A AI096375 421 TSPY-like 5 TSPYL5 85453 — TTP 193 454 211714_x_at HG-U133A BC005838 422 tubulin, beta polypeptide TUBB 203068 — TTP 197 455 212350_at HG-U133A AB029031 423 TBC1 (tre-2/USP6, BUB2, cdc16) domain TBC1D1 23216 — TTP 199 family, member 1 456 215714_s_at HG-U133A AF254822 424 SWI/SNF related, matrix associated, actin SMARCA4 6597 — TTP 203 dependent regulator of chromatin, subfamily a, member 4 457 204053_x_at HG-U133A U96180 425 phosphatase and tensin homolog (mutated in PTEN 5728 — TTP 206 multiple advanced cancers 1) 458 212058_at HG-U133A AI184562 426 U2-associated SR140 protein SR140 23350 — TTP 208 459 225265_at HG-U133B AI580100 427 RNA binding motif, single stranded RBMS1 5937 — TTP 212 interacting protein 1 460 212281_s_at HG-U133A BF038366 415 hypothetical protein MAC30 MAC30 27346 — TTP 213 461 228361_at HG-U133B AL561296 428 E2F transcription factor 2 E2F2 1870 — TTP 215 462 208974_x_at HG-U133A BC003572 429 karyopherin (importin) beta 1 KPNB1 3837 — TTP 221 463 201652_at HG-U133A NM_006837 430 COP9 constitutive photomorphogenic COPS5 10987 — TTP 224 homolog subunit 5 (Arabidopsis) 464 222398_s_at HG-U133B BC002360 431 U5 snRNP-specific protein, 116 kD U5-116KD 9343 — TTP 228 465 212610_at HG-U133A U79291 432 protein tyrosine phosphatase, non-receptor PTPN11 5781 — TTP 230 type 11 (Noonan syndrome 1) 466 222987_s_at HG-U133B NM_016456 433 transmembrane protein 9 TMEM9 252839 — TTP 231 467 241224_x_at HG-U133B AA770014 434 Down syndrome critical region gene 8 DSCR8 84677 — TTP 232 468 207057_at HG-U133A NM_004731 435 — TTP 233 469 209026_x_at HG-U133A AF141349 436 tubulin, beta polypeptide TUBB 203068 — TTP 237 470 200773_x_at HG-U133A NM_002823 437 prothymosin, alpha (gene sequence 28) PTMA 5757 — TTP 241 471 204033_at HG-U133A NM_004237 438 thyroid hormone receptor interactor 13 TRIP13 9319 — TTP 242 472 225068_at HG-U133B AK024412 439 kelch-like 12 (Drosophila) KLHL12 59349 — TTP 245 473 203022_at HG-U133A NM_006397 440 ribonuclease H2, large subunit RNASEH2A 10535 — TTP 249 474 213720_s_at HG-U133A AI831675 441 SWI/SNF related, matrix associated, actin SMARCA4 6597 — TTP 251 dependent regulator of chromatin, subfamily a, member 4 475 225081_s_at HG-U133B AK022955 442 transcription factor RAM2 RAM2 55536 — TTP 255 476 201680_x_at HG-U133A NM_015908 443 arsenate resistance protein ARS2 ARS2 51593 — TTP 256 477 223065_s_at HG-U133B BC003074 444 STARD3 N-terminal like STARD3NL 83930 — TTP 257 478 205436_s_at HG-U133A NM_002105 445 H2A histone family, member X H2AFX 3014 — TTP 263 479 213069_at HG-U133A AI148659 446 HEG homolog HEG 57493 — TTP 267 480 200073_s_at HG-U133A M94630 447 heterogeneous nuclear ribonucleoprotein D HNRPD 3184 — TTP 269 (AU-rich element RNA binding protein 1, 37 kDa) 481 200060_s_at HG-U133B BC001659 448 RNA binding protein S1, serine-rich domain RNPS1 10921 — TTP 270 482 205124_at HG-U133A NM_005919 449 MADS box transcription enhancer factor 2, MEF2B 4207 — TTP 275 polypeptide B (myocyte enhancer factor 2B) 483 206052_s_at HG-U133A NM_006527 450 stem-loop (histone) binding protein SLBP 7884 — TTP 276 484 222619_at HG-U133B AU150752 451 Zinc finger protein 281 ZNF281 23528 — TTP 277 485 225684_at HG-U133B BG496998 452 — TTP 284 486 202362_at HG-U133A NM_002884 453 RAP1A, member of RAS oncogene family RAP1A 5906 — TTP 286 487 221505_at HG-U133A AW612574 454 acidic (leucine-rich) nuclear phosphoprotein ANP32E 81611 — TTP 291 32 family, member E 488 213947_s_at HG-U133A AI867102 455 nucleoporin 210 kDa NUP210 23225 — — TTP 18 489 209188_x_at HG-U133A BC002809 456 down-regulator of transcription 1, TBP- DR1 1810 — — TTP 98 binding (negative cofactor 2) 490 210243_s_at HG-U133A AF038661 457 UDP-Gal:betaGlcNAc beta 1,4- B4GALT3 8703 — — TTP 162 galactosyltransferase, polypeptide 3 491 205449_at HG-U133A NM_013299 458 Sac3 homology domain 1 (S. cerevisiae) SHD1 29901 — — TTP 170 492 217988_at HG-U133A NM_021178 459 cyclin B1 interacting protein 1 CCNB1IP1 57820 — — TTP/resp 4 493 205361_s_at HG-U133A AI718295 460 prefoldin 4 PFDN4 5203 — — TTP/resp 7 494 202605_at HG-U133A NM_000181 461 glucuronidase, beta GUSB 2990 — — TTP/resp 9 495 225315_at HG-U133B BF344406 462 mitochondrial ribosomal protein L21 MRPL21 219927 — — TTP/resp 9 496 225261_x_at HG-U133B AJ238376 463 TH1-like (Drosophila) TH1L 51497 — — TTP/resp 10 497 223474_at HG-U133B AI932310 464 chromosome 14 open reading frame 4 C14orf4 64207 — — TTP/resp 12 498 216306_x_at HG-U133A X62006 465 polypyrimidine tract binding protein 1 PTBP1 5725 — — TTP/resp 14 499 201066_at HG-U133A NM_001916 466 cytochrome c-1 CYC1 1537 — — TTP/resp 16 500 202189_x_at HG-U133A NM_002819 467 polypyrimidine tract binding protein 1 PTBP1 5725 — — TTP/resp 20 501 211270_x_at HG-U133A BC002397 468 polypyrimidine tract binding protein 1 PTBP1 5725 — — TTP/resp 22 502 225006_x_at HG-U133B AJ238379 469 TH1-like (Drosophila) TH1L 51497 — — TTP/resp 24 503 201754_at HG-U133A NM_004374 470 cytochrome c oxidase subunit VIc COX6C 1345 — — TTP/resp 27 504 212015_x_at HG-U133A BF690062 471 polypyrimidine tract binding protein 1 PTBP1 5725 — — TTP/resp 29 505 41577_at HG-U133A AB020630 472 protein phosphatase 1, regulatory (inhibitor) PPP1R16B 26051 — — TTP/resp 31 subunit 16B 506 225865_x_at HG-U133B AJ238374 473 TH1-like (Drosophila) TH1L 51497 — — TTP/resp 40 507 211271_x_at HG-U133A BC004383 474 polypyrimidine tract binding protein 1 PTBP1 5725 — — TTP/resp 42 508 200040_at HG-U133B NM_006559 475 KH domain containing, RNA binding, signal KHDRBS1 10657 — — TTP/resp 43 transduction associated 1 509 211755_s_at HG-U133A BC005960 476 ATP synthase, H+ transporting, ATP5F1 515 — — TTP/resp 48 mitochondrial F0 complex, subunit b, isoform 1 510 222445_at HG-U133B AK025831 477 solute carrier family 39 (zinc transporter), SLC39A9 55334 — — TTP/resp 48 member 9 511 226434_at HG-U133B BF000655 478 hypothetical protein MGC22793 MGC22793 221908 — — TTP/resp 50 512 202596_at HG-U133A BC000436 479 endosulfine alpha ENSA 2029 — — TTP/resp 52 513 203739_at HG-U133A NM_006526 480 zinc finger protein 217 ZNF217 7764 — — TTP/resp 53 514 211987_at HG-U133A NM_001068 481 topoisomerase (DNA) II beta 180 kDa TOP2B 7155 — — TTP/resp 59 515 217492_s_at HG-U133A AF023139 482 phosphatase and tensin homolog (mutated in PTEN 5728 — — TTP/resp 65 multiple advanced cancers 1) 516 223354_x_at HG-U133B BC003191 483 chromosome 2 open reading frame 33 C2orf33 56947 — — TTP/resp 67 517 210792_x_at HG-U133A AF033111 484 CD27-binding (Siva) protein SIVA 10572 — — TTP/resp 71 518 209187_at HG-U133A AW516932 485 down-regulator of transcription 1, TBP- DR1 1810 — — TTP/resp 73 binding (negative cofactor 2) 519 226032_at HG-U133B AU153405 486 caspase 2, apoptosis-related cysteine protease CASP2 835 — — TTP/resp 74 (neural precursor cell expressed, developmentally down-regulated 2) 520 201493_s_at HG-U133A BE778078 487 pumilio homolog 2 (Drosophila) PUM2 23369 — — TTP/resp 78 521 204031_s_at HG-U133A NM_005016 488 poly(rC) binding protein 2 PCBP2 5094 — — TTP/resp 86 522 202720_at HG-U133A NM_015641 489 testis derived transcript (3 LIM domains) TES 26136 — — TTP/resp 94 523 212279_at HG-U133A BE779865 490 hypothetical protein MAC30 MAC30 27346 — — TTP/resp 103 524 211858_x_at HG-U133A AF088184 491 GNAS complex locus GNAS 2778 — — TTP/resp 115 525 226574_at HG-U133B AI872384 492 paraspeckle component 1 /// TPTE and PTEN PSPC1 /// 374491 — — TTP/resp 119 homologous inositol lipid phosphatase LOC374491 /// 55269 pseudogene 526 201390_s_at HG-U133A NM_001320 493 casein kinase 2, beta polypeptide CSNK2B 1460 — — TTP/resp 123 527 211940_x_at HG-U133A BE869922 494 H3 histone, family 3A H3F3A 3020 — — TTP/resp 134 528 223231_at HG-U133B AF212250 495 TatD DNase domain containing 1 TATDN1 83940 — — TTP/resp 134 529 225222_at HG-U133B AI243268 496 hippocampus abundant transcript 1 HIAT1 64645 — — TTP/resp 139 530 212315_s_at HG-U133A AA502912 388 nucleoporin 210 kDa NUP210 23225 — — TTP/resp 149 531 216515_x_at HG-U133A AL121585 497 prothymosin, alpha (gene sequence 28) PTMA 5757 — — TTP/resp 153 532 201019_s_at HG-U133A NM_001412 498 eukaryotic translation initiation factor 1A, X- EIF1AX 1964 — — TTP/resp 168 linked 533 222230_s_at HG-U133A AK022248 499 actin-related protein 10 homolog (S. cerevisiae) ACTR10 55860 — — TTP/resp 173 534 222992_s_at HG-U133B AF261090 500 NADH dehydrogenase (ubiquinone) 1 beta NDUFB9 4715 — — TTP/resp 176 subcomplex, 9, 22 kDa 535 201901_s_at HG-U133A Z14077 501 YY1 transcription factor YY1 7528 — — TTP/resp 196 536 202487_s_at HG-U133A NM_012412 502 H2A histone family, member V H2AFV 94239 — — TTP/resp 209 537 207614_s_at HG-U133A NM_003592 503 cullin 1 CUL1 8454 — — TTP/resp 210 538 202495_at HG-U133A NM_003192 504 tubulin-specific chaperone c TBCC 6903 — — TTP/resp 219 539 210949_s_at HG-U133A BC000533 505 eukaryotic translation initiation factor 3, EIF3S8 8663 — — TTP/resp 234 subunit 8, 110 kDa 540 218247_s_at HG-U133A NM_016626 506 ring finger and KH domain containing 2 RKHD2 51320 — — TTP/resp 236 541 211931_s_at HG-U133A BG505670 507 heterogeneous nuclear ribonucleoprotein A3 HNRPA3 220988 — — TTP/resp 238 542 200647_x_at HG-U133A NM_003752 508 eukaryotic translation initiation factor 3, EIF3S8 8663 — — TTP/resp 244 subunit 8, 110 kDa 543 223091_x_at HG-U133B AF258660 509 chromosome 2 open reading frame 33 C2orf33 56947 — — TTP/resp 244 544 215230_x_at HG-U133A AA679705 510 eukaryotic translation initiation factor 3, EIF3S8 8663 — — TTP/resp 272 subunit 8, 110 kDa 545 200893_at HG-U133A NM_004593 511 splicing factor, arginine/serine-rich 10 SFRS10 6434 — — TTP/resp 285 (transformer 2 homolog, Drosophila) 546 218738_s_at HG-U133A NM_016271 512 ring finger protein 138 RNF138 51444 — — TTP/resp 289 547 200844_s_at HG-U133A BE869583 513 peroxiredoxin 6 PRDX6 9588 — — TTP/resp 292 548 200082_s_at HG-U133A AI805587 514 ribosomal protein S7 RPS7 6201 — resp 1 549 224841_x_at HG-U133B BF316352 515 growth arrest-specific 5 GAS5 60674 — resp 1 550 200082_s_at HG-U133B AI805587 514 ribosomal protein S7 RPS7 6201 — resp 2 551 206790_s_at HG-U133A NM_004545 516 NADH dehydrogenase (ubiquinone) 1 beta NDUFB1 4707 — resp 2 subcomplex, 1, 7 kDa 552 224741_x_at HG-U133B BG329175 517 growth arrest-specific 5 GAS5 60674 — resp 2 553 226835_s_at HG-U133B BG330520 518 Similar to RPE-spondin 441951 — resp 3 554 224915_x_at HG-U133B AV756131 519 Similar to RPE-spondin 441951 — resp 4 555 200937_s_at HG-U133A NM_000969 520 ribosomal protein L5 RPL5 6125 — resp 5 556 220755_s_at HG-U133A NM_016947 521 chromosome 6 open reading frame 48 C6orf48 50854 — resp 11 557 201520_s_at HG-U133A BF034561 522 G-rich RNA sequence binding factor 1 GRSF1 2926 — resp 14 558 217719_at HG-U133A NM_016091 523 eukaryotic translation initiation factor 3, EIF3S6IP 51386 — resp 15 subunit 6 interacting protein 559 226227_x_at HG-U133B BF185165 524 Similar to RPE-spondin 441951 — resp 16 560 202232_s_at HG-U133A NM_006360 52 dendritic cell protein GA17 10480 — resp 17 561 208796_s_at HG-U133A BC000196 525 cyclin G1 CCNG1 900 — resp 23 562 200023_s_at HG-U133B NM_003754 526 eukaryotic translation initiation factor 3, EIF3S5 8665 — resp 26 subunit 5 epsilon, 47 kDa 563 200834_s_at HG-U133A NM_001024 527 ribosomal protein S21 RPS21 6227 — resp 27 564 201258_at HG-U133A NM_001020 528 ribosomal protein S16 RPS16 6217 — resp 36 565 200023_s_at HG-U133A NM_003754 526 eukaryotic translation initiation factor 3, EIF3S5 8665 — resp 40 subunit 5 epsilon, 47 kDa 566 225698_at HG-U133B BF314746 529 TIGA1 TIGA1 114915 — resp 41 567 200024_at HG-U133B NM_001009 530 — resp 58 568 221434_s_at HG-U133A NM_031210 531 chromosome 14 open reading frame 156 C14orf156 81892 — resp 63 569 225190_x_at HG-U133B AW402660 532 ribosomal protein L35a RPL35A 6165 — resp 70 570 200024_at HG-U133A NM_001009 530 — resp 71 571 200903_s_at HG-U133A NM_000687 533 S-adenosylhomocysteine hydrolase AHCY 191 — resp 76 572 234875_at HG-U133B AJ224082 534 — resp 84 573 225065_x_at HG-U133B AI826279 535 hypothetical protein MGC40157 MGC40157 125144 — resp 98 574 217969_at HG-U133A NM_013265 536 chromosome 11 open reading frame2 C11orf2 738 — resp 104 575 201653_at HG-U133A NM_005776 537 cornichon homolog (Drosophila) CNIH 10175 — resp 105 576 200019_s_at HG-U133B NM_001997 538 Finkel-Biskis-Reilly murine sarcoma virus FAU 2197 — resp 107 (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30 577 200030_s_at HG-U133A NM_002635 539 solute carrier family 25 (mitochondrial SLC25A3 5250 — resp 112 carrier; phosphate carrier), member 3 578 216380_x_at HG-U133A AC005011 540 — resp 121 579 200826_at HG-U133A NM_004597 541 small nuclear ribonucleoprotein D2 SNRPD2 6633 — resp 122 polypeptide 16.5 kDa 580 200030_s_at HG-U133B NM_002635 539 solute carrier family 25 (mitochondrial SLC25A3 5250 — resp 124 carrier; phosphate carrier), member 3 581 221691_x_at HG-U133A AB042278 542 nucleophosmin (nucleolar phosphoprotein NPM1 4869 — resp 127 B23, numatrin) 582 211937_at HG-U133A NM_001417 543 eukaryotic translation initiation factor 4B EIF4B 1975 — resp 132 583 208742_s_at HG-U133A U78303 544 sin3-associated polypeptide, 18 kDa SAP18 10284 — resp 146 584 200869_at HG-U133A NM_000980 545 ribosomal protein L18a RPL18A 6142 — resp 158 585 212644_s_at HG-U133A AI671747 546 chromosome 14 open reading frame 32 C14orf32 93487 — resp 160 586 222975_s_at HG-U133B AI423180 547 upstream of NRAS UNR 7812 — resp 176 587 219030_at HG-U133A NM_016058 548 CGI-121 protein CGI-121 51002 — resp 189 588 201682_at HG-U133A NM_004279 549 peptidase (mitochondrial processing) beta PMPCB 9512 — resp 195 589 207573_x_at HG-U133A NM_006476 550 ATP synthase, H+ transporting, ATP5L 10632 — resp 206 mitochondrial F0 complex, subunit g 590 209786_at HG-U133A BC001282 193 high mobility group nucleosomal binding HMGN4 10473 — resp 219 domain 4 591 200019_s_at HG-U133A NM_001997 538 Finkel-Biskis-Reilly murine sarcoma virus FAU 2197 — resp 236 (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30 592 210453_x_at HG-U133A AL050277 551 ATP synthase, H+ transporting, ATP5L 10632 — resp 248 mitochondrial F0 complex, subunit g 593 226243_at HG-U133B BF590958 552 Similar to CG14903-PA 391356 — resp 253 594 222465_at HG-U133B AF165521 553 chromosome 15 open reading frame 15 C15orf15 51187 — resp 255 595 229050_s_at HG-U133B AL533103 554 hypothetical protein MGC16037 MGC16037 84973 — resp 294 596 217915_s_at HG-U133A NM_016304 555 chromosome 15 open reading frame 15 C15orf15 51187 — resp 296 597 201532_at HG-U133A NM_002788 556 proteasome (prosome, macropain) subunit, PSMA3 5684 — resp 309 alpha type, 3 598 239237_at HG-U133B AI798822 557 LOC442534 442534 — resp 322 599 202026_at HG-U133A NM_003002 558 succinate dehydrogenase complex, subunit D, SDHD 6392 — resp 325 integral membrane protein 600 221726_at HG-U133A BE250348 559 ribosomal protein L22 RPL22 6146 — resp 326 601 201177_s_at HG-U133A NM_005499 560 SUMO-1 activating enzyme subunit 2 UBA2 10054 — resp 357 602 201892_s_at HG-U133A NM_000884 561 IMP (inosine monophosphate) dehydrogenase 2 IMPDH2 3615 — resp 360 603 200037_s_at HG-U133B NM_016587 562 chromobox homolog 3 (HP1 gamma CBX3 11335 — resp 368 homolog, Drosophila) 604 216274_s_at HG-U133A N99438 563 SEC11-like 1 (S. cerevisiae) SEC11L1 23478 — resp 376 605 214167_s_at HG-U133A AA555113 564 ribosomal protein, large, P0 RPLP0 6175 — resp 389 606 213738_s_at HG-U133A AI587323 565 ATP synthase, H+ transporting, ATP5A1 498 — resp 424 mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle 607 222410_s_at HG-U133B AF121856 566 sorting nexin 6 SNX6 58533 — resp 495 608 222784_at HG-U133B AJ249900 567 — resp 496 609 200003_s_at HG-U133B NM_000991 568 ribosomal protein L28 RPL28 6158 — resp 503 610 222427_s_at HG-U133B AK021413 569 leucyl-tRNA synthetase LARS 51520 — resp 516 611 200715_x_at HG-U133A BC000514 570 ribosomal protein L13a RPL13A 23521 — resp 524 612 201554_x_at HG-U133A NM_004130 571 glycogenin GYG 2992 — resp 526 613 200047_s_at HG-U133B NM_003403 572 YY1 transcription factor YY1 7528 — resp 529 614 215733_x_at HG-U133A AJ012833 573 cancer/testis antigen 2 CTAG2 30848 — — resp 3 615 201491_at HG-U133A NM_012111 574 AHA1, activator of heat shock 90 kDa protein AHSA1 10598 — TTP 266 ATPase homolog 1 (yeast) 616 210467_x_at HG-U133A BC003408 575 melanoma antigen family A, 12 MAGEA12 4111 — TTP 283 617 210546_x_at HG-U133A U87459 576 cancer/testis antigen 1B /// cancer/testis CTAG1B 1485 /// — — TTP/resp 1 antigen 1A /// 246100 CTAG1A 618 211674_x_at HG-U133A AF038567 577 cancer/testis antigen 1B /// cancer/testis CTAG1B 1485 /// — — TTP/resp 1 antigen 1A /// 246100 CTAG1A 619 224985_at HG-U133B BE964484 578 Neuroblastoma RAS viral (v-ras) oncogene NRAS 4893 — — TTP/resp 2 homolog 620 200043_at HG-U133A NM_004450 579 enhancer of rudimentary homolog ERH 2079 — — TTP/resp 3 (Drosophila) 621 200043_at HG-U133B NM_004450 579 enhancer of rudimentary homolog ERH 2079 — — TTP/resp 13 (Drosophila) 622 222783_s_at HG-U133B BF516292 580 SPARC related modular calcium binding 1 SMOC1 64093 — — TTP/resp 21 623 211747_s_at HG-U133A BC005938 581 LSM5 homolog, U6 small nuclear RNA LSM5 23658 — — TTP/resp 25 associated (S. cerevisiae) 624 223358_s_at HG-U133B AW269834 582 Phosphodiesterase 7A PDE7A 5150 — — TTP/resp 37 625 200921_s_at HG-U133A NM_001731 583 B-cell translocation gene 1, anti-proliferative BTG1 694 — — TTP/resp 67 626 200037_s_at HG-U133A NM_016587 562 chromobox homolog 3 (HP1 gamma CBX3 11335 — — TTP/resp 99 homolog, Drosophila) 627 208743_s_at HG-U133A BC001359 584 tyrosine 3-monooxygenase/tryptophan 5- YWHAB 7529 — — TTP/resp 118 monooxygenase activation protein, beta polypeptide 628 201825_s_at HG-U133A AL572542 585 CGI-49 protein CGI-49 51097 — — TTP/resp 143 629 200047_s_at HG-U133A NM_003403 572 YY1 transcription factor YY1 7528 — — TTP/resp 240 630 202591_s_at HG-U133A NM_003143 586 single-stranded DNA binding protein 1 SSBP1 6742 — — TTP/resp 248 631 209036_s_at HG-U133A BC001917 587 malate dehydrogenase 2, NAD MDH2 4191 — — TTP/resp 271 (mitochondrial) 632 200949_x_at HG-U133A NM_001023 588 ribosomal protein S20 RPS20 6224 — resp 30 633 219939_s_at HG-U133A NM_007158 589 upstream of NRAS UNR 7812 — resp 82 634 214003_x_at HG-U133A BF184532 590 ribosomal protein S20 RPS20 6224 — resp 118 635 208764_s_at HG-U133A D13119 591 ATP synthase, H+ transporting, ATP5G2 517 — resp 170 mitochondrial F0 complex, subunit c (subunit 9), isoform 2 636 201011_at HG-U133A NM_002950 592 ribophorin I RPN1 6184 — resp 179 637 222035_s_at HG-U133A AI984479 593 poly(A) polymerase alpha PAPOLA 10914 — resp 187 638 209066_x_at HG-U133A M26700 594 ubiquinol-cytochrome c reductase binding UQCRB 7381 — resp 298 protein 639 212807_s_at HG-U133A BF447105 595 sortilin 1 SORT1 6272 — resp 349 640 212266_s_at HG-U133A AW084582 596 splicing factor, arginine/serine-rich 5 SFRS5 6430 — resp 362 641 217846_at HG-U133A NM_005051 597 glutaminyl-tRNA synthetase QARS 5859 — resp 379 642 202579_x_at HG-U133A NM_006353 598 high mobility group nucleosomal binding HMGN4 10473 — resp 451 domain 4 643 202105_at HG-U133A NM_001551 599 immunoglobulin (CD79A) binding protein 1 IGBP1 3476 — resp 599 644 203380_x_at HG-U133A NM_006925 600 splicing factor, arginine/serine-rich 5 SFRS5 6430 — resp 683 645 208668_x_at HG-U133A BC003689 601 high-mobility group nucleosomal binding HMGN2 3151 — TTP 67 domain 2 646 212718_at HG-U133A BF797555 602 poly(A) polymerase alpha PAPOLA 10914 — TTP 85 647 218233_s_at HG-U133A NM_017601 603 chromosome 6 open reading frame 49 C6orf49 29964 — TTP 127 648 218482_at HG-U133A NM_020189 604 e(y)2 protein e(y)2 56943 — TTP 226 649 218850_s_at HG-U133A NM_014240 605 LIM domains containing 1 LIMD1 8994 — TTP 264 650 230769_at HG-U133B AI916261 606 FLJ37099 protein FLJ37099 163259 — — TTP 1 651 207654_x_at HG-U133A NM_001938 607 down-regulator of transcription 1, TBP- DR1 1810 — — TTP 227 binding (negative cofactor 2) 652 210532_s_at HG-U133A AF116639 608 chromosome 14 open reading frame 2 C14orf2 9556 — — TTP/resp 1 653 209899_s_at HG-U133A AF217197 609 fuse-binding protein-interacting repressor SIAHBP1 22827 — — TTP/resp 4 654 211783_s_at HG-U133A BC006177 610 metastasis associated 1 MTA1 9112 — — TTP/resp 55 655 201840_at HG-U133A NM_006156 611 neural precursor cell expressed, NEDD8 4738 — — TTP/resp 71 developmentally down-regulated 8 656 200920_s_at HG-U133A AL535380 612 B-cell translocation gene 1, anti-proliferative BTG1 694 — — TTP/resp 87 657 222789_at HG-U133B R45958 613 round spermatid basic protein 1 RSBN1 54665 — — TTP/resp 222

1B Predictive Markers Upregulated Indicators of Response and/or Long Time to Progression SEQ Entrez Type of ProbeSet Rep Public ID Gene Gene TTP Response speci- No. ID chip ID NO: Title Symbol ID marker marker ficity Rank 658 219073_s_at HG-U133A NM_017784 614 oxysterol binding protein-like 10 OSBPL10 114884 + + resp 116 659 227168_at HG-U133B BF475488 615 hypothetical gene supported by LOC440823 440823 + resp 3 AK098833 660 204122_at HG-U133A NM_003332 616 TYRO protein tyrosine kinase TYROBP 7305 + resp 6 binding protein 661 209101_at HG-U133A M92934 617 connective tissue growth factor CTGF 1490 + resp 6 662 204208_at HG-U133A NM_003800 618 RNA guanylyltransferase and 5′- RNGTT 8732 + resp 8 phosphatase 663 223044_at HG-U133B AL136944 619 solute carrier family 40 SLC40A1 30061 + resp 9 (iron-regulated transporter), member 1 664 213915_at HG-U133A NM_005601 620 natural killer cell group 7 NKG7 4818 + resp 10 sequence 665 224616_at HG-U133B BG110975 621 dynein, cytoplasmic, light DNCLI2 1783 + resp 11 intermediate polypeptide 2 666 214574_x_at HG-U133A NM_007161 622 leukocyte specific transcript 1 LST1 7940 + resp 12 667 204834_at HG-U133A NM_006682 623 fibrinogen-like 2 FGL2 10875 + resp 13 668 212646_at HG-U133A D42043 624 raft-linking protein RAFTLIN 23180 + resp 18 669 231078_at HG-U133B H69701 625 Mitochondrial solute carrier MSCP 51312 + resp 20 protein 670 230499_at HG-U133B AA805622 626 Baculoviral IAP repeat-containing 3 BIRC3 330 + resp 21 671 208540_x_at HG-U133A NM_021039 627 + resp 24 672 203568_s_at HG-U133A NM_006355 628 tripartite motif-containing 38 TRIM38 10475 + resp 29 673 200941_at HG-U133A AK026575 629 heat shock factor binding protein 1 HSBP1 3281 + resp 31 674 222368_at HG-U133A AW972351 630 + resp 33 675 1729_at HG-U133A L41690 631 TNFRSF1A-associated via death TRADD 8717 + resp 34 domain 676 212136_at HG-U133A AW517686 632 ATPase, Ca++ transporting, plasma ATP2B4 493 + resp 36 membrane 4 677 213193_x_at HG-U133A AL559122 633 T cell receptor beta constant 1 TRBC1 28639 + resp 38 678 203290_at HG-U133A NM_002122 634 major histocompatibility complex, HLA- 3117 /// 3118 + resp 40 class II, DQ alpha 1 /// major DQA1 /// histocompatibility complex, class HLA- II, DQ alpha 2 DQA2 679 229147_at HG-U133B AW070877 635 + resp 42 680 221495_s_at HG-U133A AF322111 636 KIAA1049 protein KIAA1049 22980 + resp 46 681 203221_at HG-U133A AI758763 637 transducin-like enhancer of split 1 TLE1 7088 + resp 56 (E(sp1) homolog, Drosophila) 682 203542_s_at HG-U133A AI690205 638 Kruppel-like factor 9 KLF9 687 + resp 57 683 213275_x_at HG-U133A W47179 639 Cathepsin B CTSB 1508 + resp 64 684 216063_at HG-U133A N55205 640 + resp 65 685 213311_s_at HG-U133A BF000251 641 KIAA1049 protein KIAA1049 22980 + resp 66 686 202436_s_at HG-U133A AU144855 642 cytochrome P450, family 1, subfamily CYP1B1 1545 + resp 70 B, polypeptide 1 687 215051_x_at HG-U133A BF213829 643 allograft inflammatory factor 1 AIF1 199 + resp 73 688 238025_at HG-U133B AA706818 644 mixed lineage kinase domain-like MLKL 197259 + resp 73 689 200860_s_at HG-U133A BC000779 645 CCR4-NOT transcription complex, CNOT1 23019 + resp 74 subunit 1 690 200696_s_at HG-U133A NM_000177 646 gelsolin (amyloidosis, Finnish type) GSN 2934 + resp 79 691 201705_at HG-U133A NM_002811 647 proteasome (prosome, macropain) 26S PSMD7 5713 + resp 79 subunit, non-ATPase, 7 (Mov34 homolog) 692 220792_at HG-U133A NM_018699 648 PR domain containing 5 PRDM5 11107 + resp 80 693 219910_at HG-U133A NM_007076 649 Huntingtin interacting protein E HYPE 11153 + resp 83 694 211981_at HG-U133A NM_001845 650 collagen, type IV, alpha 1 COL4A1 1282 + resp 85 695 210950_s_at HG-U133A BC003573 651 farnesyl-diphosphate FDFT1 2222 + resp 86 farnesyltransferase 1 696 212135_s_at HG-U133A AW517686 632 ATPase, Ca++ transporting, plasma ATP2B4 493 + resp 86 membrane 4 697 217889_s_at HG-U133A NM_024843 652 cytochrome b reductase 1 CYBRD1 79901 + resp 90 698 204207_s_at HG-U133A AB012142 653 RNA guanylyltransferase and 5′- RNGTT 8732 + resp 91 phosphatase 699 213274_s_at HG-U133A AA020826 654 cathepsin B CTSB 1508 + resp 93 700 243780_at HG-U133B AW575863 655 CDNA FLJ46553 fis, clone + resp 96 THYMU3038879 701 209118_s_at HG-U133A AF141347 656 tubulin, alpha 3 TUBA3 7846 + resp 98 702 205051_s_at HG-U133A NM_000222 657 v-kit Hardy-Zuckerman 4 feline KIT 3815 + resp 101 sarcoma viral oncogene homolog 703 202497_x_at HG-U133A AI631159 658 solute carrier family 2 SLC2A3 6515 + resp 102 (facilitated glucose transporter), member 3 704 208791_at HG-U133A M25915 659 clusterin (complement lysis CLU 1191 + resp 105 inhibitor, SP-40, 40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J) 705 209607_x_at HG-U133A U08032 660 sulfotransferase family, cytosolic, SULT1A3 6818 + resp 108 1A, phenol-preferring, member 3 706 203973_s_at HG-U133A NM_005195 661 CCAAT/enhancer binding protein CEBPD 1052 + resp 111 (C/EBP), delta 707 209047_at HG-U133A AL518391 662 aquaporin 1 (channel-forming AQP1 358 + resp 117 integral protein, 28 kDa) 708 212007_at HG-U133A AI927512 663 UBX domain containing 2 UBXD2 23190 + resp 119 709 224917_at HG-U133B BF674052 664 likely ortholog of rat vacuole VMP1 81671 + resp 124 membrane protein 1 710 213574_s_at HG-U133A AA861608 665 Karyopherin (importin) beta 1 KPNB1 3837 + resp 129 711 206666_at HG-U133A NM_002104 666 granzyme K (serine protease, GZMK 3003 + resp 146 granzyme 3; tryptase II) 712 210666_at HG-U133A AF050145 667 iduronate 2-sulfatase (Hunter IDS 3423 + resp 148 syndrome) 713 209013_x_at HG-U133A AF091395 668 triple functional domain (PTPRF TRIO 7204 + resp 153 interacting) 714 213164_at HG-U133A AI867198 669 solute carrier family 5 (inositol SLC5A3 6526 + resp 153 transporters), member 3 715 205641_s_at HG-U133A NM_003789 670 TNFRSF1A-associated via death domain TRADD 8717 + resp 155 716 226599_at HG-U133B AA527080 671 KIAA1727 protein KIAA1727 85462 + resp 155 717 210835_s_at HG-U133A AF222711 672 C-terminal binding protein 2 CTBP2 1488 + resp 159 718 226430_at HG-U133B AI394438 673 hypothetical protein LOC253981 LOC253981 253981 + resp 160 719 213396_s_at HG-U133A AA456929 674 A kinase (PRKA) anchor protein 10 AKAP10 11216 + resp 161 720 209018_s_at HG-U133A BF432478 675 PTEN induced putative kinase 1 PINK1 65018 + resp 164 721 239629_at HG-U133B AI634046 676 + resp 168 722 212724_at HG-U133A BG054844 677 Rho family GTPase 3 RND3 390 + resp 172 723 219577_s_at HG-U133A NM_019112 678 ATP-binding cassette, sub-family A ABCA7 10347 + resp 175 (ABC1), member 7 724 206150_at HG-U133A NM_001242 679 tumor necrosis factor receptor TNFRSF7 939 + resp 177 superfamily, member 7 725 238063_at HG-U133B AA806283 680 hypothetical protein FLJ32028 FLJ32028 201799 + resp 188 726 202292_x_at HG-U133A NM_007260 681 lysophospholipase II LYPLA2 11313 + resp 191 727 212041_at HG-U133A AL566172 682 ATPase, H+ transporting, lysosomal ATP6V0D1 9114 + resp 199 38 kDa, V0 subunit d isoform 1 728 205990_s at HG-U133A NM_003392 683 wingless-type MMTV integration site WNT5A 7474 + resp 200 family, member 5A 729 212944_at HG-U133A AK024896 684 Mitochondrial ribosomal protein S6 MRPS6 64968 + resp 203 730 224159_x_at HG-U133B AF220023 685 tripartite motif-containing 4 TRIM4 89122 + resp 205 731 235638_at HG-U133B AI167789 686 Ras association (RalGDS/AF-6) domain RASSF6 166824 + resp 206 family 6 732 212588_at HG-U133A Y00062 687 protein tyrosine phosphatase, PTPRC 5788 + resp 209 receptor type, C 733 202283_at HG-U133A NM_002615 688 serine (or cysteine) proteinase SERPINF1 5176 + resp 211 inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 734 221804_s_at HG-U133A BE565675 689 family with sequence similarity 45, FAM45B /// 404636 /// 55855  + resp 215 member B /// family with sequence FAM45A similarity 45, member A 735 203909_at HG-U133A NM_006359 690 solute carrier family 9 SLC9A6 10479 + resp 216 (sodium/hydrogen exchanger), isoform 6 736 200675_at HG-U133A NM_004356 691 CD81 antigen (target of CD81 975 + resp 217 antiproliferative antibody 1) 737 209939_x_at HG-U133A AF005775 692 CASP8 and FADD-like apoptosis CFLAR 8837 + resp 218 regulator 738 212884_x_at HG-U133A AI358867 693 + resp 219 739 206337_at HG-U133A NM_001838 694 chemokine (C-C motif) receptor 7 CCR7 1236 + resp 220 740 208178_x_at HG-U133A NM_007118 695 triple functional domain (PTPRF TRIO 7204 + resp 220 interacting) 741 225626_at HG-U133B AK000680 696 phosphoprotein associated with PAG 55824 + resp 221 glycosphingolipid-enriched microdomains 742 201024_x_at HG-U133A BG261322 697 eukaryotic translation initiation EIF5B 9669 + resp 223 factor 5B 743 204115_at HG-U133A NM_004126 698 guanine nucleotide binding protein GNG11 2791 + resp 224 (G protein), gamma 11 744 212240_s_at HG-U133A AI679268 699 phosphoinositide-3-kinase, PIK3R1 5295 + resp 224 regulatory subunit 1 (p85 alpha) 745 202615_at HG-U133A BF222895 700 guanine nucleotide binding protein GNAQ 2776 + resp 225 (G protein), q polypeptide 746 210580_x_at HG-U133A L25275 701 sulfotransferase family, cytosolic, SULT1A3 6818 + resp 226 1A, phenol-preferring, member 3 747 242121_at HG-U133B AW973232 702 Ring finger protein 12 RNF12 51132 + resp 226 748 213539_at HG-U133A NM_000732 703 CD3D antigen, delta polypeptide CD3D 915 + resp 233 (TiT3 complex) 749 218505_at HG-U133A NM_024673 704 FLJ12270 protein FLJ12270 79726 + resp 235 750 212982_at HG-U133A AI621223 705 zinc finger, DHHC domain ZDHHC17 23390 + resp 249 containing 17 751 202803_s_at HG-U133A NM_000211 706 integrin, beta 2 (antigen CD18 (p95), ITGB2 3689 + resp 251 lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) 752 236368_at HG-U133B BF059292 707 KIAA0368 KIAA0368 23392 + resp 261 753 218223_s_at HG-U133A NM_016274 708 CK2 interacting protein 1; HQ0024c CKIP-1 51177 + resp 262 protein 754 203186_s_at HG-U133A NM_002961 709 S100 calcium binding protein A4 S100A4 6275 + resp 264 (calcium protein, calvasculin, metastasin, murine placental homolog) 755 219563_at HG-U133A NM_024633 710 chromosome 14 open reading frame 139 C14orf139 79686 + resp 266 756 219290_x_at HG-U133A NM_014395 711 dual adaptor of phosphotyrosine and DAPP1 27071 + resp 268 3-phosphoinositides 757 214085_x_at HG-U133A AI912583 712 + resp 270 758 208648_at HG-U133A W60953 713 valosin-containing protein VCP 7415 + resp 272 759 211339_s_at HG-U133A D13720 714 IL2-inducible T-cell kinase ITK 3702 + resp 274 760 213095_x_at HG-U133A AF299327 715 allograft inflammatory factor 1 AIF1 199 + resp 291 761 221731_x_at HG-U133A BF218922 716 chondroitin sulfate proteoglycan 2 CSPG2 1462 + resp 302 (versican) 762 201828_x_at HG-U133A NM_003928 717 CAAX box 1 CXX1 8933 + resp 305 763 203988_s_at HG-U133A NM_004480 718 fucosyltransferase 8 (alpha (1,6) FUT8 2530 + resp 306 fucosyltransferase) 764 225918_at HG-U133B AI742940 719 Hypothetical protein LOC146346 LOC146346 146346 + resp 311 765 215949_x_at HG-U133A BF002659 720 immunoglobulin heavy constant mu IGHM 3507 + resp 312 766 209164_s_at HG-U133A BC002976 721 cytochrome b-561 CYB561 1534 + resp 314 767 201998_at HG-U133A AI743792 722 ST6 beta-galactosamide alpha-2,6- ST6GAL1 6480 + resp 315 sialyltranferase 1 768 202484_s_at HG-U133A AF072242 723 methyl-CpG binding domain protein 2 MBD2 8932 + resp 316 769 215588_x_at HG-U133A AK024958 724 RIO kinase 3 (yeast) RIOK3 8780 + resp 316 770 235028_at HG-U133B BG288330 725 CDNA FLJ42313 fis, clone + resp 317 TRACH2019425 771 238701_x_at HG-U133B BE176566 726 FLJ45803 protein FLJ45803 399948 + resp 319 772 202771_at HG-U133A NM_014745 727 family with sequence similarity 38, FAM38A 9780 + resp 320 member A 773 235327_x_at HG-U133B BG111015 728 UBX domain containing 4 UBXD4 165324 + resp 326 774 210357_s_at HG-U133A BC000669 729 spermine oxidase SMOX 54498 + resp 328 775 204588_s_at HG-U133A NM_003982 730 solute carrier family 7 (cationic SLC7A7 9056 + resp 333 amino acid transporter, y+ system), member 7 776 32069_at HG-U133A AB014515 731 Nedd4 binding protein 1 N4BP1 9683 + resp 334 777 203868_s_at HG-U133A NM_001078 732 vascular cell adhesion molecule 1 VCAM1 7412 + resp 336 778 201012_at HG-U133A NM_000700 733 annexin A1 ANXA1 301 + resp 337 779 231093_at HG-U133B BF514552 734 Fc receptor-like protein 3 FCRH3 115352 + resp 340 780 213425_at HG-U133A AI968085 735 wingless-type MMTV integration site WNT5A 7474 + resp 342 family, member 5A 781 214494_s_at HG-U133A NM_005200 736 spastic paraplegia 7, paraplegin SPG7 6687 + resp 342 (pure and complicated autosomal recessive) 782 214902_x_at HG-U133A AL080232 737 FLJ42393 protein FLJ42393 401105 + resp 344 783 202908_at HG-U133A NM_006005 738 Wolfram syndrome 1 (wolframin) WFS1 7466 + resp 348 784 205968_at HG-U133A NM_002252 739 potassium voltage-gated channel, KCNS3 3790 + resp 349 delayed-rectifier, subfamily S, member 3 785 202449_s_at HG-U133A NM_002957 740 retinoid X receptor, alpha RXRA 6256 + resp 355 786 209539_at HG-U133A D25304 741 Rac/Cdc42 guanine nucleotide ARHGEF6 9459 + resp 355 exchange factor (GEF) 6 787 241223_x_at HG-U133B AI821721 742 + resp 356 788 234675_x_at HG-U133B AK027219 743 CDNA: FLJ23566 fis, clone LNG10880 + resp 369 789 212994_at HG-U133A BE543527 744 THO complex 2 THOC2 57187 + resp 375 790 225929_s_at HG-U133B AA233374 745 chromosome 17 open reading frame 27 C17orf27 57674 + resp 377 791 215111_s_at HG-U133A AK027071 746 transforming growth factor beta 1 TGFB1I4 8848 + resp 381 induced transcript 4 792 204872_at HG-U133A NM_007005 747 transducin-like enhancer of split 4 TLE4 7091 + resp 382 (E(sp1) homolog, Drosophila) 793 208082_x_at HG-U133A NM_030757 748 + resp 398 794 227749_at HG-U133B AI703496 749 Transcribed locus + resp 407 795 213572_s_at HG-U133A AI554300 750 serine (or cysteine) proteinase SERPINB1 1992 + resp 408 inhibitor, clade B (ovalbumin), member 1 796 212754_s_at HG-U133A AI760249 751 KIAA1040 protein KIAA1040 23041 + resp 410 797 203123_s_at HG-U133A AU154469 752 solute carrier family 11 SLC11A2 4891 + resp 412 (proton-coupled divalent metal ion transporters), member 2 798 214726_x_at HG-U133A AL556041 753 adducin 1 (alpha) ADD1 118 + resp 415 799 212810_s_at HG-U133A W72527 754 solute carrier family 1 (glutamate/ SLC1A4 6509 + resp 434 neutral amino acid transporter), member 4 800 207730_x_at HG-U133A NM_017932 755 KIAA1881 KIAA1881 114782 + resp 437 801 225361_x_at HG-U133B AI348001 756 similar to hypothetical LOC159090 159090 + resp 439 protein MGC17347 802 201778_s_at HG-U133A NM_014774 757 KIAA0494 gene product KIAA0494 9813 + resp 442 803 216858_x_at HG-U133A AL080112 758 + resp 445 804 214696_at HG-U133A AF070569 759 hypothetical protein MGC14376 MGC14376 84981 + resp 456 805 218066_at HG-U133A NM_006598 760 solute carrier family 12 SLC12A7 10723 + resp 457 (potassium/chloride transporters), member 7 806 210563_x_at HG-U133A U97075 761 CASP8 and FADD-like apoptosis CFLAR 8837 + resp 461 regulator 807 201057_s_at HG-U133A NM_004487 762 golgi autoantigen, golgin subfamily GOLGB1 2804 + resp 465 b, macrogolgin (with transmembrane signal), 1 808 209183_s_at HG-U133A AL136653 763 chromosome 10 open reading frame 10 C10orf10 11067 + resp 469 809 226474_at HG-U133B AA005023 764 nucleotide-binding oligomerization NOD27 84166 + resp 472 domains 27 810 225507_at HG-U133B BF591408 765 chromosome 6 open reading frame 111 C6orf111 25957 + resp 474 811 212177_at HG-U133A AW081113 766 chromosome 6 open reading frame 111 C6orf111 25957 + resp 476 812 216510_x_at HG-U133A AB035175 767 immunoglobulin heavy constant gamma 1 IGHG1 ///  3500 /// 390714 + resp 478 (G1m marker) /// similar to Ig heavy LOC390714 chain V-III region VH26 precursor 813 215600_x_at HG-U133A AK022174 768 F-box and WD-40 domain protein 12 FBXW12 285231 + resp 483 814 215811_at HG-U133A AF238870 769 + resp 484 815 220940_at HG-U133A NM_025190 770 KIAA1641 KIAA1641 57730 + resp 497 816 217728_at HG-U133A NM_014624 771 S100 calcium binding protein A6 S100A6 6277 + resp 499 (calcyclin) 817 232266_x_at HG-U133B AK024379 772 Cell division cycle 2-like 5 CDC2L5 8621 + resp 507 (cholinesterase-related cell division controller) 818 201674_s_at HG-U133A BC000729 773 A kinase (PRKA) anchor protein 1 AKAP1 8165 + resp 511 819 206846_s_at HG-U133A NM_006044 774 histone deacetylase 6 HDAC6 10013 + resp 515 820 202587_s_at HG-U133A BC001116 775 adenylate kinase 1 AK1 203 + resp 519 821 211034_s_at HG-U133A BC006270 776 AF-1 specific protein phosphatase FLJ30092 196515 + resp 523 822 209485_s_at HG-U133A W19983 777 oxysterol binding protein-like 1A OSBPL1A 114876 + resp 524 823 232008_s_at HG-U133B AF283775 778 bobby sox homolog (Drosophila) BBX 56987 + resp 528 824 218155_x_at HG-U133A AK026565 779 hypothetical protein FLJ10534 FLJ10534 55720 + resp 529 825 207986_x_at HG-U133A NM_001915 780 + resp 534 826 234981_x_at HG-U133B BE537881 781 similar to mouse 2310016A09Rik gene LOC134147 134147 + resp 537 827 226659_at HG-U133B Z97832 782 differentially expressed in FDCP 6 DEF6 50619 + resp 540 homolog (mouse) 828 201141_at HG-U133A NM_002510 783 glycoprotein (transmembrane) nmb GPNMB 10457 + resp 549 829 221973_at HG-U133A AI983904 784 Hypothetical protein LOC150759 LOC150759 150759 + resp 551 830 206380_s_at HG-U133A NM_002621 785 properdin P factor, complement PFC 5199 + resp 552 831 215179_x_at HG-U133A AK023843 786 Placental growth factor, vascular PGF 5228 + resp 554 endothelial growth factor-related protein 832 211582_x_at HG-U133A AF000424 787 leukocyte specific transcript 1 LST1 7940 + resp 556 833 217761_at HG-U133A NM_018269 788 membrane-type 1 matrix MTCBP-1 55256 + resp 557 metalloproteinase cytoplasmic tail binding protein-1 834 210915_x_at HG-U133A M15564 789 T cell receptor beta constant 1 TRBC1 28639 + resp 561 835 233702_x_at HG-U133B AK024599 790 CDNA: FLJ20946 fis, clone ADSE01819 + resp 562 836 204842_x_at HG-U133A BC002763 791 protein kinase, cAMP-dependent, PRKAR2A 5576 + resp 563 regulatory, type II, alpha 837 33323_r_at HG-U133A X57348 792 stratifin SFN 2810 + resp 565 838 204232_at HG-U133A NM_004106 793 Fc fragment of IgE, high affinity I, FCER1G 2207 + resp 567 receptor for; gamma polypeptide 839 233056_x_at HG-U133B AK024674 794 discs, large (Drosophila) homolog- DLGAP4 22839 + resp 569 associated protein 4 840 215553_x_at HG-U133A AK024315 795 WD repeat domain 45 WDR45 11152 + resp 574 841 222380_s_at HG-U133A AI907083 796 Similar to Microneme antigen 391733 + resp 578 842 60471_at HG-U133A AA625133 797 Ras and Rab interactor 3 RIN3 79890 + resp 586 843 206929_s_at HG-U133A NM_005597 798 nuclear factor I/C (CCAAT-binding NFIC 4782 + resp 591 transcription factor) 844 211452_x_at HG-U133A AF130054 799 + resp 592 845 239748_x_at HG-U133B H09533 800 + resp 596 846 222187_x_at HG-U133A X78262 801 Ras-GTPase-activating protein SH3- G3BP 10146 + resp 603 domain-binding protein 847 208246_x_at HG-U133A NM_017618 802 Thymidine kinase 2, mitochondrial TK2 7084 + resp 605 848 243198_at HG-U133B AA020920 803 testis expressed gene 9 TEX9 374618 + resp 609 849 211992_at HG-U133A AI445745 804 WNK lysine deficient protein kinase 1 WNK1 65125 + resp 612 850 217198_x_at HG-U133A U80164 805 immunoglobulin heavy locus /// IGH@ /// 3492 /// 3500 + resp 614 immunoglobulin heavy constant IGHG1 gamma 1 (G1m marker) 851 34210_at HG-U133A N90866 806 CD52 antigen (CAMPATH-1 antigen) CD52 1043 + resp 616 852 231828_at HG-U133B AL117474 807 Homo sapiens, clone IMAGE: 5218355, + resp 619 mRNA 853 202040_s_at HG-U133A NM_005056 808 Jumonji, AT rich interactive domain JARID1A 5927 + resp 622 1A (RBBP2-like) 854 222357_at HG-U133A AW974823 809 zinc finger and BTB domain ZBTB20 26137 + resp 631 containing 20 855 238668_at HG-U133B AI130690 810 Transcribed locus + resp 633 856 236715_x_at HG-U133B BF056139 811 + resp 640 857 241347_at HG-U133B AA936632 812 KIAA1618 KIAA1618 57714 + resp 645 858 208459_s_at HG-U133A NM_015024 813 exportin 7 XPO7 23039 + resp 648 859 208238_x_at HG-U133A NM_013344 814 + resp 667 860 204661_at HG-U133A NM_001803 815 CD52 antigen (CAMPATH-1 antigen) CD52 1043 + resp 668 861 202450_s_at HG-U133A NM_000396 816 cathepsin K (pycnodysostosis) CTSK 1513 + resp 675 862 209377_s_at HG-U133A AF274949 817 high mobility group nucleosomal HMGN3 9324 + resp 681 binding domain 3 863 215577_at HG-U133A AU146791 818 Ubiquitin-conjugating enzyme E2E 1 UBE2E1 7324 + resp 688 (UBC4/5 homolog, yeast) 864 221253_s_at HG-U133A NM_030810 819 thioredoxin domain containing 5 TXNDC5 81567 + TTP 92 865 216231_s_at HG-U133A AW188940 820 beta-2-microglobulin B2M 567 + TTP 156 866 223577_x_at HG-U133B AA827878 821 + TTP 194 867 228759_at HG-U133B BG236289 822 cAMP responsive element binding CREB3L2 64764 + TTP 204 protein3-like 2 868 221992_at HG-U133A AI925734 823 Hypothetical protein LOC283970 LOC283970 283970 + TTP 207 869 212739_s_at HG-U133A AL523860 824 non-metastatic cells 4, protein NME4 4833 + TTP 246 expressed in 870 201063_at HG-U133A NM_002901 825 reticulocalbin 1, EF-hand calcium RCN1 5954 + TTP 247 binding domain 871 227013_at HG-U133B AI535735 826 LATS, large tumor suppressor, LATS2 26524 + TTP 250 homolog 2 (Drosophila) 872 AFFX- HG-U133B AFFX- + TTP 254 BioC-3_at BioC-3 873 210889_s_at HG-U133A M31933 827 Fc fragment of IgG, low affinity IIb, FCGR2B 2213 + TTP 274 receptor (CD32) 874 213601_at HG-U133A AB011537 828 slit homolog 1 (Drosophila) SLIT1 6585 + + TTP/ 111 resp 875 210944_s_at HG-U133A BC003169 829 calpain 3, (p94) CAPN3 825 + + TTP/ 122 resp 876 32811_at HG-U133A X98507 830 myosin IC MYO1C 4641 + + TTP/ 150 resp 877 213348_at HG-U133A N33167 831 cyclin-dependent kinase inhibitor 1C CDKN1C 1028 + resp 132 (p57, Kip2) 878 200710_at HG-U133A NM_000018 832 acyl-Coenzyme A dehydrogenase, very ACADVL 37 + resp 198 long chain 879 220232_at HG-U133A NM_024906 833 stearoyl-CoA desaturase 4 SCD4 79966 + resp 272 880 209345_s_at HG-U133A AL561930 834 phosphatidylinositol 4-kinase type II PI4KII 55361 + resp 350 881 231825_x_at HG-U133B AK025060 835 activating transcription factor 7 ATF7IP 55729 + resp 374 interacting protein 882 215067_x_at HG-U133A AU147942 836 peroxiredoxin 2 PRDX2 7001 + resp 447 883 215499_at HG-U133A AA780381 837 Mitogen-activated protein kinase MAP2K3 5606 + resp 482 kinase 3 884 206323_x_at HG-U133A NM_002547 838 oligophrenin 1 OPHN1 4983 + resp 505 885 220725_x_at HG-U133A NM_025095 839 Dynein, axonemal, heavy polypeptide 3 DNAH3 55567 + resp 537 886 237475_x_at HG-U133B AI151104 840 Homo sapiens, clone IMAGE: 4829003, + resp 581 mRNA 887 228919_at HG-U133B AA601031 841 + resp 589 888 215504_x_at HG-U133A AF131777 842 Homo sapiens, clone IMAGE: 4822875, + resp 604 mRNA 889 216524_x_at HG-U133A AL049260 843 + resp 657 890 221569_at HG-U133A AL136797 844 Abelson helper integration site AHI1 54806 + + TTP/ 253 resp 891 228658_at HG-U133B R54042 845 hypothetical protein LOC150271 LOC150271 150271 + resp 16 892 210538_s_at HG-U133A U37546 846 baculoviral IAP repeat-containing 3 BIRC3 330 + resp 37 893 202439_s_at HG-U133A NM_000202 847 iduronate 2-sulfatase (Hunter IDS 3423 + resp 107 syndrome) 894 212221_x_at HG-U133A AV703259 848 iduronate 2-sulfatase (Hunter IDS 3423 + resp 165 syndrome) 895 211316_x_at HG-U133A AF009616 849 CASP8 and FADD-like apoptosis CFLAR 8837 + resp 196 regulator 896 209136_s_at HG-U133A BG390445 850 ubiquitin specific protease 10 USP10 9100 + resp 318 897 201811_x_at HG-U133A NM_004844 851 SH3-domain binding protein 5 SH3BP5 9467 + resp 359 (BTK-associated) 898 222391_at HG-U133B AL080250 852 transmembrane protein 30A TMEM30A 55754 + resp 421 899 214179_s_at HG-U133A H93013 853 nuclear factor (erythroid-derived NFE2L1 4779 + resp 439 2)-like 1 900 201810_s_at HG-U133A AL562152 854 SH3-domain binding protein 5 SH3BP5 9467 + resp 474 (BTK-associated) 901 212616_at HG-U133A BF668950 855 chromodomain helicase DNA binding CHD9 80205 + resp 475 protein 9 902 205504_at HG-U133A NM_000061 856 Bruton agammaglobulinemia tyrosine BTK 695 + resp 487 kinase 903 200759_x_at HG-U133A NM_003204 857 nuclear factor (erythroid-derived NFE2L1 4779 + resp 611 2)-like 1 904 209276_s_at HG-U133A AF162769 858 glutaredoxin (thioltransferase) GLRX 2745 + TTP 151 905 202727_s_at HG-U133A NM_000416 859 interferon gamma receptor 1 IFNGR1 3459 + TTP 168 906 202011_at HG-U133A NM_003257 860 tight junction protein 1 (zona TJP1 7082 + + TTP 63 occludens 1) 907 206662_at HG-U133A NM_002064 861 glutaredoxin (thioltransferase) GLRX 2745 + + TTP/ 30 resp 908 209475_at HG-U133A AF106069 862 ubiquitin specific protease 15 USP15 9958 + + TTP/ 46 resp 909 235661_at HG-U133B T99553 863 Transcribed locus + + TTP/ 201 resp 910 235875_at HG-U133B BF510711 864 Solute carrier family 1 (glutamate/ SLC1A4 6509 + resp 329 neutral amino acid transporter), member 4 911 225373_at HG-U133B BE271644 865 PP2135 protein PP2135 64115 + + TTP 189

TABLE 2 GLUCOCORTICOID PREDICTIVE MARKER IDENTIFICATION 2A Predictive Markers Upregulated Indicators of Non-Reponse and/or Short Time to Progression SEQ Entrez Type of ProbeSet Rep Public ID Gene Gene TTP Response speci- No. ID chip ID NO: Title Symbol ID marker marker ficity Rank 912 208918_s_at HG-U133A AI334128 866 NAD kinase FLJ13052 65220 − resp 2 913 208235_x_at HG-U133A NM_021123 867 G antigen 5 /// G antigen 7 /// GAGE5 /// 2577 /// − resp 3 G antigen 7B GAGE7 /// 2579 /// 26748 GAGE7B 914 221810_at HG-U133A AA631242 868 RAB15, member RAS onocogene family RAB15 376267 − resp 5 915 212725_s_at HG-U133A N37081 869 hypothetical protein TI-227H TI-227H 29793 − resp 8 916 200964_at HG-U133A NM_003334 870 ubiquitin-activating enzyme E1 UBE1 7317 − resp 9 (A1S9T and BN75 temperature sensitivity complementing) 917 226670_s_at HG-U133B AL109839 871 Chromosome 20 open reading C20orf119 80336 − resp 12 frame 119 918 222753_s_at HG-U133B AL136660 872 signal peptidase complex subunit 3 SPCS3 60559 − resp 13 homolog (S. cerevisiae) 919 213373_s_at HG-U133A BF439983 873 caspase 8, apoptosis-related CASP8 841 − resp 19 cysteine protease 920 202148_s_at HG-U133A NM_006907 874 pyrroline-5-carboxylate reductase 1 PYCR1 5831 − resp 26 921 212337_at HG-U133A AI687738 875 hypothetical protein TI-227H TI-227H 29793 − resp 28 922 211761_s_at HG-U133A BC005975 876 calcyclin binding protein CACYBP 27101 − resp 36 923 201381_x_at HG-U133A AF057356 877 calcyclin binding protein CACYBP 27101 − resp 38 924 225364_at HG-U133B BE222274 878 serine/threonine kinase 4 STK4 6789 − resp 39 925 200665_s_at HG-U133A NM_003118 879 secreted protein, acidic, SPARC 6678 − resp 48 cysteine-rich (osteonectin) 926 201577_at HG-U133A NM_000269 880 non-metastatic cells 1, protein NME1 4830 − resp 50 (NM23A) expressed in 927 226914_at HG-U133B AU158936 881 Actin related protein 2/3 complex, ARPC5L 81873 − resp 51 subunit 5-like 928 225401_at HG-U133B BF977145 882 kidney predominant protein NCU-G1 MGC31963 112770 − resp 52 929 222154_s_at HG-U133A AK002064 883 DNA polymerase-transactivated DNAPTP6 26010 − resp 57 protein 6 930 200791_s_at HG-U133A NM_003870 884 IQ motif containing GTPase IQGAP1 8826 − resp 65 activating protein 1 931 202555_s_at HG-U133A NM_005965 885 myosin, light polypeptide kinase MYLK 4638 − resp 66 932 208801_at HG-U133A BE856385 886 signal recognition particle 72 kDa SRP72 6731 − resp 72 933 227556_at HG-U133B AI094580 887 non-metastatic cells 7, protein NME7 29922 − resp 84 expressed in (nucleoside-diphosphate kinase) 934 213135_at HG-U133A U90902 888 T-cell lymphoma invasion and TIAM1 7074 − resp 98 metastasis 1 935 206656_s_at HG-U133A BC000353 889 chromosome 20 open reading frame 3 C20orf3 57136 − resp 104 936 206640_x_at HG-U133A NM_001477 890 G antigen 2 /// G antigen 4 /// GAGE2 /// 2574 /// − resp 1 G antigen 5 /// G antigen 6 /// GAGE4 /// 2576 /// G antigen 7 /// G antigen 7B GAGE5 /// 2577 /// GAGE6 /// 2578 /// GAGE7 /// 2579 /// 26748 GAGE7B 937 208155_x_at HG-U133A NM_001476 891 G antigen 4 /// G antigen 5 /// GAGE4 /// 2576 /// − resp 2 G antigen 6 /// G antigen 7B GAGE5 /// 2577 /// GAGE6 /// 2578 /// 26748 GAGE7B 938 207086_x_at HG-U133A NM_001474 892 G antigen 2 /// G antigen 4 /// GAGE2 /// 2574 /// − resp 3 G antigen 5 /// G antigen 6 /// GAGE4 /// 2576 /// G antigen 7 /// G antigen 7B /// GAGE5 /// 2577 /// G antigen 8 GAGE6 /// 2578 /// GAGE7 /// 2579 /// GAGE7B /// 26748 /// 26749 GAGE8 939 207739_s_at HG-U133A NM_001472 893 G antigen 1 /// G antigen 2 /// GAGE1 /// 2543 /// − resp 5 G antigen 3 /// G antigen 4 /// GAGE2 /// 2574 /// G antigen 5 /// G antigen 6 /// GAGE3 /// 2575 /// G antigen 7 /// G antigen 7B /// GAGE4 /// 2576 /// G antigen 8 GAGE5 /// 2577 /// GAGE6 /// 2578 /// GAGE7 /// 2579 /// GAGE7B /// 26748 /// 26749 GAGE8 940 207663_x_at HG-U133A NM_001473 894 G antigen 3 GAGE3 2575 − resp 8 941 205013_s_at HG-U133A NM_000675 895 adenosine A2a receptor ADORA2A 135 − resp 13 942 201506_at HG-U133A NM_000358 896 transforming growth factor, TGFBI 7045 − resp 17 beta-induced, 68 kDa 943 241224_x_at HG-U133B AA770014 434 Down syndrome critical region gene 8 DSCR8 84677 − resp 21 944 204960_at HG-U133A NM_005608 897 protein tyrosine phosphatase, PTPRCAP 5790 − resp 24 receptor type, C-associated protein 945 235863_at HG-U133B AI805145 898 homolog of mouse skeletal muscle FLJ32416 126306 − resp 28 sarcoplasmic reticulum protein JP-45 946 228116_at HG-U133B AW167298 899 Hypothetical LOC283029 283029 − resp 29 947 208890_s_at HG-U133A BC004542 900 plexin B2 PLXNB2 23654 − resp 30 948 242881_x_at HG-U133B BG285837 901 hypothetical LOC389048 LOC389048 389048 − resp 33 949 212311_at HG-U133A AA522514 902 KIAA0746 protein KIAA0746 23231 − resp 35 950 224318_s_at HG-U133B AF311326 903 hypothetical protein FLJ10081 FLJ10081 55683 − resp 37 951 224806_at HG-U133B BE563152 904 LOC440448 440448 − resp 54 952 208072_s_at HG-U133A NM_003648 905 diacylglycerol kinase, delta 130 kDa DGKD 8527 − resp 57 953 231887_s_at HG-U133B AB033100 906 KIAA1274 KIAA1274 27143 − resp 58 954 212443_at HG-U133A AB011112 907 KIAA0540 protein KIAA0540 23218 − resp 60 955 200859_x_at HG-U133A NM_001456 908 filamin A, alpha (actin binding FLNA 2316 − resp 63 protein 280) 956 204912_at HG-U133A NM_001558 909 interleukin 10 receptor, alpha IL10RA 3587 − resp 66 957 211373_s_at HG-U133A U34349 910 presenilin 2 (Alzheimer disease 4) PSEN2 5664 − resp 68 958 213008_at HG-U133A BG403615 911 hypothetical protein FLJ10719 FLJ10719 55215 − resp 77 959 218695_at HG-U133A NM_019037 912 exosome component 4 EXOSC4 54512 − resp 77 960 43427_at HG-U133A AI970898 913 hypothetical protein LOC283445 LOC283445 283445 − resp 84 961 203523_at HG-U133A NM_002339 914 lymphocyte-specific protein 1 LSP1 4046 − resp 87 962 212287_at HG-U133A BF382924 915 suppressor of zeste 12 homolog SUZ12 23512 − resp 88 (Drosophila) 963 203020_at HG-U133A NM_014857 916 RAB GTPase activating protein 1-like RABGAP1L 9910 − resp 99 964 201071_x_at HG-U133A NM_012433 917 splicing factor 3b, subunit 1, SF3B1 23451 − resp 105 155 kDa 965 47553_at HG-U133A AA813332 918 deafness, autosomal recessive 31 DFNB31 25861 − resp 106 966 222244_s_at HG-U133A AK000749 919 hypothetical protein FLJ20618 FLJ20618 55000 − resp 117 967 208794_s_at HG-U133A D26156 920 SWI/SNF related, matrix associated, SMARCA4 6597 − resp 119 actin dependent regulator of chromatin, subfamily a, member 4 968 239481_at HG-U133B AI864183 921 hypothetical protein FLJ37659 FLJ37659 286499 − resp 133 969 208858_s_at HG-U133A BC004998 922 likely ortholog of mouse membrane MBC2 23344 − TTP 3 bound C2 domain containing protein 970 200011_s_at HG-U133A NM_001659 923 ADP-ribosylation factor 3 ARF3 377 − TTP 16 971 201003_x_at HG-U133A NM_003349 924 − TTP 18 972 216194_s_at HG-U133A AD001527 925 cytoskeleton associated protein 1 CKAP1 1155 − TTP 19 973 202670_at HG-U133A AI571419 926 mitogen-activated protein kinase MAP2K1 5604 − TTP 25 kinase 1 974 205903_s_at HG-U133A NM_002249 927 potassium intermediate/small KCNN3 3782 − TTP 26 conductance calcium-activated channel, subfamily N, member 3 975 226760_at HG-U133B BF666325 928 hypothetical protein LOC203411 LOC203411 203411 − TTP 29 976 204839_at HG-U133A NM_015918 929 processing of precursor 5, POP5 51367 − TTP 30 ribonuclease P/MRP subunit (S. cerevisiae) 977 224233_s_at HG-U133B BC002535 930 misato FLJ10504 55154 − TTP 36 978 204808_s_at HG-U133A NM_014254 931 transmembrane protein 5 TMEM5 10329 − TTP 42 979 212013_at HG-U133A D86983 932 Melanoma associated gene D2S448 7837 − TTP 43 980 201012_at HG-U133A NM_000700 733 annexin A1 ANXA1 301 − TTP 47 981 225685_at HG-U133B AI801777 933 CDC42 effector protein (Rho GTPase CDC42EP3 10602 − TTP 48 binding) 3 982 202001_s_at HG-U133A NM_002490 934 NADH dehydrogenase (ubiquinone) 1 NDUFA6 4700 − TTP 51 alpha subcomplex, 6, 14 kDa 983 202911_at HG-U133A NM_000179 935 mutS homolog 6 (E. coli) MSH6 2956 − TTP 52 984 221807_s_at HG-U133A BG399562 936 hypothetical protein PP2447 PP2447 80305 − TTP 53 985 210978_s_at HG-U133A BC002616 937 transgelin 2 TAGLN2 8407 − TTP 54 986 201475_x_at HG-U133A NM_004990 938 methionine-tRNA synthetase MARS 4141 − TTP 60 987 207918_s_at HG-U133A NM_003308 939 testis specific protein, Y-linked TSPY1 /// 64591 /// 7258 − TTP 65 1 /// testis specific protein, TSPY2 Y-linked 2 988 208270_s_at HG-U133A NM_020216 940 arginyl aminopeptidase RNPEP 6051 − TTP 66 (aminopeptidase B) 989 201157_s_at HG-U133A AF020500 941 N-myristoyltransferase 1 NMT1 4836 − TTP 67 990 218135_at HG-U133A NM_016570 942 PTX1 protein PTX1 51290 − TTP 76 991 222606_at HG-U133B AA824298 943 − TTP 83 992 208679_s_at HG-U133A AF279893 944 actin related protein 2/3 complex, ARPC2 10109 − TTP 84 subunit 2, 34 kDa 993 215171_s_at HG-U133A AK023063 945 translocase of inner mitochondrial TIMM17A 10440 − TTP 86 membrane 17 homolog A (yeast) 994 208284_x_at HG-U133A NM_013421 946 gamma-glutamyltransferase 1 GGT1 2678 − TTP 92 995 230172_at HG-U133B AL039706 947 family with sequence similarity 14, FAM14B 122509 − TTP 95 member B 996 217900_at HG-U133A NM_018060 948 mitochondrial isoleucine tRNA FLJ10326 55699 − TTP 96 synthetase 997 201804_x_at HG-U133A NM_001281 949 cytoskeleton associated protein 1 CKAP1 1155 − TTP 107 998 231736_x_at HG-U133B NM_020300 950 microsomal glutathione MGST1 4257 − TTP 110 S-transferase 1 999 201966_at HG-U133A NM_004550 951 NADH dehydrogenase (ubiquinone) Fe—S NDUFS2 4720 − TTP 112 protein 2, 49 kDa (NADH-coenzyme Q reductase) 1000 212024_x_at HG-U133A U80184 952 flightless I homolog (Drosophila) FLII 2314 − TTP 115 1001 200980_s_at HG-U133A NM_000284 953 pyruvate dehydrogenase (lipoamide) PDHA1 5160 − TTP 116 alpha 1 1002 218296_x_at HG-U133A NM_018116 954 misato FLJ10504 55154 − TTP 117 1003 232520_s_at HG-U133B AK023585 955 NSFL1 (p97) cofactor (p47) NSFL1C 55968 − TTP 120 1004 218556_at HG-U133A NM_014182 956 ORMl-like 2 (S. cerevisiae) ORMDL2 29095 − TTP 124 1005 203371_s_at HG-U133A NM_002491 957 NADH dehydrogenase (ubiquinone) 1 NDUFB3 4709 − TTP 126 beta subcomplex, 3, 12 kDa 1006 209919_x_at HG-U133A L20490 958 gamma-glutamyltransferase 1 GGT1 2678 − TTP 129 1007 217966_s_at HG-U133A NM_022083 959 chromosome 1 open reading frame 24 C1orf24 116496 − TTP 136 1008 218720_x_at HG-U133A NM_012410 960 seizure related 6 homolog SEZ6L2 26470 − TTP 141 (mouse)-like 2 1009 214853_s_at HG-U133A AI091079 961 SHC (Src homology 2 domain SHC1 6464 − TTP 144 containing) transforming protein 1 1010 212012_at HG-U133A BF342851 962 Melanoma associated gene D2S448 7837 − TTP 145 1011 214749_s_at HG-U133A AK000818 963 armadillo repeat containing, ARMCX6 54470 − TTP 147 X-linked 6 1012 202017_at HG-U133A NM_000120 964 epoxide hydrolase 1, microsomal EPHX1 2052 − TTP 148 (xenobiotic) 1013 225313_at HG-U133B AI627538 965 chromosome 20 open reading frame 177 C20orf177 63939 − TTP 151 1014 217967_s_at HG-U133A AF288391 966 chromosome 1 open reading frame 24 C1orf24 116496 − TTP 154 1015 205902_at HG-U133A AJ251016 967 potassium intermediate/small KCNN3 3782 − TTP 161 conductance calcium-activated channel, subfamily N, member 3 1016 200616_s_at HG-U133A BC000371 968 KIAA0152 KIAA0152 9761 − TTP 162 1017 201387_s_at HG-U133A NM_004181 969 ubiquitin carboxyl-terminal UCHL1 7345 − TTP 171 esterase L1 (ubiquitin thiolesterase) 1018 200916_at HG-U133A NM_003564 970 transgelin 2 TAGLN2 8407 − TTP 180 1019 224955_at HG-U133B AI590088 971 TEA domain family member 1 (SV40 TEAD1 7003 − TTP 183 transcriptional enhancer factor) 1020 244040_at HG-U133B N47474 972 Potassium intermediate/small KCNN3 3782 − TTP 185 conductance calcium-activated channel, subfamily N, member 3 1021 212371_at HG-U133A AL049397 973 CGI-146 protein PNAS-4 51029 − TTP 186 1022 238761_at HG-U133B BE645241 974 Mediator of RNA polymerase II MED28 80306 − TTP 187 transcription, subunit 28 homolog (yeast) 1023 216705_s_at HG-U133A X02189 975 adenosine deaminase ADA 100 − − resp 6 1024 218058_at HG-U133A NM_014593 976 CXXC finger 1 (PHD domain) CXXC1 30827 − − resp 7 1025 201377_at HG-U133A NM_014847 977 ubiquitin associated protein 2-like UBAP2L 9898 − − resp 17 1026 204639_at HG-U133A NM_000022 978 adenosine deaminase ADA 100 − − resp 21 1027 201307_at HG-U133A AL534972 979 septin 11 SEPT11 55752 − − resp 22 1028 225105_at HG-U133B BF969397 980 hypothetical protein LOC387882 387882 − − resp 41 1029 209836_x_at HG-U133A AF060511 981 LAT1-3TM protein LAT1-3TM 81893 − − resp 43 1030 201897_s_at HG-U133A NM_001826 982 CDC28 protein kinase regulatory CKS1B 1163 − − resp 53 subunit 1B 1031 201349_at HG-U133A NM_004252 983 solute carrier family 9 (sodium/ SLC9A3R1 9368 − − resp 66 hydrogen exchanger), isoform 3 regulator 1 1032 217836_s_at HG-U133A NM_018253 984 YY1 associated protein 1 YY1AP1 55249 − − resp 70 1033 208972_s_at HG-U133A AL080089 985 ATP synthase, H+ transporting, ATP5G1 516 − − resp 71 mitochondrial F0 complex, subunit c (subunit 9), isoform 1 1034 226219_at HG-U133B AW575123 986 hypothetical protein LOC257106 LOC257106 257106 − − resp 88 1035 202403_s_at HG-U133A AA788711 987 collagen, type I, alpha 2 COL1A2 1278 − − TTP 1 1036 213513_x_at HG-U133A BG034239 988 actin related protein 2/3 complex, ARPC2 10109 − − TTP 2 subunit 2, 34 kDa 1037 207988_s_at HG-U133A NM_005731 989 actin related protein 2/3 complex, ARPC2 10109 − − TTP 6 subunit 2, 34 kDa 1038 207493_x_at HG-U133A NM_003147 990 synovial sarcoma, X breakpoint 2 SSX2 6757 − − TTP 13 1039 218151_x_at HG-U133A NM_024531 991 G protein-coupled receptor 172A GPR172A 79581 − − TTP 15 1040 222518_at HG-U133B BF525399 992 ADP-ribosylation factor guanine ARFGEF2 10564 − − TTP 47 nucleotide-exchange factor 2 (brefeldin A-inhibited) 1041 218041_x_at HG-U133A NM_018573 993 solute carrier family 38, member 2 SLC38A2 54407 − − TTP 53 1042 217871_s_at HG-U133A NM_002415 994 macrophage migration inhibitory MIF 4282 − − TTP 108 factor (glycosylation-inhibiting factor) 1043 215603_x_at HG-U133A AI344075 995 gamma-glutamyltransferase 1 /// GGT1 ///  2678 /// 91227 − − TTP/ 3 gamma-glutamyltransferase-like 4 GGTL4 resp 1044 202671_s_at HG-U133A NM_003681 996 pyridoxal (pyridoxine, vitamin B6) PDXK 8566 − − TTP/ 7 kinase resp 1045 243606_at HG-U133B BE883167 997 Transcribed locus, moderately − − TTP/ 8 similar to NP_055301.1 neuronal resp thread protein AD7c-NTP [Homo sapiens] 1046 216829_at HG-U133A X72475 998 immunoglobulin kappa constant IGKC 3514 − − TTP/ 12 resp 1047 207131_x_at HG-U133A NM_013430 999 gamma-glutamyltransferase 1 GGT1 2678 − − TTP/ 21 resp 1048 212539_at HG-U133A AI422099 1000 chromodomain helicase DNA binding CHD1L 9557 − − TTP/ 26 protein 1-like resp 1049 221676_s_at HG-U133A BC002342 1001 coronin, actin binding protein, 1C CORO1C 23603 − − TTP/ 31 resp 1050 221970_s_at HG-U133A AU158148 1002 DKFZP586L0724 protein DKFZP586L0724 25926 − − TTP/ 31 resp 1051 200991_s_at HG-U133A NM_014748 1003 sorting nexin 17 SNX17 9784 − − TTP/ 34 resp 1052 218592_s_at HG-U133A NM_017829 1004 cat eye syndrome chromosome region, CECR5 27440 − − TTP/ 42 candidate 5 resp 1053 205213_at HG-U133A NM_014716 1005 centaurin, beta 1 CENTB1 9744 − − TTP/ 43 resp 1054 229711_s_at HG-U133B AA902480 1006 Carboxypeptidase M CPM 1368 − − TTP/ 45 resp 1055 211759_x_at HG-U133A BC005969 1007 cytoskeleton associated protein 1 CKAP1 1155 − − TTP/ 46 resp 1056 205788_s_at HG-U133A NM_014827 1008 − − TTP/ 49 resp 1057 200793_s_at HG-U133A NM_001098 1009 aconitase 2, mitochondrial ACO2 50 − − TTP/ 56 resp 1058 211417_x_at HG-U133A L20493 1010 gamma-glutamyltransferase 1 GGT1 2678 − − TTP/ 61 resp 1059 208095_s_at HG-U133A NM_001222 1011 signal recognition particle 72 kDa SRP72 6731 − − TTP/ 66 resp 1060 200782_at HG-U133A NM_001154 1012 annexin A5 ANXA5 308 − − TTP/ 72 resp 1061 218014_at HG-U133A NM_024844 1013 pericentrin 1 PCNT1 79902 − − TTP/ 75 resp 1062 223096_at HG-U133B AF161469 1014 nucleolar protein NOP5/NOP58 NOP5/NOP58 51602 − − TTP/ 112 resp 1063 232010_at HG-U133B AA129444 1015 follistatin-like 5 FSTL5 56884 − − resp 27 1064 227167_s_at HG-U133B AW511319 1016 Mesenchymal stem cell protein DSC96 − − TTP 14 1065 224918_x_at HG-U133B AI220117 1017 microsomal glutathione MGST1 4257 − − TTP 105 S-transferase 1 1066 225904_at HG-U133B N64686 1018 LOC126731 LOC126731 126731 − − resp 13 1067 235353_at HG-U133B AI887866 1019 KIAA0746 protein KIAA0746 23231 − − resp 46 1068 203606_at HG-U133A NM_004553 1020 NADH dehydrogenase (ubiquinone) Fe—S NDUFS6 4726 − − resp 127 protein 6, 13 kDa (NADH-coenzyme Q reductase) 1069 208683_at HG-U133A M23254 1021 calpain 2, (m/II) large subunit CAPN2 824 − − TTP 177 1070 200734_s_at HG-U133A BG341906 1022 ADP-ribosylation factor 3 ARF3 377 − − TTP/ 5 resp

2B Predictive Markers Upregulated Indicators of Response and/or Long Time to Progression SEQ Entrez Type of ProbeSet Rep Public ID Gene Gene TTP Response speci- No. ID chip ID NO: Title Symbol ID marker marker ficity Rank 1071 229233_at HG-U133B H05240 1023 neuregulin 3 NRG3 10718 + resp 1 1072 225524_at HG-U133B AU152178 1024 anthrax toxin receptor 2 ANTXR2 118429 + resp 4 1073 201465_s_at HG-U133A BC002646 1025 v-jun sarcoma virus 17 oncogene JUN 3725 + resp 6 homolog (avian) 1074 201464_x_at HG-U133A BG491844 1026 v-jun sarcoma virus 17 oncogene JUN 3725 + resp 11 homolog (avian) 1075 217731_s_at HG-U133A NM_021999 1027 integral membrane protein 2B ITM2B 9445 + resp 12 1076 208961_s_at HG-U133A AB017493 1028 Kruppel-like factor 6 KLF6 1316 + resp 14 1077 230493_at HG-U133B AW664964 1029 WGAR9166 LOC387914 387914 + resp 15 1078 221220_s_at HG-U133A NM_017988 1030 SCY1-like 2 (S. cerevisiae) SCYL2 55681 + resp 16 1079 211560_s_at HG-U133A AF130113 1031 aminolevulinate, delta-, ALAS2 212 + resp 19 synthase 2 (sideroblastic/ hypochromic anemia) 1080 AFFX-r2- HG-U133A AFFX-r2- + resp 22 Hs18SrRNA-5_at Hs18SrRNA-5 1081 220751_s_at HG-U133A NM_016348 1032 chromosome 5 open reading C5orf4 10826 + resp 23 frame 4 1082 201432_at HG-U133A NM_001752 1033 catalase CAT 847 + resp 24 1083 206871_at HG-U133A NM_001972 1034 elastase 2, neutrophil ELA2 1991 + resp 24 1084 208781_x_at HG-U133A AF062483 1035 sorting nexin 3 SNX3 8724 + resp 32 1085 202687_s_at HG-U133A U57059 1036 tumor necrosis factor (ligand) TNFSF10 8743 + resp 33 superfamily, member 10 1086 212603_at HG-U133A NM_005830 1037 mitochondrial ribosomal MRPS31 10240 + resp 34 protein S31 1087 217144_at HG-U133A X04801 1038 ubiquitin B UBB 7314 + resp 34 1088 AFFX- HG-U133A AFFX- + resp 35 HUMRGE/ HUMRGE/ M10098_5_at M10098_5 1089 208960_s_at HG-U133A BE675435 1039 Kruppel-like factor 6 KLF6 1316 + resp 38 1090 224688_at HG-U133B BE962299 1040 Hypothetical protein FLJ10099 FLJ10099 55069 + resp 40 1091 209930_s_at HG-U133A L13974 1041 nuclear factor NFE2 4778 + resp 42 (erythroid-derived 2), 45 kDa 1092 224606_at HG-U133B BG250721 1042 Homo sapiens, clone IMAGE: + resp 42 4096273, mRNA 1093 205225_at HG-U133A NM_000125 1043 estrogen receptor 1 ESR1 2099 + resp 46 1094 AFFX-r2- HG-U133B AFFX-r2- + resp 46 Hs18SrRNA-5_at Hs18SrRNA-5 1095 205383_s_at HG-U133A NM_015642 1044 zinc finger and BTB domain ZBTB20 26137 + resp 47 containing 20 1096 207459_x_at HG-U133A NM_002100 1045 glycophorin B (includes Ss GYPB 2994 + resp 50 blood group) 1097 221824_s_at HG-U133A AA770170 1046 membrane-associated ring finger MARCH8 220972 + resp 56 (C3HC4) 8 1098 210504_at HG-U133A U65404 1047 Kruppel-like factor 1 KLF1 10661 + resp 57 (erythroid) 1099 56256_at HG-U133A AA150165 1048 SID1 transmembrane family, SIDT2 51092 + resp 57 member 2 1100 214407_x_at HG-U133A AI240545 1049 glycophorin B (includes Ss GYPB 2994 + resp 58 blood group) 1101 213281_at HG-U133A BE327172 1050 + resp 61 1102 228360_at HG-U133B BF060747 1051 hypothetical protein LOC130576 LOC130576 130576 + resp 69 1103 205389_s_at HG-U133A AI659683 1052 ankyrin 1, erythrocytic ANK1 286 + resp 74 1104 209140_x_at HG-U133A L42024 1053 major histocompatibility HLA-B 3106 + resp 76 complex, class I, B 1105 205838_at HG-U133A NM_002099 1054 glycophorin A (includes MN GYPA 2993 + resp 79 blood group) 1106 216389_s_at HG-U133A AF283773 1055 WD repeat domain 23 WDR23 80344 + resp 79 1107 AFFX- HG-U133B AFFX- + resp 80 HUMRGE/ HUMRGE/ M10098_5_at M10098_5 1108 202364_at HG-U133A NM_005962 1056 MAX interactor 1 MXI1 4601 + resp 81 1109 223309_x_at HG-U133B BG025248 1057 intracellular membrane- IPLA2 50640 + resp 83 associated calcium-independent (GAMMA) phospholipase A2 gamma 1110 219497_s_at HG-U133A NM_022893 1058 B-cell CLL/lymphoma 11A (zinc BCL11A 53335 + resp 88 finger protein) 1111 206834_at HG-U133A NM_000519 1059 hemoglobin, delta HBD 3045 + resp 89 1112 210648_x_at HG-U133A AB047360 1060 sorting nexin 3 SNX3 8724 + resp 97 1113 211820_x_at HG-U133A U00179 1061 glycophorin A (includes MN GYPA 2993 + resp 116 blood group) 1114 208621_s_at HG-U133A BF663141 1062 villin 2 (ezrin) VIL2 7430 + resp 5 1115 213515_x_at HG-U133A AI133353 1063 hemoglobin, gamma G HBG2 3048 + resp 9 1116 217732_s_at HG-U133A AF092128 1064 integral membrane protein 2B ITM2B 9445 + resp 9 1117 223952_x_at HG-U133B AF240698 1065 dehydrogenase/reductase (SDR DHRS9 10170 + resp 10 family) member 9 1118 204419_x_at HG-U133A NM_000184 1066 hemoglobin, gamma G HBG2 3048 + resp 11 1119 204848_x_at HG-U133A NM_000559 1067 hemoglobin, gamma A /// HBG1 /// 3047 /// 3048 + resp 12 hemoglobin, gamma G HBG2 1120 218717_s_at HG-U133A NM_018192 1068 leprecan-like 1 LEPREL1 55214 + resp 13 1121 221911_at HG-U133A BE881590 1069 hypothetical protein LOC221810 LOC221810 221810 + resp 14 1122 224009_x_at HG-U133B AF240697 1070 dehydrogenase/reductase (SDR DHRS9 10170 + resp 16 family) member 9 1123 235278_at HG-U133B BF032500 1071 Homo sapiens, clone IMAGE: + resp 18 4513167, mRNA 1124 234419_x_at HG-U133B AJ275401 1072 + resp 20 1125 234390_x_at HG-U133B Z27446 1073 IG rearranged H-chain mRNA + resp 21 V-region 1126 216542_x_at HG-U133A AJ275355 1074 hypothetical protein MGC27165 MGC27165 283650 + resp 22 1127 219799_s_at HG-U133A NM_005771 1075 dehydrogenase/reductase (SDR DHRS9 10170 + resp 26 family) member 9 1128 221841_s_at HG-U133A BF514079 1076 Kruppel-like factor 4 (gut) KLF4 9314 + resp 27 1129 206181_at HG-U133A NM_003037 1077 signaling lymphocytic activation SLAMF1 6504 + resp 29 molecule family member 1 1130 219377_at HG-U133A NM_022751 1078 chromosome 18 open reading C18orf11 64762 + resp 30 frame 11 1131 228415_at HG-U133B AA205444 1079 Adaptor-related protein complex AP1S2 8905 + resp 31 1, sigma 2 subunit 1132 204466_s_at HG-U133A BG260394 1080 synuclein, alpha (non A4 SNCA 6622 + resp 38 component of amyloid precursor) 1133 203751_x_at HG-U133A AI762296 1081 jun D proto-oncogene JUND 3727 + resp 44 1134 220059_at HG-U133A NM_012108 1082 BCR downstream signaling 1 BRDG1 26228 + resp 49 1135 203502_at HG-U133A NM_001724 1083 2,3-bisphosphoglycerate mutase BPGM 669 + resp 51 1136 217865_at HG-U133A NM_018434 1084 ring finger protein 130 RNF130 55819 + resp 51 1137 202206_at HG-U133A AW450363 1085 ADP-ribosylation factor-like 7 ARL7 10123 + resp 52 1138 209968_s_at HG-U133A U63041 1086 neural cell adhesion molecule 1 NCAM1 4684 + resp 52 1139 208729_x_at HG-U133A D83043 1087 major histocompatibility HLA-B 3106 + resp 53 complex, class I, B 1140 208029_s_at HG-U133A NM_018407 1088 lysosomal associated protein LAPTM4B 55353 + resp 54 transmembrane 4 beta 1141 217478_s_at HG-U133A X76775 1089 major histocompatibility HLA-DMA 3108 + resp 55 complex, class II, DM alpha 1142 201849_at HG-U133A NM_004052 1090 BCL2/adenovirus E1B 19 kDa BNIP3 664 + resp 58 interacting protein 3 1143 216833_x_at HG-U133A U05255 1091 glycophorin B (includes Ss GYPB /// 2994 /// 2996 + resp 61 blood group) /// glycophorin E GYPE 1144 37028_at HG-U133A U83981 1092 protein phosphatase 1, PPP1R15A 23645 + resp 74 regulatory (inhibitor) subunit 15A 1145 209357_at HG-U133A AF109161 1093 Cbp/p300-interacting CITED2 10370 + resp 75 transactivator, with Glu/ Asp-rich carboxy-terminal domain, 2 1146 209295_at HG-U133A AF016266 1094 tumor necrosis factor receptor TNFRSF10B 8795 + resp 82 superfamily, member 10b 1147 202511_s_at HG-U133A AK001899 1095 APG5 autophagy 5-like APG5L 9474 + resp 86 (S. cerevisiae) 1148 208812_x_at HG-U133A BC004489 1096 major histocompatibility HLA-B /// 3106 /// 3107 + resp 91 complex, class I, B /// major HLA-C histocompatibility complex, class I, C 1149 204992_s_at HG-U133A NM_002628 1097 profilin 2 PFN2 5217 + resp 92 1150 203685_at HG-U133A NM_000633 1098 B-cell CLL/lymphoma 2 BCL2 596 + resp 93 1151 224693_at HG-U133B AI133137 1099 chromosome 20 open reading C20orf108 116151 + resp 94 frame 108 1152 211530_x_at HG-U133A M90686 1100 HLA-G histocompatibility HLA-G 3135 + resp 98 antigen, class I, G 1153 204621_s_at HG-U133A AI935096 1101 nuclear receptor subfamily 4, NR4A2 4929 + resp 102 group A, member 2 1154 200633_at HG-U133A NM_018955 1102 ubiquitin B UBB 7314 + resp 104 1155 221004_s_at HG-U133A NM_030926 1103 integral membrane protein 2C ITM2C 81618 + resp 105 1156 229713_at HG-U133B AW665227 1104 + resp 108 1157 203428_s_at HG-U133A AB028628 1105 ASF1 anti-silencing function 1 ASF1A 25842 + resp 110 homolog A (S. cerevisiae) 1158 218858_at HG-U133A NM_022783 1106 DEP domain containing 6 DEPDC6 64798 + resp 116 1159 204622_x_at HG-U133A NM_006186 1107 nuclear receptor subfamily 4, NR4A2 4929 + resp 117 group A, member 2 1160 200628_s_at HG-U133A M61715 1108 tryptophanyl-tRNA synthetase WARS 7453 + resp 124 1161 216248_s_at HG-U133A S77154 1109 nuclear receptor subfamily 4, NR4A2 4929 + resp 130 group A, member 2 1162 235341_at HG-U133B AL119957 1110 DnaJ (Hsp40) homolog, subfamily DNAJC3 5611 + resp 135 C, member 3 1163 200905_x_at HG-U133A NM_005516 1111 major histocompatibility HLA-E 3133 + TTP 64 complex, class I, E 1164 218539_at HG-U133A NM_017943 1112 F-box protein 34 FBXO34 55030 + TTP 68 1165 200912_s_at HG-U133A NM_001967 1113 eukaryotic translation EIF4A2 1974 + TTP 69 initiation factor 4A, isoform 2 1166 217456_x_at HG-U133A M31183 1114 major histocompatibility HLA-E 3133 + TTP 85 complex, class I, E 1167 212510_at HG-U133A AA135522 1115 glycerol-3-phosphate GPD1L 23171 + TTP 98 dehydrogenase 1-like 1168 201334_s_at HG-U133A AB002380 1116 Rho guanine nucleotide exchange ARHGEF12 23365 + TTP 130 factor (GEF) 12 1169 202333_s_at HG-U133A AA877765 1117 ubiquitin-conjugating enzyme UBE2B 7320 + TTP 131 E2B (RAD6 homolog) 1170 214080_x_at HG-U133A AI815793 1118 protein kinase C substrate 80K-H PRKCSH 5589 + TTP 138 1171 223356_s_at HG-U133B BG529919 1119 mitochondrial translational MTIF3 219402 + TTP 139 initiation factor 3 1172 201886_at HG-U133A NM_025230 1120 WD repeat domain 23 WDR23 80344 + TTP 146 1173 228831_s_at HG-U133B AL039870 1121 guanine nucleotide binding GNG7 2788 + TTP 167 protein (G protein), gamma 7 1174 201637_s_at HG-U133A NM_005087 1122 fragile X mental retardation, FXR1 8087 + TTP 170 autosomal homolog 1 1175 202812_at HG-U133A NM_000152 1123 glucosidase, alpha; acid (Pompe GAA 2548 + TTP 174 disease, glycogen storage disease type II) 1176 201871_s_at HG-U133A NM_015853 1124 ORF LOC51035 51035 + TTP 182 1177 225582_at HG-U133B AA425726 1125 KIAA1754 KIAA1754 85450 + + resp 1 1178 208855_s_at HG-U133A AF083420 1126 serine/threonine kinase 24 STK24 8428 + + TTP 27 (STE20 homolog, yeast) 1179 212760_at HG-U133A AB002347 1127 ubiquitin protein ligase E3 UBR2 23304 + + TTP 30 component n-recognin 2 1180 203836_s_at HG-U133A D84476 1128 mitogen-activated protein MAP3K5 4217 + + TTP 40 kinase kinase kinase 5 1181 221555_x_at HG-U133A AU145941 1129 CDC14 cell division cycle 14 CDC14B 8555 + + TTP 44 homolog B (S. cerevisiae) 1182 209966_x_at HG-U133A AF094518 1130 estrogen-related receptor gamma ESRRG 2104 + + TTP/ 14 resp 1183 210347_s_at HG-U133A AF080216 1131 B-cell CLL/lymphoma 11A (zinc BCL11A 53335 + + TTP/ 23 finger protein) resp 1184 201466_s_at HG-U133A NM_002228 1132 v-jun sarcoma virus 17 oncogene JUN 3725 + + TTP/ 34 homolog (avian) resp 1185 204710_s_at HG-U133A NM_016003 1133 WIPI49-like protein 2 WIPI-2 26100 + + TTP/ 80 resp 1186 209054_s_at HG-U133A AF083389 1134 Wolf-Hirschhorn syndrome WHSC1 7468 + resp 33 candidate 1 1187 222891_s_at HG-U133B AI912275 1135 B-cell CLL/lymphoma 11A (zinc BCL11A 53335 + resp 35 finger protein) 1188 219759_at HG-U133A NM_022350 1136 leukocyte-derived arginine LRAP 64167 + resp 40 aminopeptidase 1189 202442_at HG-U133A NM_001284 1137 adaptor-related protein complex AP3S1 1176 + resp 83 3, sigma 1 subunit 1190 218191_s_at HG-U133A NM_018368 1138 chromosome 6 open reading C6orf209 55788 + resp 15 frame 209 1191 202643_s_at HG-U133A AI738896 1139 tumor necrosis factor, TNFAIP3 7128 + resp 36 alpha-induced protein 3 1192 221297_at HG-U133A NM_018654 1140 G protein-coupled receptor, GPRC5D 55507 + resp 43 family C, group 5, member D 1193 211529_x_at HG-U133A M90684 1141 HLA-G histocompatibility HLA-G 3135 + resp 50 antigen, class I, G 1194 217436_x_at HG-U133A M80469 1142 + resp 59 1195 211528_x_at HG-U133A M90685 1143 HLA-G histocompatibility HLA-G 3135 + resp 83 antigen, class I, G 1196 211911_x_at HG-U133A L07950 1144 major histocompatibility HLA-B /// 3106 /// 3107 + resp 93 complex, class I, B /// major HLA-C histocompatibility complex, class I, C 1197 222146_s_at HG-U133A AK026674 1145 transcription factor 4 TCF4 6925 + resp 107 1198 224566_at HG-U133B AI042152 1146 trophoblast-derived noncoding TncRNA 283131 + resp 113 RNA 1199 225282_at HG-U133B AL137764 1147 hypothetical protein AL133206 LOC64744 64744 + resp 118 1200 201951_at HG-U133A BF242905 1148 Activated leukocyte cell ALCAM 214 + + resp 28 adhesion molecule 1201 203845_at HG-U133A AV727449 1149 p300/CBP-associated factor PCAF 8850 + + TTP 14 1202 221778_at HG-U133A BE217882 1150 KIAA1718 protein KIAA1718 80853 + + TTP/ 59 resp

TABLE 3 AGRESSIVENESS PREDICTIVE MARKER IDENTIFICATION proteasome proteasome gluco- gluco- SEQ Entrez inhibitor inhibitor corticoid corticoid ProbeSet Rep Public ID Gene Gene TTP Response TTP Response No. ID chip ID NO: Title Symbol ID marker marker marker marker Rank 1203 210386_s_at HG-U133A BC001906 1151 metaxin 1 MTX1 4580 − − 1 1204 211639_x_at HG-U133A L23518 1152 Immunoglobulin heavy constant mu IGHM 3507 − 2 1205 211637_x_at HG-U133A L23516 1153 similar to Ig heavy chain V-I LOC388078 388078 − 3 region HG3 precursor 1206 211644_x_at HG-U133A L14458 1154 HRV Fab 027-VL /// HRV Fab IGKC 3514 + 4 026-VL /// Ig light chain gene variable domain (CLL-L3B) /// HRV Fab N27-VL /// Immunoglobulin kappa constant 1207 219593_at HG-U133A NM_016582 1155 solute carrier family 15, member 3 SLC15A3 51296 + 7 1208 208671_at HG-U133A AF164794 1156 tumor differentially expressed 2 TDE2 57515 + 8 1209 201438_at HG-U133A NM_004369 1157 collagen, type VI, alpha 3 COL6A3 1293 − 11 1210 201937_s_at HG-U133A NM_012100 1158 aspartyl aminopeptidase DNPEP 23549 − 12 1211 216576_x_at HG-U133A AF103529 1159 − 12 1212 217281_x_at HG-U133A AJ239383 1160 immunoglobulin heavy constant IGHG1 /// 283650 /// + 13 gamma 1 (G1m marker) /// IGHM /// 3500 /// 3507 immunoglobulin heavy constant MGC27165 mu /// hypothetical protein MGC27165 1213 224634_at HG-U133B AI911518 1161 G patch domain containing 4 GPATC4 54865 − 15 1214 235802_at HG-U133B BE676703 1162 chromosome 14 open reading frame C14orf175 122618 − 16 175 1215 203182_s_at HG-U133A NM_003138 1163 SFRS protein kinase 2 SRPK2 6733 − − 17 1216 211643_x_at HG-U133A L14457 1164 + 18 1217 226646_at HG-U133B AI831932 1165 Kruppel-like factor 2 (lung) KLF2 10365 + 18 1218 203641_s_at HG-U133A BF002844 1166 COBL-like 1 COBLL1 22837 + 19 1219 207238_s_at HG-U133A NM_002838 1167 protein tyrosine phosphatase, PTPRC 5788 − 19 receptor type, C 1220 220807_at HG-U133A NM_005331 1168 hemoglobin, theta 1 HBQ1 3049 + 22 1221 205890_s_at HG-U133A NM_006398 1169 ubiquitin D UBD 10537 + 23 1222 208850_s_at HG-U133A AL558479 1170 Thy-1 cell surface antigen /// THY1 ///  7070 /// 94105 − 23 Thy-1 co-transcribed LOC94105 1223 226350_at HG-U133B AU155565 1171 choroideremia-like (Rab escort CHML 1122 − 24 protein 2) 1224 225636_at HG-U133B H98105 1172 signal transducer and activator of STAT2 6773 − 36 transcription 2, 113 kDa 1225 208677_s_at HG-U133A AL550657 1173 basigin (OK blood group) BSG 682 + 37 1226 212473_s_at HG-U133A BE965029 1174 flavoprotein oxidoreductase MICAL2 MICAL2 9645 + 39 1227 212987_at HG-U133A AL031178 1175 F-box protein 9 FBXO9 26268 + 39 1228 211919_s_at HG-U133A AF348491 1176 chemokine (C-X-C motif) receptor 4 CXCR4 7852 + 40 1229 212139_at HG-U133A D86973 1177 GCN1 general control of amino-acid GCN1L1 10985 − 41 synthesis 1-like 1 (yeast) 1230 213730_x_at HG-U133A BE962186 1178 transcription factor 3 (E2A TCF3 6929 − 42 immunoglobulin enhancer binding factors E12/E47) 1231 216398_at HG-U133A U05255 1091 + 43 1232 211254_x_at HG-U133A AF031549 1179 Rhesus blood group-associated RHAG 6005 + 45 glycoprotein 1233 217028_at HG-U133A AJ224869 1180 chemokine (C-X-C motif) receptor 4 CXCR4 7852 + 46 1234 212226_s_at HG-U133A AA628586 1181 phosphatidic acid phosphatase type PPAP2B 8613 + 47 2B 1235 213457_at HG-U133A BF739959 1182 malignant fibrous histiocytoma MFHAS1 9258 + 47 amplified sequence 1 1236 202124_s_at HG-U133A AV705253 1183 amyotrophic lateral sclerosis 2 ALS2CR3 66008 + 48 (juvenile) chromosome region, candidate 3 1237 205859_at HG-U133A NM_004271 1184 lymphocyte antigen 86 LY86 9450 + 49 1238 214157_at HG-U133A AA401492 1185 GNAS complex locus GNAS 2778 − 51 1239 212956_at HG-U133A AI348094 1186 KIAA0882 protein KIAA0882 23158 + 52 1240 219371_s_at HG-U133A NM_016270 1187 Kruppel-like factor 2 (lung) KLF2 10365 + 52 1241 218847_at HG-U133A NM_006548 1188 IGF-II mRNA-binding protein 2 IMP-2 10644 + 54 1242 222976_s_at HG-U133B BC000771 1189 tropomyosin 3 TPM3 7170 − 58 1243 203837_at HG-U133A NM_005923 1190 mitogen-activated protein kinase MAP3K5 4217 + 63 kinase kinase 5 1244 201178_at HG-U133A NM_012179 1191 F-box protein 7 FBXO7 25793 + 64 1245 210776_x_at HG-U133A M31222 1192 transcription factor 3 (E2A TCF3 6929 − 64 immunoglobulin enhancer binding factors E12/E47) 1246 203697_at HG-U133A U91903 1193 frizzled-related protein FRZB 2487 − 67 1247 229721_x_at HG-U133B AI655697 1194 Der1-like domain family, member 3 DERL3 91319 − 72 1248 200984_s_at HG-U133A X16447 1195 CD59 antigen p18-20 (antigen CD59 966 + 74 identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) 1249 223322_at HG-U133B BC004270 1196 Ras association (RalGDS/AF-6) RASSF5 83593 − 77 domain family 5 1250 201061_s_at HG-U133A M81635 1197 stomatin STOM 2040 + 78 1251 203132_at HG-U133A NM_000321 1198 retinoblastoma 1 (including RB1 5925 + 79 osteosarcoma) 1252 205308_at HG-U133A NM_016010 1199 CGI-62 protein CGI-62 51101 + 81 1253 221478_at HG-U133A AL132665 1200 BCL2/adenovirus E1B 19 kDa BNIP3L 665 + 82 interacting protein 3-like 1254 214170_x_at HG-U133A AA669797 1201 fumarate hydratase FH 2271 − 87 1255 202345_s_at HG-U133A NM_001444 1202 fatty acid binding protein 5 FABP5 2171 − 91 (psoriasis-associated) 1256 210088_x_at HG-U133A M36172 1203 myosin, light polypeptide 4, MYL4 4635 + 92 alkali; atrial, embryonic 1257 200044_at HG-U133A NM_003769 1204 splicing factor, arginine/ SFRS9 8683 − 93 serine-rich 9 1258 205390_s_at HG-U133A NM_000037 1205 ankyrin 1, erythrocytic ANK1 286 + 95 1259 209160_at HG-U133A AB018580 1206 aldo-keto reductase family 1, AKR1C3 8644 + 97 member C3 (3-alpha hydroxysteroid dehydrogenase, type II) 1260 201561_s_at HG-U133A NM_014944 1207 calsyntenin 1 CLSTN1 22883 − 101 1261 201803_at HG-U133A NM_000938 1208 polymerase (RNA) II (DNA directed) POLR2B 5431 − 101 polypeptide B, 140 kDa 1262 214948_s_at HG-U133A AL050136 1209 TATA element modulatory factor TMF1 441347 /// 7110  − 102 1 /// Similar to family with sequence similarity 9, member C 1263 204158_s_at HG-U133A NM_006019 1210 T-cell, immune regulator 1, ATPase, TCIRG1 10312 − 103 H+ transporting, lysosomal V0 protein a isoform 3 1264 200792_at HG-U133A NM_001469 1211 thyroid autoantigen 70 kDa (Ku G22P1 2547 − 106 antigen) 1265 200593_s_at HG-U133A BC003621 1212 heterogeneous nuclear HNRPU 3192 − 114 ribonucleoprotein U (scaffold attachment factor A) 1266 200872_at HG-U133A NM_002966 1213 S100 calcium binding protein A10 S100A10 6281 + 114 (annexin II ligand, calpactin I, light polypeptide (p11)) 1267 225532_at HG-U133B AI889160 1214 Cdk5 and Abl enzyme substrate 1 CABLES1 91768 − 121 1268 210105_s_at HG-U133A M14333 1215 FYN oncogene related to SRC, FGR, FYN 2534 − 122 YES 1269 217274_x_at HG-U133A X52005 1216 myosin, light polypeptide 4, MYL4 4635 + 122 alkali; atrial, embryonic 1270 200654_at HG-U133A J02783 1217 procollagen-proline, P4HB 5034 − 123 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55) 1271 208851_s_at HG-U133A AL161958 1218 Thy-1 cell surface antigen /// THY1 ///  7070 /// 94105 − 137 Thy-1 co-transcribed LOC94105 1272 225716_at HG-U133B AI357639 1219 Full-length cDNA clone CS0DK008YI09 − 140 of HeLa cells Cot 25-normalized of Homo sapiens (human) 1273 200619_at HG-U133A NM_006842 1220 − 142 1274 200634_at HG-U133A NM_005022 1221 profilin 1 PFN1 5216 − 149 1275 222584_at HG-U133B AL573591 1222 misato FLJ10504 55154 − 156 1276 212591_at HG-U133A AA887480 1223 KIAA0117 protein KIAA0117 23029 − 158 1277 224855_at HG-U133B AL561868 1224 pyrroline-5-carboxylate reductase PYCR2 29920 − 159 family, member 2 1278 202004_x_at HG-U133A NM_003001 1225 succinate dehydrogenase complex, SDHC 6391 − 168 subunit C, integral membrane protein, 15 kDa 1279 218585_s_at HG-U133A NM_016448 1226 RA-regulated nuclear RAMP 51514 − 175 matrix-associated protein 1280 210131_x_at HG-U133A D49737 1227 − 178 1281 201275_at HG-U133A NM_002004 1228 farnesyl diphosphate synthase FDPS 2224 − − − 4 (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase) 1282 223531_x_at HG-U133B AF151035 1229 G protein-coupled receptor 89 GPR89 51463 − − − 5 1283 208694_at HG-U133A U47077 1230 protein kinase, DNA-activated, PRKDC 5591 − 6 catalytic polypeptide 1284 225463_x_at HG-U133B BF941168 1231 G protein-coupled receptor 89 GPR89 51463 − − 10 1285 200090_at HG-U133A BG168896 398 farnesyltransferase, CAAX box, FNTA 2339 − − 11 alpha 1286 212165_at HG-U133A AF070537 1232 chromosome 1 open reading frame 37 C1orf37 92703 − − 11 1287 217978_s_at HG-U133A NM_017582 1233 ubiquitin-conjugating enzyme E2Q UBE2Q 55585 − − − 11 (putative) 1288 220642_x_at HG-U133A NM_016334 1234 G protein-coupled receptor 89 GPR89 51463 − − − 22 1289 201209_at HG-U133A NM_004964 1235 histone deacetylase 1 HDAC1 3065 − − 24 1290 222140_s_at HG-U133A AK021758 1236 G protein-coupled receptor 89 GPR89 51463 − − − 27 1291 201764_at HG-U133A NM_024056 1237 hypothetical protein MGC5576 MGC5576 79022 − − − 33 1292 201698_s_at HG-U133A NM_003769 1204 splicing factor, arginine/ SFRS9 8683 − − 40 serine-rich 9 1293 203362_s_at HG-U133A NM_002358 1238 MAD2 mitotic arrest deficient-like MAD2L1 4085 − 41 1 (yeast) 1294 225793_at HG-U133B AW500180 1239 Lix1 homolog (mouse) like LIX1L 128077 − − 41 1295 201664_at HG-U133A AL136877 1240 SMC4 structural maintenance of SMC4L1 10051 − − 44 chromosomes 4-like 1 (yeast) 1296 220607_x_at HG-U133A NM_016397 1241 TH1-like (Drosophila) TH1L 51497 − 62 1297 226525_at HG-U133B N51102 1242 Serine/threonine kinase 17b (apoptosis- STK17B 9262 − − 63 inducing) 1298 222654_at HG-U133B AI302253 1243 myo-inositol monophosphatase A3 IMPA3 54928 − 68 1299 205367_at HG-U133A NM_020979 1244 adaptor protein with pleckstrin homology APS 10603 − − 74 and src homology 2 domains 1300 200080_s_at HG-U133B AI955655 1245 H3 histone, family 3A H3F3A 3020 − 81 1301 208775_at HG-U133A D89729 1246 exportin 1 (CRM1 homolog, yeast) XPO1 7514 − 93 1302 206102_at HG-U133A NM_021067 1247 KIAA0186 gene product KIAA0186 9837 − 103 1303 222998_at HG-U133B AL136937 1248 homolog of yeast MAF1 MAF1 84232 − 114 1304 225644_at HG-U133B BF060776 1249 hypothetical protein FLJ33814 FLJ33814 150275 − 125 1305 224815_at HG-U133B AA148301 1250 COMM domain containing 7 COMMD7 149951 − 128 1306 210460_s_at HG-U133A AB033605 1251 proteasome (prosome, macropain) 26S PSMD4 5710 − 137 subunit, non-ATPase, 4 1307 203316_s_at HG-U133A NM_003094 1252 small nuclear ribonucleoprotein SNRPE 6635 − 141 polypeptide E 1308 219010_at HG-U133A NM_018265 1253 hypothetical protein FLJ10901 FLJ10901 55765 − − 144 1309 211946_s_at HG-U133A AL096857 1254 BAT2 domain containing 1 BAT2D1 23215 − 154 1310 200080_s_at HG-U133A AI955655 1245 H3 histone, family 3A H3F3A 3020 − 157 1311 222443_s_at HG-U133B AF182415 1255 RNA binding motif protein 8A RBM8A 9939 − − 157 1312 202282_at HG-U133A NM_004493 1256 hydroxyacyl-Coenzyme A HADH2 3028 − 158 dehydrogenase, type II 1313 203344_s_at HG-U133A NM_002894 1257 retinoblastoma binding protein 8 RBBP8 5932 − 163 1314 231715_s_at HG-U133B NM_013328 1258 pyrroline-5-carboxylate reductase PYCR2 29920 − 169 family, member 2 1315 211036_x_at HG-U133A BC006301 1259 anaphase promoting complex ANAPC5 51433 − 186 subunit 5 1316 200044_at HG-U133B NM_003769 1204 splicing factor, arginine/ SFRS9 8683 − 195 serine-rich 9 1317 208755_x_at HG-U133A BF312331 1260 H3 histone, family 3A H3F3A 3020 − 205 1318 211609_x_at HG-U133A U51007 1261 proteasome (prosome, macropain) 26S PSMD4 5710 − 214 subunit, non-ATPase, 4 1319 201663_s_at HG-U133A NM_005496 1262 SMC4 structural maintenance of SMC4L1 10051 − 216 chromosomes 4-like 1 (yeast) 1320 212766_s_at HG-U133A AW294587 1263 hypothetical protein FLJ12671 FLJ12671 81875 − 225 1321 219816_s_at HG-U133A NM_018107 1264 RNA binding motif protein 23 RBM23 55147 − 236 1322 200614_at HG-U133A NM_004859 1265 clathrin, heavy polypeptide (Hc) CLTC 1213 − 243 1323 200843_s_at HG-U133A NM_004446 1266 glutamyl-prolyl-tRNA synthetase EPRS 2058 − 281 1324 200709_at HG-U133A NM_000801 1267 FK506 binding protein 1A, 12 kDa FKBP1A 2280 − 288 1325 208758_at HG-U133A D89976 1268 5-aminoimidazole-4-carboxamide ATIC 471 − 293 ribonucleotide formyltransferase/ IMP cyclohydrolase 1326 212345_s_at HG-U133A BE675139 1269 cAMP responsive element binding CREB3L2 64764 + 119 protein 3-like 2 1327 212699_at HG-U133A BE222801 1270 secretory carrier membrane SCAMP5 192683 + 171 protein 5 1328 206626_x_at HG-U133A BC001003 1271 synovial sarcoma, X breakpoint 1 SSX1 6756 − − − 10 1329 211678_s_at HG-U133A AF090934 1272 zinc finger protein 313 ZNF313 55905 − 12 1330 208854_s_at HG-U133A AA586774 1273 serine/threonine kinase 24 (STE20 STK24 8428 − − 14 homolog, yeast) 1331 218051_s_at HG-U133A NM_022908 1274 hypothetical protein FLJ12442 FLJ12442 64943 − − 18 1332 206621_s_at HG-U133A NM_022170 1275 Williams-Beuren syndrome chromosome WBSCR1 7458 − 23 region 1 1333 216471_x_at HG-U133A X79200 1276 synovial sarcoma, X breakpoint 2 SSX2 6757 − − − 24 1334 212433_x_at HG-U133A AA630314 1277 ribosomal protein S2 RPS2 6187 − 26 1335 202929_s_at HG-U133A NM_001355 1278 D-dopachrome tautomerase DDT 1652 − 33 1336 217972_at HG-U133A NM_017812 1279 coiled-coil-helix-coiled-coil-helix CHCHD3 54927 − 41 domain containing 3 1337 39835_at HG-U133A U93181 1280 SET binding factor 1 SBF1 6305 − − 42 1338 213166_x_at HG-U133A BG332462 1281 − 63 1339 210006_at HG-U133A BC002571 1282 DKFZP564O243 protein DKFZP564O243 25864 − 75 1340 232652_x_at HG-U133B AF207829 1283 SCAN domain containing 1 SCAND1 51282 − − 108 1341 201630_s_at HG-U133A NM_004300 1284 acid phosphatase 1, soluble ACP1 52 − 144 1342 200966_x_at HG-U133A NM_000034 1285 aldolase A, fructose-bisphosphate ALDOA 226 − − 165 1343 218561_s_at HG-U133A NM_020408 1286 chromosome 6 open reading frame 149 C6orf149 57128 − 202 1344 200652_at HG-U133A NM_003145 1287 signal sequence receptor, beta SSR2 6746 − 212 (translocon-associated protein beta) 1345 225359_at HG-U133B BF666961 1288 homolog of yeast TIM14 TIM14 131118 − 225 1346 201486_at HG-U133A NM_002902 1289 reticulocalbin 2, EF-hand calcium RCN2 5955 − 242 binding domain 1347 55093_at HG-U133A AA534198 1290 chondroitin sulfate CSGlcA-T 54480 − 253 glucuronyltransferase 1348 224890_s_at HG-U133B BE727643 1291 similar to CG14977-PA LOC389541 389541 − 257 1349 203258_at HG-U133A NM_006442 1292 DR1-associated protein 1 (negative DRAP1 10589 − 285 cofactor 2 alpha) 1350 202012_s_at HG-U133A AA196245 1293 exostoses (multiple) 2 EXT2 2132 − 351 1351 209669_s_at HG-U133A BC003049 1294 PAI-1 mRNA-binding protein PAI-RBP1 26135 − 361 1352 215096_s_at HG-U133A AU145746 1295 esterase D/formylglutathione ESD 2098 − 386 hydrolase 1353 224576_at HG-U133B AK000752 1296 endoplasmic reticulum-golgi KIAA1181 57222 − 415 intermediate compartment 32 kDa protein 1354 224217_s_at HG-U133B AF094700 1297 Fas (TNFRSF6) associated factor 1 FAF1 11124 − 448 1355 225502_at HG-U133B AL161725 1298 dedicator of cytokinesis 8 DOCK8 81704 − 467 1356 218802_at HG-U133A NM_017918 1299 hypothetical protein FLJ20647 FLJ20647 55013 − 487 1357 209609_s_at HG-U133A BC004517 1300 mitochondrial ribosomal protein L9 MRPL9 65005 − − 19 1358 211060_x_at HG-U133A BC006383 1301 GPAA1P anchor attachment protein 1 GPAA1 8733 − − 28 homolog (yeast) 1359 222997_s_at HG-U133B BC004566 1302 mitochondrial ribosomal protein S21 MRPS21 54460 − − − 57 1360 201144_s_at HG-U133A NM_004094 1303 eukaryotic translation initiation EIF2S1 1965 − − − − 59 factor 2, subunit 1 alpha, 35 kDa 1361 200910_at HG-U133A NM_005998 1304 chaperonin containing TCP1, subunit CCT3 7203 − − 61 3 (gamma) 1362 218336_at HG-U133A NM_012394 1305 prefoldin 2 PFDN2 5202 − − − 61 1363 203832_at HG-U133A NM_003095 1306 enolase 1, (alpha) /// small nuclear ENO1 ///  2023 /// 6636 − − 90 ribonucleoprotein polypeptide F SNRPF 1364 208822_s_at HG-U133A U18321 1307 death associated protein 3 DAP3 7818 − − 99 1365 200057_s_at HG-U133A NM_007363 201 non-POU domain containing, octamer- NONO 4841 − − 113 binding 1366 202244_at HG-U133A NM_002796 1308 proteasome (prosome, macropain) PSMB4 5692 − − − 129 subunit, beta type, 4 1367 203594_at HG-U133A NM_003729 1309 RNA terminal phosphate cyclase RTCD1 8634 − − 171 domain 1 1368 215450_at HG-U133A W87901 1310 − − 178 1369 223377_x_at HG-U133B AF035947 1311 cytokine inducible SH2-containing CISH 1154 + + + 2 protein 1370 209813_x_at HG-U133A M16768 1312 T cell receptor gamma variable TRGV9 /// 445347 /// 6983 + 5 9 /// TCR gamma alternate reading TARP frame protein 1371 216491_x_at HG-U133A U80139 1313 Immunoglobulin heavy constant IGHM ///  3500 /// 3507 + − 9 mu /// Immunoglobulin heavy IGHG1 constant gamma 1 (G1m marker) 1372 204891_s_at HG-U133A NM_005356 1314 lymphocyte-specific protein LCK 3932 + 13 tyrosine kinase 1373 204141_at HG-U133A NM_001069 1315 tubulin, beta 2 TUBB2 7280 + + 26 1374 203661_s_at HG-U133A BC002660 1316 tropomodulin 1 TMOD1 7111 + + 31 1375 221558_s_at HG-U133A AF288571 1317 lymphoid enhancer-binding factor 1 LEF1 51176 + − 39 1376 200660_at HG-U133A NM_005620 1318 S100 calcium binding protein A11 S100A11 6282 + + 41 (calgizzarin) 1377 206206_at HG-U133A NM_005582 1319 lymphocyte antigen 64 homolog, LY64 4064 + 59 radioprotective 105 kDa (mouse) 1378 211719_x_at HG-U133A BC005858 1320 fibronectin 1 FN1 2335 + 69 1379 212332_at HG-U133A BF110947 1321 retinoblastoma-like 2 (p130) RBL2 5934 + 70 1380 214486_x_at HG-U133A AF041459 1322 CASP8 and FADD-like apoptosis CFLAR 8837 + 93 regulator 1381 217202_s_at HG-U133A U08626 1323 glutamate-ammonia ligase (glutamine GLUL 2752 + 115 synthase) 1382 203567_s_at HG-U133A AU157590 1324 tripartite motif-containing 38 TRIM38 10475 + 121 1383 205590_at HG-U133A NM_005739 1325 RAS guanyl releasing protein 1 RASGRP1 10125 + 142 (calcium and DAG-regulated) 1384 226505_x_at HG-U133B AI148567 1326 ubiquitin specific protease 32 USP32 84669 + 143 1385 210972_x_at HG-U133A M15565 1327 T cell receptor alpha locus TRA@ 6955 + 144 1386 209473_at HG-U133A AV717590 1328 ectonucleoside triphosphate ENTPD1 953 + 158 diphosphohydrolase 1 1387 226085_at HG-U133B AA181060 1329 Chromobox homolog 5 (HP1 alpha CBX5 23468 + 167 homolog, Drosophila) 1388 37831_at HG-U133A AB011117 1330 signal-induced proliferation- SIPA1L3 23094 + 170 associated 1 like 3 1389 210426_x_at HG-U133A U04897 1331 RAR-related orphan receptor A RORA 6095 + 176 1390 210987_x_at HG-U133A M19267 1332 Tropomyosin 1 (alpha) TPM1 7168 + 182 1391 217878_s_at HG-U133A AI203880 1333 cell division cycle 27 CDC27 996 + 192 1392 220169_at HG-U133A NM_024943 1334 hypothetical protein FLJ23235 FLJ23235 80008 + 197 1393 210681_s_at HG-U133A AF153604 1335 ubiquitin specific protease 15 USP15 9958 + 199 1394 213327_s_at HG-U133A AI820101 1336 + 199 1395 211994_at HG-U133A AI742553 1337 Clone A9A2BRB5 (CAC)n/(GTG)n + 205 repeat-containing mRNA. 1396 216557_x_at HG-U133A U92706 1338 immunoglobulin heavy constant IGHG1 3500 + 222 gamma 1 (G1m marker) 1397 202096_s_at HG-U133A NM_000714 1339 benzodiazapine receptor (peripheral) BZRP 706 + 233 1398 212660_at HG-U133A AI735639 1340 PHD finger protein 15 PHF15 23338 + 246 1399 243699_at HG-U133B BG432887 1341 Full-length cDNA clone CS0DI020YI19 + 249 of Placenta Cot 25-normalized of Homo sapiens (human) 1400 45749_at HG-U133A AA400206 1342 hypothetical protein FLJ13725 FLJ13725 79567 + 273 1401 207571_x_at HG-U133A NM_004848 1343 chromosome 1 open reading frame 38 C1orf38 9473 + 281 1402 211993_at HG-U133A AI768512 1344 WNK lysine deficient protein WNK1 65125 + 286 kinase 1 1403 226682_at HG-U133B AW006185 1345 hypothetical protein LOC283666 LOC283666 283666 + 299 1404 205464_at HG-U133A NM_000336 1346 sodium channel, nonvoltage-gated 1, SCNN1B 6338 + 306 beta (Liddle syndrome) 1405 202748_at HG-U133A NM_004120 1347 guanylate binding protein 2, GBP2 2634 + 309 interferon-inducible 1406 204151_x_at HG-U133A NM_001353 1348 aldo-keto reductase family 1, AKR1C1 1645 + 315 member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase) 1407 205442_at HG-U133A NM_021647 1349 Microfibrillar-associated protein MFAP3L 9848 + 329 3-like 1408 218559_s_at HG-U133A NM_005461 1350 v-maf musculoaponeurotic MAFB 9935 + 329 fibrosarcoma oncogene homolog B (avian) 1409 210479_s_at HG-U133A L14611 1351 RAR-related orphan receptor A RORA 6095 + 333 1410 228157_at HG-U133B AI125646 1352 Zinc finger protein 207 ZNF207 7756 + 340 1411 216449_x_at HG-U133A AK025862 1353 tumor rejection antigen (gp96) 1 TRA1 7184 + 357 1412 204416_x_at HG-U133A NM_001645 1354 apolipoprotein C-I APOC1 341 + 368 1413 219229_at HG-U133A NM_013272 1355 solute carrier organic anion SLCO3A1 28232 + 377 transporter family, member 3A1 1414 201853_s_at HG-U133A NM_021873 1356 cell division cycle 25B CDC25B 994 + 382 1415 201039_s_at HG-U133A BF572938 1357 RAD23 homolog A (S. cerevisiae) RAD23A 5886 + 406 1416 212607_at HG-U133A N32526 1358 v-akt murine thymoma viral oncogene AKT3 10000 + 433 homolog 3 (protein kinase B, gamma) 1417 209901_x_at HG-U133A U19713 1359 allograft inflammatory factor 1 AIF1 199 + 522 1418 205896_at HG-U133A NM_003059 1360 solute carrier family 22 (organic SLC22A4 6583 + 525 cation transporter), member 4 1419 213566_at HG-U133A NM_005615 1361 ribonuclease, RNase A family, k6 RNASE6 6039 + 535 1420 211986_at HG-U133A BG287862 1362 AHNAK nucleoprotein (desmoyokin) AHNAK 195 + 547 1421 201220_x_at HG-U133A NM_001329 1363 C-terminal binding protein 2 CTBP2 1488 + 627 1422 202201_at HG-U133A NM_000713 1364 biliverdin reductase B (flavin BLVRB 645 + 664 reductase (NADPH)) 1423 224920_x_at HG-U133B AA909044 1365 myeloid-associated differentiation MYADM 91663 + 686 marker 1424 209340_at HG-U133A S73498 1366 UDP-N-acteylglucosamine UAP1 6675 − − 1 pyrophosphorylase 1 1425 208642_s_at HG-U133A AA205834 1367 X-ray repair complementing XRCC5 7520 − 38 defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80 kDa) 1426 206632_s_at HG-U133A NM_004900 1368 apolipoprotein B mRNA editing APOBEC3B 9582 − 59 enzyme, catalytic polypeptide-like 3B 1427 206218_at HG-U133A NM_002364 1369 melanoma antigen family B, 2 MAGEB2 4113 − 63 1428 214612_x_at HG-U133A U10691 1370 melanoma antigen family A, 6 MAGEA6 4105 − 65 1429 232231_at HG-U133B AL353944 1371 Runt-related transcription factor 2 RUNX2 860 − 87 1430 220057_at HG-U133A NM_020411 1372 X antigen family, member 1 XAGE1 9503 − − − 15 1431 220565_at HG-U133A NM_016602 1373 chemokine (C-C motif) receptor 10 CCR10 2826 − 177 1432 224518_s_at HG-U133B BC006436 1374 zinc finger protein 559 ZNF559 84527 − 200 1433 200713_s_at HG-U133A NM_012325 1375 microtubule-associated protein, MAPRE1 22919 − 289 RP/EB family, member 1 1434 210497_x_at HG-U133A BC002818 1376 synovial sarcoma, X breakpoint 2 SSX2 6757 − − − 2 1435 209486_at HG-U133A BC004546 1377 disrupter of silencing 10 SAS10 57050 − 104 1436 217466_x_at HG-U133A L48784 1378 ribosomal protein S2 RPS2 6187 − 135 1437 204836_at HG-U133A NM 000170 1379 glycine dehydrogenase GLDC 2731 − − 14 (decarboxylating; glycine decarboxylase, glycine cleavage system protein P) 1438 212750_at HG-U133A AB020630 472 protein phosphatase 1, regulatory PPP1R16B 26051 − − 32 (inhibitor) subunit 16B 1439 225239_at HG-U133B AI355441 1380 CDNA FLJ26120 fis, clone SYN00419 + + 45 1440 211474_s_at HG-U133A BC004948 1381 serine (or cysteine) proteinase SERPINB6 5269 + 343 inhibitor, clade B (ovalbumin), member 6 1441 53987_at HG-U133A AL041852 1382 RAN binding protein 10 RANBP10 57610 + 364 1442 203642_s_at HG-U133A NM_014900 1383 COBL-like 1 COBLL1 22837 + 6 1443 208908_s_at HG-U133A AF327443 1384 calpastatin CAST 831 + + 21 1444 207467_x_at HG-U133A NM_001750 1385 calpastatin CAST 831 + + 32 1445 213011_s_at HG-U133A BF116254 1386 triosephosphate isomerase 1 TPI1 7167 − 35 1446 200953_s_at HG-U133A NM_001759 1387 cyclin D2 CCND2 894 + 36 1447 216526_x_at HG-U133A AK024836 1388 major histocompatibility complex, HLA-C 3107 + 89 class I, C 1448 201952_at HG-U133A AA156721 1389 + 184 1449 222680_s_at HG-U133B AK001261 1390 RA-regulated nuclear RAMP 51514 − − 5 matrix-associated protein 1450 201697_s_at HG-U133A NM_001379 1391 DNA (cytosine-5-)-methyl- DNMT1 1786 − 7 transferase 1 1451 209644_x_at HG-U133A U38945 1392 cyclin-dependent kinase inhibitor 2A CDKN2A 1029 − − − 25 (melanoma, p16, inhibits CDK4) 1452 215690_x_at HG-U133A AL157437 1393 GPAA1P anchor attachment protein 1 GPAA1 8733 − − 35 homolog (yeast) 1453 200822_x_at HG-U133A NM_000365 1394 triosephosphate isomerase 1 TPI1 7167 − − 100 1454 213828_x_at HG-U133A AA477655 1395 H3 histone, family 3A H3F3A 3020 − 287 1455 218603_at HG-U133A NM_016217 1396 headcase homolog (Drosophila) HECA 51696 + + + 43 1456 218795_at HG-U133A NM_016361 1397 acid phosphatase 6, lysophosphatidic ACP6 51205 − 158 1457 215823_x_at HG-U133A U64661 1398 poly(A) binding protein, PABPC3 /// 26986 /// 5042 − 339 cytoplasmic 3 /// poly(A) binding PABPC1 protein, cytoplasmic 1 1458 213160_at HG-U133A D86964 1399 dedicator of cytokinesis 2 DOCK2 1794 − 460 1459 213811_x_at HG-U133A AW062341 1400 transcription factor 3 (E2A TCF3 6929 − − − 12 immunoglobulin enhancer binding factors E12/E47) 1460 201618_x_at HG-U133A NM_003801 1401 GPAA1P anchor attachment protein 1 GPAA1 8733 − − − − 39 homolog (yeast) 1461 203560_at HG-U133A NM_003878 1402 gamma-glutamyl hydrolase GGH 8836 − − 76 (conjugase, folylpolygammaglutamyl hydrolase) 1462 225317_at HG-U133B AL574669 1403 acyl-Coenzyme A binding domain ACBD6 84320 − − 95 containing 6 1463 215001_s_at HG-U133A AL161952 1404 glutamate-ammonia ligase (glutamine GLUL 2752 + + 52 synthase) 1464 220547_s_at HG-U133A NM_019054 1405 family with sequence similarity 35, FAM35A 54537 + 77 member A 1465 213415_at HG-U133A AI768628 1406 chloride intracellular channel 2 CLIC2 1193 + + 78 1466 203038_at HG-U133A NM_002844 1407 protein tyrosine phosphatase, PTPRK 5796 + + 111 receptor type, K 1467 210564_x_at HG-U133A AF009619 1408 CASP8 and FADD-like apoptosis CFLAR 8837 + 149 regulator 1468 209508_x_at HG-U133A AF005774 1409 CASP8 and FADD-like apoptosis CFLAR 8837 + 234 regulator 1469 208485_x_at HG-U133A NM_003879 1410 CASP8 and FADD-like apoptosis CFLAR 8837 + 254 regulator 1470 37986_at HG-U133A M60459 1411 erythropoietin receptor EPOR 2057 + 354 1471 232213_at HG-U133B AU147506 1412 Pellino homolog 1 (Drosophila) PELI1 57162 + 32 1472 232304_at HG-U133B AK026714 1413 Pellino homolog 1 (Drosophila) PELI1 57162 + 37 1473 218319_at HG-U133A NM_020651 1414 pellino homolog 1 (Drosophila) PELI1 57162 + 85 1474 204173_at HG-U133A NM_002475 1415 myosin light chain 1 slow a MLC1SA 140465 − − − 25 Classification Methods

Various algorithms are currently available that can be used to classify patient samples using a given set of features. Therefore, the combination of markers selected through the feature selection process may be used in any of the available algorithms in order to derive a prediction equation as to whether the patient sample is sensitive or resistant. The classification methods used to illustrate the use of multiple markers for patient sample clasdification in the present invention were: 1) Linear Predictive Score (“LPS”); and 2) k-nearest neighbors.

The Linear Predictive Score was implemented as described by Wright et al., “A gene-expression based method to diagnose clinically distinct groups of diffuse large B cell lymphoma.” PNAS 100(17):9991-9996 (2003), the contents of which are incorporated herein by reference. As described by Wright et al., the LPS score for a vector X is computed as:

${{LPS}(X)} = {\sum\limits_{j}\;{a_{j}X_{j}}}$ where X_(j) represents the log expression value for the j^(th) feature in the set, and a_(j) is a scaling factor representing the degree to which the j^(th) feature is associated with the outcome to be predicted. As in Wright et al., we used the t-statistics of the features for the scaling factors. Given the LPS score, the likelihood that a sample is in the first of the two classes is determined using this formula:

${{P\left( {X \in S_{1}} \right)} = \frac{\phi\left( {{{{LPS}(X)};{\hat{\mu}}_{1}},{\hat{\sigma}}_{1}^{2}} \right)}{{\phi\left( {{{{LPS}(X)};{\hat{\mu}}_{1}},{\hat{\sigma}}_{1}^{2}} \right)} + {\phi\left( {{{{LPS}(X)};{\hat{\mu}}_{2}},{\hat{\sigma}}_{2}^{2}} \right)}}},$ where ϕ(x; μ, σ²) represents the normal density function with mean μ and variance σ², and {circumflex over (μ)}₁, {circumflex over (σ)}₁ ², {circumflex over (μ)}₂and {circumflex over (σ)}₂ ² are the observed means and variances of the LPS scores for category 1 and category 2. In our case, for example, category 1 would be responders, and category 2 would be non-responders. Then the prediction for a new sample would be that it would be in the first class with probability P(X∈S₁) and in the second class with probability P(X∈S₂)=1−P(X∈S₁).

The k-nearest neighbor classification method computes the similarity between a query profile and each of the profiles in the training set [Introduction to Machine Learning by Ethem ALPAYDIN, The MIT Press, October 2004, ISBN 0-262-01211-1]. The k most similar profiles are selected, and a vote is taken amongst their class labels to determine the prediction for the query profile. Here, we used k=1.

Feature Selection

Feature selection is the process of determining a subset of the thousands of available features in the dataset, resulting in a combination of features that form a marker set or model, to classify patients by treatment outcome. There are many approaches to selecting features. Here we report two approaches to generate example marker sets: (1) top N most significant features, and (2) a standard feature selection method, sequential forward feature selection (See, Dash and Liu, “Feature Selection for Classification,” Intelligent Data Analysis 1:131-156, 1997). We now describe how feature selection is applied to our dataset.

As a first step, only features associated with the outcome variable are considered as candidates for a feature set. For the LPS models models, all features with multiple-test-adjusted p-values less than 0.05 were determined. For the k-nearest-neighbor models, the top 100 PFC markers were determined In either case, sequential forward selection starts with no markers in the set. At each iteration, a new feature set is formed by adding a feature selected by an evaluation function. Iteration terminates when no feature can be added that improves the evaluation function. The evaluation function is the number of samples correctly predicted either (1) by the model built on all of the samples, or (2) in leave-one-out cross-validation (Dash and Liu, 1997). Ties are broken by using the feature that has a higher univariate association with the outcome variable. Multiple marker sets can be generated by repeated rounds of feature selection, each time removing the features already selected.

Specific Application of Class Prediction

Linear Predictor Score (LPS)

Using the 162 bortezomib-treated patients classified into Responsive or Nonresponsive groups, the table below shows the markers in the first LPS predictive set we built from our data set. Also indicated is whether the marker is more highly expressed in Responsive (R) or in Non-responsive (N) patients. The probe set annotations are those provided by Affymetrix.

TABLE 4 LPS Predictive Marker Set SEQ Sub Gene ID set Order Probe Set Chip Symbol Description NO: Direction 1 1 210532_s_at A C14orf2 chromosome 14 open reading 608 N frame 2 1 2 206790_s_at A NDUFB1 NADH dehydrogenase 516 N (ubiquinone) 1 beta subcomplex, 1, 7 kDa 1 3 200082_s_at A RPS7 ribosomal protein S7 514 N 2 4 217988_at A CCNB1IP1 cyclin B1 interacting protein 1 459 N 2 5 200937_s_at A RPL5 ribosomal protein L5 520 N 2 6 213941_x_at A RPS7 ribosomal protein S7 2 N 2 7 224616_at A DNCLI2 dynein, cytoplasmic, light 621 R intermediate polypeptide 2 2 8 224985_at A SS18 synovial sarcoma 578 N translocation, chromosome 18 2 9 233252_s_at A STRBP spermatid perinuclear RNA 9 N binding protein 3 10 206621_s_at A WBSCR1 Williams-Beuren syndrome 1275 N chromosome region 1 3 11 208540_x_at B S100A11P S100 calcium binding protein 627 R A11 pseudogene 3 12 202605_at A GUSB glucuronidase, beta 461 N 4 13 201637_s_at A FXR1 fragile X mental retardation, 1122 N autosomal homolog 1 4 14 209475_at B USP15 ubiquitin specific protease 15 862 R 4 15 200626_s_at B MATR3 matrin 3 54 N 4 16 219939_s_at A UNR upstream of NRAS 589 N 4 17 219910_at A HYPE Huntingtin interacting protein E 649 R 5 18 200034_s_at A RPL6 ribosomal protein L6 29 N 5 19 201784_s_at A SMAP small acidic protein 134 N 5 20 211316_x_at A CFLAR CASP8 and FADD-like 849 R apoptosis regulator 5 21 213080_x_at A RPL5 ribosomal protein L5 145 N

It will be appreciated that additional marker sets may be obtained by employing the methods described herein, and methods standard in the field, for identifying models. There are many highly correlated features that could be substituted for each other in the models; these are not all listed. Similar methods may be employed utilizing one or more markers from the identified marker sets of the present invention in order to generate Predictive Marker Sets.

The present invention is not to be limited in scope by the specific embodiments described that are intended as illustrations of aspects of the invention. Functionally equivalent methods and components are within the scope of the invention, in addition to those shown and described herein and will become apparent to those skilled in the art from the foregoing description, using no more than routine experimentation. Such equivalents are intended to be encompassed by the following claims.

All references cited herein, including journal articles, patents, and databases are expressly incorporated by reference. 

What is claimed is:
 1. A method for treating hematological cancer in a patient with a cancer therapy regimen comprising: a) measuring the level of expression of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive marker or markers numbered 1-547 in Table 1A, 658-871 in Table 1B, 873-876 in Table 1B, 912-1062 in Table 2A, 1071-1079, 1081-1087, 1089-1093, 1095-1106, and/or 1108-1185 in Table 2B, in a patient sample comprising hematological tumor cells, wherein the sequences recognized by probesets of the predictive markers: i) numbered 1-547 consist of SEQ ID NOs: 1-513, ii) numbered 658-871 and 873-876 consist of SEQ ID NOs:614-830, iii) numbered 912-1062 consist of SEQ ID NOs:866-1014, 434 and 733, and iv) numbered 1071-1079, 1081-1087, 1089-1093, 1095-1106 and 1108-1185 consist of SEQ ID NOs:1023-1133; b) comparing the level of expression of the at least one nucleic acid sequence to a reference expression level of that sequence to determine whether the level of expression of the at least one nucleic acid sequence is upregulated in the patient sample comprising tumor cells, thereby identifying whether expression in the sample includes a profile of expression of the predictive marker or markers; c) selecting a patient whose predictive marker profile indicates that the patient will respond to the cancer therapy regimen; and d) treating the patient with the cancer therapy regimen, wherein the hematological cancer is multiple myeloma, wherein the hematological tumor cells are multiple myeloma tumor cells, and wherein the cancer therapy regimen is proteasome inhibition-based therapy and/or glucocorticoid based therapy.
 2. The method of claim 1 wherein the level of expression of the at least one nucleic acid sequence is measured by detection of mRNA.
 3. The method of claim 1 wherein i) upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 1-547 indicates nonresponsiveness to proteasome inhibition therapy and the patient would not benefit from this cancer therapy regimen, ii) upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 658-871 and 873-876 indicates responsiveness to proteasome inhibition therapy and the patient would benefit from this cancer therapy regimen, iii) upregulation of at least one sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 912-1062 indicates nonresponsiveness to glucocorticoid therapy and the patient would not benefit from this cancer therapy regimen; and iv) upregulation of at least one sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 1071-1079, 1081-1087, 1089-1093, 1095-1106 and 1108-1185 indicates responsiveness to glucocorticoid therapy and the patient would benefit from this cancer therapy.
 4. The method of claim 1 wherein the profile of expression is determined by a predictive marker set comprising two or more predictive markers.
 5. A method for continuing a cancer therapy regimen for treating a hematological cancer in a patient comprising: a) treating the patient with a cancer therapy regimen comprising proteasome inhibition therapy and/or glucocorticoid therapy, b) obtaining a tumor sample from the patient, wherein the tumor sample comprises hematological tumor cells; c) measuring the level of expression of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive marker or markers numbered 1-547 in Table 1A, 658-871 in Table 1B, 873-876 in Table 1B, 912-1062 in Table 2A, 1071-1079, 1081-1087, 1089-1093, 1095-1106, 1108-1185 in Table 2B, and/or 1203-1423 in Table 3in the tumor sample, wherein the sequences recognized by probesets of the predictive marker or markers: i) numbered 1-547 consist of SEQ ID NOs: 1-513, ii) numbered 658-871 and 873-876 consist of SEQ ID NOs:614-830, iii) numbered 912-1062 consist of SEQ ID NOs:866-1014, 434 and 733, and iv) numbered 1071-1079, 1081-1087, 1089-1093, 1095-1106 and 1108-1185 consist of SEQ ID NOs:1023-1133, thereby determining the expression profile of the predictive marker or markers; and d) continuing treatment of the hematological cancer when the expression profile of the predictive marker or markers in the tumor sample demonstrates responsiveness; wherein the hematological cancer is multiple myeloma and wherein the hematological tumor cells are multiple myeloma tumor cells.
 6. The method of claim 5 wherein the level of expression of the at least one nucleic acid is determined by detection of mRNA.
 7. The method of claim 5 wherein the cancer therapy regimen comprises a proteasome inhibition-based regimen therapy.
 8. The method of claim 5 wherein the expression profile is determined by a predictive marker set comprising two or more predictive markers.
 9. The method of claim 5, wherein the proteasome inhibition-based regimen for treating the tumor comprises treatment with a proteasome inhibitor is selected from the group consisting of a peptidyl aldehyde, a peptidyl boronic acid, a peptidyl boronic ester, a vinyl sulfone, an epoxyketone, and a lactacystin analog.
 10. The method of claim 4, wherein the predictive marker set is identified by applying a statistical analysis method to the expression level of each marker to select features associated with responsiveness or non-responsiveness.
 11. The method of claim 10, wherein the statistical analysis method is the linear predictive score method or the k-nearest neighbors model.
 12. The method of claim 1, wherein the proteasome inhibition-based therapy comprises treatment with a proteasome inhibitor selected from the group consisting of a peptidyl aldehyde, a peptidyl boronic acid, a peptidyl boronic ester, a vinyl sulfone, an epoxyketone, and a lactacystin analog.
 13. The method of claim 12, wherein the proteasome inhibition-based therapy comprises treatment with bortezomib.
 14. The method of claim 7, wherein the proteasome inhibition-based therapy comprises treatment with bortezomib.
 15. The method of claim 4, wherein the predictive marker set comprises at least 10 markers.
 16. The method of claim 11, wherein the predictive marker set comprises markers identified in Table
 4. 17. The method of claim 8, wherein the predictive marker set comprises at least 10 markers.
 18. The method of claim 1 wherein the tumor sample is a blood sample.
 19. The method of claim 5 wherein the tumor sample is a blood sample. 